3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
- Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too?
- 12/21/2024
|
My Top 10 Stocks to Buy for 2025
- It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too.
- 12/21/2024
|
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
- The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday. The post Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock appeared first on Investor's Business Daily.
- 12/20/2024
|
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
- The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in the market for cystic fibrosis.
- 12/20/2024
|
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See.
- 12/20/2024
|
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In ad.
- 12/20/2024
|
Shareholders that lost money on Vertex Pharmaceuticals Incorporated (VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTX
- NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
- 12/20/2024
|
Vertex Pharmaceuticals Incorporated Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VRTX
- NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
- 12/20/2024
|
VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo
- Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.
- 12/20/2024
|
Cramer's Mad Dash: Vertex Pharmaceuticals
- CNBC's Jim Cramer delivers his daily Mad Dash.
- 12/20/2024
|
Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
- BOSTON, MA / ACCESSWIRE / December 20, 2024 / Block & Leviton is investigating Vertex Pharmaceuticals Inc. (Nasdaq:VRTX) for potential securities law violations. Investors who have lost money in their Vertex Pharmaceuticals Inc. investment should contact the firm to learn more about how they might recover those losses.
- 12/20/2024
|
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
- Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study. The post Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
- 12/20/2024
|
Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot
- The CNBC 'Halftime Report' Investment Committee weighs in on 'Stocks on the Move' and their picks.
- 12/19/2024
|
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
- On Thursday, Vertex Pharmaceuticals Incorporated VRTX announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip that radiates down the back of the thigh into the leg.
- 12/19/2024
|
Vertex Pharmaceuticals Stock Heads for Worst Day in 4 Years
- Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) are plummeting today, down 13% at $389.21, after the biotech company's non-opioid painkiller, Suzetrigine, matched the placebo in a phase 2 study.
- 12/19/2024
|
Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
- Block & Leviton is investigating Vertex Pharmaceuticals (Nasdaq: VRTX) for potential securities fraud. Investors who lost money should contact the firm.
- 12/19/2024
|
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
- Vertex Pharmaceuticals (VRTX) shares sank Thursday morning after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.
- 12/19/2024
|
Cramer's Stop Trading: Vertex Pharmaceuticals
- CNBC's Jim Cramer explains why he is keeping an eye on shares of Vertex Pharmaceuticals.
- 12/19/2024
|
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
- Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results.
- 12/19/2024
|
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR). The study met its primary endpoint with statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS). Efficacy Results The study's primary endpoint was a within-group change from base.
- 12/19/2024
|
2 Unstoppable Stocks to Buy and Hold for the Next Decade
- What do Apple (AAPL -2.14%) and Vertex Pharmaceuticals (VRTX -4.63%) have in common? At first glance, not much.
- 12/19/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
- Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 12/18/2024
|
4 Big Drug Stocks That May Continue to Outperform in 2025
- Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.
- 12/17/2024
|
Why Vertex Pharmaceuticals (VRTX) Outpaced the Stock Market Today
- Vertex Pharmaceuticals (VRTX) closed at $468.09 in the latest trading session, marking a +0.94% move from the prior day.
- 12/16/2024
|
BMY vs. VRTX: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors?
- 12/16/2024
|
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
- Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies generally see at least stability in revenue.
- 12/16/2024
|
3 Unstoppable Stocks to Buy Right Now
- Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals.
- 12/15/2024
|
The Ultimate Biotech Stock to Buy With $500 Right Now
- Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, biotech stocks can be highly volatile.
- 12/12/2024
|
Biotech Roundup: 3 Stocks to Watch
- Most recently in the ever-growing biotech industry , investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and Drug Administration's (FDA) next commissioner, and Robert F.
- 12/11/2024
|
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
- I'm updating my recent “Buy” thesis on Vertex Pharmaceuticals Incorporated — spoiler alert, I am as bullish, if not more so, than I was back in September, despite a recent sell-off. Vertex's CF franchise remains robust, with TRIKAFTA generating $2.77bn in Q3 revenues and the upcoming Vanzacaftor triple therapy expected to drive further growth. Casgevy, a CRISPR-based therapy for Sickle Cell Disease and TDT, shows promising commercial potential, with multi-billion-dollar peak revenue projections and expanding global approvals.
- 12/11/2024
|
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
- In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $469.29, indicating a -0.99% shift from the previous trading day.
- 12/10/2024
|
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
- Jefferies has upgraded Vertex Pharmaceuticals Inc. VRTX, citing the company's robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion opportunity) and “triple pill” regimens.
- 12/09/2024
|
2 No-Brainer Stocks to Buy Before the End of 2024
- I think the stock market's valuation has become frothy. And I'm in good company; Warren Buffett's actions show that he shares this opinion.
- 12/09/2024
|
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy. The results, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, continue to demonstrate the transformative, durable cli.
- 12/08/2024
|
3 No-Brainer Growth Stocks to Buy in December
- Growth. It's what most investors want more than anything else from their stocks. Some stocks can deliver more of it than others.
- 12/07/2024
|
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
- Things aren't getting much better for Pfizer (PFE -1.29%). The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it has produced during the past two years.
- 12/05/2024
|
Why Is Vertex (VRTX) Down 8.6% Since Last Earnings Report?
- Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
- 12/04/2024
|
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
- Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 12/04/2024
|
GILD vs. VRTX: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors?
- 11/29/2024
|
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
- What you do in the present makes a huge difference in how successful you'll be in the future. This is true in a wide array of activities -- including investing.
- 11/28/2024
|
Vertex Pharma: Why I Am Buying This Dip
- Vertex Pharmaceuticals reported strong Q3 earnings, yet the stock has pulled back, presenting a buying opportunity. The company's robust pipeline, particularly Suzetrigine for acute pain and CASGEVY gene therapy, positions Vertex for significant growth. Vertex's financial health, with no traditional debt and substantial cash reserves, supports its aggressive push into new therapeutic areas and product launches.
- 11/25/2024
|
Got $500? 1 Biotech Stock to Buy and Hold Forever
- Got $500? 1 Biotech Stock to Buy and Hold Forever
- 11/22/2024
|
Buy Signal Flashing For Struggling Biotech
- Biotech Vertex Pharmaceuticals (VRTX) has been struggling on the charts over the past few weeks, putting a dent in its now 10% year-to-date gain. The stock's 5.6% post-earnings pop earlier this month has already been erased, and VRTX is now trading at its lowest level since June.
- 11/20/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM ET Company Participants Stuart Arbuckle - EVP, COO Conference Call Participants Paul Matteis - Stifel Paul Matteis Great, good morning. It's my pleasure to be moderating this chat with Stuart Arbuckle, COO of Vertex Pharmaceuticals.
- 11/19/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
- Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
- 11/19/2024
|
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
- 3 Growth Stocks You Can Buy Right Now Without Any Hesitation
- 11/18/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 9:00 AM ET Company Participants Reshma Kewalramani - President and CEO Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good morning, and thank you for joining Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit, one of the therapeutic analysts, and my privilege to welcome Dr. Reshma Kewalramani, President and CEO of Vertex.
- 11/15/2024
|
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
- Regulators are reviewing what could become a multi-billion-dollar drug.
- 11/13/2024
|
GILD or VRTX: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
- 11/12/2024
|
Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Points
- Meta stock and Nvidia peer Broadcom are among among five S&P 500 stocks on IBD Leaderboard that are near buy points. The post Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Points appeared first on Investor's Business Daily.
- 11/09/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
- Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 11/08/2024
|
2 Biotech Stocks You Can Buy Hand Over Fist This Month
- Both stocks have made significant breakthroughs.
- 11/08/2024
|
Vertex Pharmaceuticals (VRTX) Just Overtook the 20-Day Moving Average
- Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average, which suggests a short-term bullish trend.
- 11/06/2024
|
Vertex Pharmaceuticals (VRTX) Crossed Above the 50-Day Moving Average: What That Means for Investors
- From a technical perspective, Vertex Pharmaceuticals (VRTX) is looking like an interesting pick, as it just reached a key level of support. VRTX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
- 11/06/2024
|
Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 11/05/2024
|
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
- Vertex reported strong Q3 results driven by the growth of the cystic fibrosis franchise and raised the full-year revenue guidance range by $100 million at the mid-point. Casgevy finally generated commercial revenue in Q3 and Vertex continues to work in the background to get treatment centers up and running and patients treated. The VX-880 clinical program is progressing to the pivotal stage and povetacicept generated promising data in membranous nephropathy patients.
- 11/05/2024
|
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
- None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
- 11/05/2024
|
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
- Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.
- 11/05/2024
|
5 Top Stocks to Buy in November
- From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know where to look.
- 11/05/2024
|
My 2 Favorite Growth Stocks to Buy Hand Over Fist in November
- The sky's the limit for these stocks.
- 11/05/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2024 Earnings Call Transcript
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Dr. Reshma Kewalramani - President and CEO Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Jessica Fye - J.P. Morgan Salveen Richter - Goldman Sachs Chris Garcia - Morgan Stanley Mohit Bansal - Wells Fargo Tazeen Ahmad - Bank of America Michael Yee - Jefferies Evan Seigerman - BMO Capital Markets Phil Nadeau - TD Cowen Debjit Chattopadhyay - Guggenheim Partners Olivia Brayer - Cantor Fitzgerald Liisa Bayko - Evercore ISI Operator Good day.
- 11/04/2024
|
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
- Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.
- 11/04/2024
|
Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms
- Vertex Pharmaceuticals beat third-quarter expectations on Monday. Though the company raised its sales outlook, Vertex stock was muted.
- 11/04/2024
|
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
- Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.
- 11/04/2024
|
Vertex Reports Third Quarter 2024 Financial Results
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to $10.8 billion to $10.9 billion. “The third quarter marked another period of strong progress, with continued revenue growth and outstanding execution across the business, and we are again increasing our full-year product revenue guidance,” said Reshma Kewalramani, M.D., Chief.
- 11/04/2024
|
Prediction: Vertex Pharmaceuticals (VRTX) Could Be The Next Stock Split Stock
- Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices.
- 10/31/2024
|
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
- The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $475.08, representing a +1% change from its previous close.
- 10/30/2024
|
Vertex (VRTX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
- Besides Wall Street's top -and-bottom-line estimates for Vertex (VRTX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
- 10/30/2024
|
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
- VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
- 10/29/2024
|
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note
- Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day.
- 10/28/2024
|
Top Stocks To Buy Now? 2 Biotech Stocks To Watch
- Biotech stocks to keep an eye on in the stock market right now.
- 10/28/2024
|
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/28/2024
|
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and APOL1-mediated kidney disease (AMKD). These updates demonstrate the transformative potential of Vertex's investigational therapies in multiple serious kidney diseases, and include positive new data on povetacicept, a dual inhibitor of the BAFF and APRIL pathways, in IgAN and pMN,.
- 10/25/2024
|
The Smartest Growth Stock to Buy With $500 Right Now
- This stock might not be available for under $500 for long.
- 10/25/2024
|
Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
- Its latest report of clinical data suggests it has a winner on its hands.
- 10/24/2024
|
BMY or VRTX: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a better bang for their buck right now?
- 10/22/2024
|
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
- Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 10/22/2024
|
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
- In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $478.09, denoting a -1.02% change from the preceding trading day.
- 10/21/2024
|
Vertex Pharmaceuticals: A Long-Term Growth Monster
- Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown great potential, and their recent M&A activity has proven they can invest intelligently in order to create shareholder value. While the value of their shares has appreciated over 100% over the last 24 months, the company remains fairly valued due to their reliable recurring CF-treatment revenue and robust pipeline.
- 10/21/2024
|
Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030
- There's no need to change a winning formula.
- 10/19/2024
|
Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place from October 18-22, 2024 in Philadelphia, Pennsylvania. Abstract A1187 — “Randomized, Placebo-Controlled, Phase 3 Trials of S.
- 10/18/2024
|
Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
- Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex treatment process and high costs, alongside competition from Bluebird Bio, make the launch challenging. Suzetrigine's potential in chronic pain, a large market with significant unmet needs, could drive substantial revenue if clinical data is positive.
- 10/18/2024
|
Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note
- Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $484.94, moving +0.67% from the previous trading session.
- 10/14/2024
|
Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever
- These profitable companies are facing long-term growth runways.
- 10/13/2024
|
3 No-Brainer Growth Stocks to Buy in October
- These stocks look like slam-dunk picks for growth investors.
- 10/13/2024
|
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
- None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
- 10/11/2024
|
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2024 Earnings Call.” The conference call will be webcast live and a link to the webcast can.
- 10/10/2024
|
2 Biotech Stocks to Buy Hand Over Fist in October
- These longtime leading biotech stocks still have plenty of upside ahead.
- 10/09/2024
|
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
- Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
- 10/09/2024
|
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
- Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $448.16, signifying a -1.57% move from its prior day's close.
- 10/07/2024
|
3 Top Stocks That Could Still Rocket Higher in 2024
- Upcoming Food and Drug Administration decisions could push these stocks through the roof.
- 10/04/2024
|
2 Superior Growth Stocks That Are Screaming Buys Right Now
- These companies have plenty of growth runway left.
- 10/04/2024
|
Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing
- In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $465.08, denoting a +0.48% change from the preceding trading day.
- 09/30/2024
|
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 09/26/2024
|
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor (“vanza triple”) — the potential next-in-class triple combination medicine — will take place at the North American Cystic Fibrosis Conference (NACFC). Vertex also announced presentations describing long-term outcomes in people with cystic fibrosis (CF) ages 2 to 11 years tak.
- 09/26/2024
|
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
- Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 09/25/2024
|
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
- Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $460, moving -1.06% from the previous trading session.
- 09/23/2024
|
The Best Biotech Stock to Invest $1,000 in Right Now
- Vertex Pharmaceuticals is unusually resilient for a biotech stock. The company has spectacular growth prospects with multiple promising late-stage programs.
- 09/22/2024
|
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
- Diversification can help improve your portfolio's prospects in both bull and bear markets. Vertex is a top healthcare stock with an impressive track record and a superior outlook.
- 09/21/2024
|
Biotech stock plays outside of GLP-1 weight-loss market
- BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 weight-loss space. The sky-high demand for GLP-1 weight-loss drugs has led the biotech sector to reach new heights over the last year, and Seigerman believes the trend is as "hot as ever.
- 09/19/2024
|
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
- Moderna hopes to win approvals for 10 programs by 2027. Vertex Pharmaceuticals could have multiple new blockbuster drugs on the market over the next few years.
- 09/18/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Management presents at Cantor Global Healthcare Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Olivia Brayer Joining us this morning at our Cantor Global Healthcare Conference. Really excited to have another year of it.
- 09/17/2024
|
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
- Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.
- 09/16/2024
|
Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
- Vertex stock is significantly undervalued due to the underestimated potential of its pain treatment drug, VX-548, which could become a blockbuster. VX-548 has shown to be more effective than placebos and potentially more powerful than NSAIDs and ibuprofen in post-surgery pain relief. VX-548 appears to fill the therapeutic gap between NSAIDs and opioids.
- 09/15/2024
|
3 Stocks to Buy and Hold Forever
- AbbVie has proved it can adapt to a fast-changing environment. Eli Lilly has a sustainable culture of growth.
- 09/14/2024
|
Prediction: These 3 Phenomenal Stocks Are Set to Soar
- One of these stocks stands to benefit from interest rate cuts that could be on the way. Another will soon launch a new product that could become its most successful ever.
- 09/14/2024
|
Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?
- Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 09/13/2024
|
Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?
- VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.
- 09/11/2024
|
Vertex Pharmaceuticals, Inc. (VRTX) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
- Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Morgan Stanley Conference Call September 5, 2024 11:30 AM ET Company Participants Reshma Kewalramani - President and CEO Charlie Wagner - CFO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley.
- 09/05/2024
|
Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
- Vertex Pharmaceuticals, a leader in Cystic Fibrosis treatment, reported strong financials in Q2 but faces limited growth in CF due to high market penetration. Despite a GAAP net loss in Q2, Vertex remains highly profitable, with promising assets like Casgevy and Suzetrigine poised for future growth. Vertex's high valuation ratios suggest potential overvaluation, but its focused pipeline and blockbuster potential justify optimism for significant long-term revenue growth.
- 09/05/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
- Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
- 09/02/2024
|
3 No-Brainer Stocks to Buy in September
- Eli Lilly is a growth machine that never runs out of opportunities. Novo Nordisk is still gaining momentum.
- 08/31/2024
|
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
- Abbott Labs produces medications as just one of its revenue sources. AbbVie has shown a knack for expanding the markets of its drugs.
- 08/30/2024
|
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
- Vertex enjoys a monopoly that could soon grow stronger. The company could have multiple potential blockbuster drugs on the way.
- 08/30/2024
|
Jupiter Endovascular Receives FDA Approval for U.S. Pivotal Study of Vertex Pulmonary Embolectomy System Using Endoportal Control
- MENLO PARK, Calif.--(BUSINESS WIRE)-- #FDA--FDA approves U.S. pivotal trial of Jupiter Endovascular pulmonary embolism system with Endoportal Control technology.
- 08/29/2024
|
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
- Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.
- 08/28/2024
|
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
- Vertex Pharmaceuticals is different from Novo Nordisk in several ways. The two companies could compete against each other in the future.
- 08/23/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
- Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 08/21/2024
|
These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond
- Healthcare and tech remain top areas for long-term investors. Vertex Pharmaceuticals is looking ahead to several near-term launches, while its existing portfolio remains robust.
- 08/18/2024
|
3 Fantastic Growth Stocks to Buy in August
- Eli Lilly is a biopharma giant that could still deliver strong growth. Novo Nordisk's growth story isn't over thanks to Ozempic, Wegovy, and a promising pipeline.
- 08/17/2024
|
BMY vs. VRTX: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors?
- 08/15/2024
|
Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why
- Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.
- 08/15/2024
|
3 Biotech Stocks to Buy on the Dip: August 2024
- With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many of the most prominent biomedical developers see their stock price rise or fall based on their drug success.
- 08/15/2024
|
Prediction: These 4 Future Technologies Will Be Millionaire-Makers -- and Here Are the Top Stocks to Buy Now to Profit From Them
- Investors should focus on the future, not the past. Four emerging technologies hold tremendous potential.
- 08/15/2024
|
2 Biotech Stocks To Watch In August 2024
- Biotech stocks to keep on your radar this month.
- 08/13/2024
|
2 Biotech Stocks to Buy Hand Over Fist in August
- Vertex's newest approval and late-stage pipeline should yield stronger financial results. Smaller biotech Sarepta Therapeutics continues to innovate in its core therapeutic area.
- 08/12/2024
|
The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna
- Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.
- 08/09/2024
|
Here's How to Play Vertex (VRTX) Stock After Q2 Loss, Price Dip
- Vertex (VRTX) is a great stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.
- 08/08/2024
|
The 3 Best Biotech Stocks to Buy in August 2024
- Amid the stock market turmoil, wagering on the best biotech stocks could be a savvy move. The stock market has been tumultuous lately, which could spur a pivot toward defensive biotech stocks.
- 08/08/2024
|
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
- LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel), from today. The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY's use in the NHS. The United Kingdom (U.K.) Medicines and Healthcare p.
- 08/07/2024
|
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
- 08/06/2024
|
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
- Vertex Pharmaceuticals is a rare-disease drugmaker with over $10 billion in annual sales. The company's lead drug is the only available treatment for cystic fibrosis, a life-threatening progressive disease.
- 08/06/2024
|
Investing in biotech outside of weight-loss drugs
- GLP-1 weight-loss drugs have pushed the biotech sector to new heights as demand steadily increases. But despite the drugs' popularity, there are other investment opportunities within the biotech sector.
- 08/05/2024
|
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
- These growth stocks are leading in their respective markets. Vertex Pharmaceuticals is the dominant force in the cystic fibrosis treatment industry, but it is in the midst of a multiyear period during which it's targeting multiple blockbuster launches.
- 08/05/2024
|
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
- The biotech industry, often recognized for its rapid innovation, can set investors up for outsized returns in the stock market. However, not all biotech companies have the capability of doing so.
- 08/04/2024
|
3 Unstoppable Stocks to Buy in August
- Novo Nordisk is big but has plenty of room to grow. Vertex Pharmaceuticals' existing products and pipeline programs give it multiple growth catalysts.
- 08/03/2024
|
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
- Johnson & Johnson hasn't performed that well in the past decade. By contrast, Vertex Pharmaceuticals and Intuitive Surgical have been exceptional.
- 08/03/2024
|
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/02/2024
|
Vertex Raises Guidance Despite Q2's Bottom-Line Losses
- Product revenues increased by 6% to $2.65 billion, in line with market expectations. Management raised full-year product revenue guidance by $100 million.
- 08/02/2024
|
3 Biotech Stocks That Could Have Investors Grinning Soon
- Investing in biotech stocks is a thrilling ride. These innovative businesses developing breakthrough drugs can generate enormous profits for investors but also destroy significant value if their investigational therapies fail to make it to market.
- 08/02/2024
|
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
- Thursday, Vertex Pharmaceuticals Incorporated VTRX reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion.
- 08/02/2024
|
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
- Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.
- 08/02/2024
|
Should You Invest in Vertex (VRTX) Based on Bullish Wall Street Views?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 08/02/2024
|
Vertex Pharma: Driving Growth Through Suzetrigine And Next-Gen Cystic Fibrosis Treatment
- Vertex Pharmaceuticals has consistently outperformed the S&P 500 and iShares Biotechnology ETF, reflecting its robust growth and market position. VRTX's diversified pipeline includes cystic fibrosis treatment, Vanzacaftor Triple, and the non-opioid pain management drug Suzetrigine, both with PDUFA dates expected in January 2025. Positioning the company for substantial future growth. The potential approvals of Vanza Triple will reinforce the Company's leadership in CF, while Suzetrigine's and the NOPAIN Act in 2025 will facilitate its entry into the lucrative pain management market.
- 08/02/2024
|
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
- There's a simple explanation for Vertex's glaring Q2 loss. The company raised its full-year product revenue guidance.
- 08/02/2024
|
Vertex Pharmaceuticals, Inc. (VRTX) Q2 2024 Earnings Call Transcript
- Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Reshma Kewalramani - Chief Executive Officer, President Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer. Susie Lisa - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs David Risinger - Leerink Partners Jessica Fye - J.P.
- 08/01/2024
|
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
- Vertex Pharmaceuticals (VRTX) came out with a quarterly loss of $12.83 per share versus the Zacks Consensus Estimate of a loss of $11.50. This compares to earnings of $3.89 per share a year ago.
- 08/01/2024
|
Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatments
- Vertex Pharmaceuticals raised its annual revenue forecast on Thursday, betting on robust demand for its cystic fibrosis (CF) treatments.
- 08/01/2024
|
Vertex Reports Second Quarter 2024 Financial Results
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2024, and raised its full year product revenue guidance to $10.65 to $10.85 billion. “Vertex delivered another strong quarter of revenue growth coupled with outstanding execution across the business, and we are increasing our full year product revenue guidance,” said Reshma Kewalramani, M.D., Chief Executive Officer, and President of Ver.
- 08/01/2024
|
Got $500? 2 Compelling Growth Stocks to Buy and Hold Forever
- Investing cash in great businesses can set your portfolio up for long-term success. Vertex is paving a profitable path from a portfolio of existing and likely blockbusters.
- 08/01/2024
|
The Top 3 Biotech Stocks to Buy Now Summer 2024
- In the bustling world of biotechnology, innovation remains the cornerstone of growth. Some biotech stocks, known for their groundbreaking research and rapid adaptation to health challenges, are particularly well-positioned to do well in the future.
- 07/31/2024
|
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
- Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
- 07/30/2024
|
Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration
- LOS ANGELES--(BUSINESS WIRE)--Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration.
- 07/30/2024
|
BMY vs. VRTX: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?
- 07/30/2024
|
Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?
- Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
- 07/29/2024
|
Curious about Vertex (VRTX) Q2 Performance? Explore Wall Street Estimates for Key Metrics
- Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
- 07/29/2024
|
2 No-Brainer Growth Stocks to Buy With $1,000 Right Now
- These businesses are on very different growth trajectories in opposite industries, but each can have something to offer the long-term investor. Vertex Pharmaceuticals is building out a pipeline of potential blockbusters that could rival its current portfolio.
- 07/28/2024
|
Is Vertex Pharmaceuticals' Monopoly in Danger?
- Vertex's dominance in the cystic fibrosis drug market could be challenged. Even in the worst-case scenario, its challenger's products won't be launched soon.
- 07/25/2024
|
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
- Vertex Pharmaceuticals has built a billion-dollar cystic fibrosis business over time. But the company today may be preparing for a new era of growth, thanks to the strength of its pipeline.
- 07/25/2024
|
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
- In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $490.80, denoting a +0.1% change from the preceding trading day.
- 07/24/2024
|
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
- Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 07/24/2024
|
7 Biotech Stocks to Keep on Your Clinical Radar
- Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.
- 07/23/2024
|
Here's Why Vertex Pharmaceuticals (VRTX) Gained But Lagged the Market Today
- In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $495.91, indicating a +0.88% shift from the previous trading day.
- 07/22/2024
|
3 Gene Editing Stocks Shaping the Future of Medicine
- Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.
- 07/22/2024
|
2 Historically Flawless Metrics Suggest the Stock Market Can Plunge: Here Are 3 Stocks I've Sold Ahead of What May Be a Big Move for Wall Street
- U.S. M2 money supply has done something that no one has witnessed since the Great Depression. Meanwhile, the benchmark S&P 500 is at one of its priciest valuations in history.
- 07/21/2024
|
The 3 Best Neuroscience Biotech Stocks to Buy Now
- Problems with the central nervous system are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it's extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website Labiotech reported last year.
- 07/19/2024
|
3 Gene Editing Stocks That Could Grow Your Wealth
- Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals.
- 07/17/2024
|
Add These 5 Hot Biotech Stocks In July
- Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing in companies that are working to treat or heal medical ailments that cause issues for people around the world.
- 07/17/2024
|
The Zacks Analyst Blog ASML, SAP, Nvidia, Vertex and EssilorLuxxottica
- ASML, SAP, Nvidia, Vertex and EssilorLuxxottica are included in this Analyst Blog.
- 07/16/2024
|
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
- Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $490.85, signifying a +0.43% move from its prior day's close.
- 07/15/2024
|
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
- Vertex Pharmaceuticals and Axsome Therapeutics are moving toward key regulatory approvals. Thanks to solid tailwinds, both biotechs should handsomely reward investors over the long run.
- 07/15/2024
|
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
- Many top companies have announced stock splits this year after their shares surged in recent times. These operations lower the price of each individual share, making the stock more accessible for a broader range of investors.
- 07/15/2024
|
Got $1,000? 2 Incredible Growth Stocks to Buy and Hold Forever
- These healthcare businesses are booming. Vertex Pharmaceuticals is raking in approvals, cash, and profits.
- 07/14/2024
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
- 07/10/2024
|
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
- Vertex's stock has risen 18% since last December, matching the SPY index, bolstered by promising Phase 2 data for VX-548 in diabetic peripheral neuropathy. Vertex is expanding into gene therapies and other rare disease treatments, recently acquiring Alpine Immune Sciences for $4.9 billion to enhance its rare disease pipeline. Q1 2024 earnings exceeded expectations with a 13% revenue increase, primarily from their cystic fibrosis drug, Trikafta/Kaftrio.
- 07/09/2024
|
3 No-Brainer Stocks to Buy in July
- Eli Lilly could be headed for a market capitalization above $1 trillion. Regeneron has overcome bumps and shows no signs of slowing down.
- 07/08/2024
|
3 Pharma Stocks Already Ushering in the Next Biotech Boom
- Let's get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative.
- 07/08/2024
|
Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).
- Vertex has built an empire from cystic fibrosis treatment, generating billions of dollars in annual revenue. The company is set to dominate the market through the late 2030s -- and possibly beyond.
- 07/06/2024
|
The 3 Best Biotech Stocks to Buy in July 2024
- Investing in biotech can be pretty unpredictable. Biotech stocks are highly volatile, and picking carefully can be the difference between losing all your capital and making unimaginable profits.
- 07/05/2024
|
1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever
- Vertex Pharmaceuticals has significantly outpaced the market in the past few decades. The company owes its performance to a well-defined strategy and its innovative abilities.
- 07/05/2024
|
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
- Vertex Pharmaceuticals is working on a therapy to treat diabetes. The latest data about that therapy's performance looks solid.
- 07/05/2024
|
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
- Amgen is much cheaper than Eli Lilly. Vertex Pharmaceuticals has several major growth drivers.
- 07/04/2024
|
3 Top-Rated Gene Editing Stocks Actually Making Money
- Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9.
- 07/03/2024
|
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
- The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.
- 07/03/2024
|
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
- One of the most important sectors in any country's economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results.
- 07/02/2024
|
3 Breakout Biotech Stocks on Track to Double by 2032
- With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful selection of industry leaders.
- 07/01/2024
|
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
- If you have some cash on hand to invest long term, there are plenty of stocks begging to be bought. Vertex expects several product launches even as its mainstay portfolio continues to drive profitability.
- 07/01/2024
|
2 Superior Growth Stocks to Buy if You Have $1,000 Right Now
- The rare disease drug industry is fast-growing, while the music streaming space is also expanding at a rapid clip. Vertex is raking in profits from its cystic fibrosis drug franchise, but is also planning new additions to its portfolio.
- 06/28/2024
|
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
- Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH.
- 06/28/2024
|
2 Healthcare Stocks That Are Screaming Buys in June
- A rare-disease drugmaker and a top pharmaceutical stock have what it takes to deliver solid returns over the long run. Vertex Pharmaceuticals' flagship business continues to expand market share and profits.
- 06/28/2024
|
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
- While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
- 06/27/2024
|
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- 06/27/2024
|
3 Biotech Stocks That Could Make Your Grandchildren Rich
- In the world of investing, biotech stocks represent a unique blend of high risk and high reward. After a period of volatility in the broader markets in 2022 and 2023, biotech stocks are now drawing attention for their potential to deliver substantial long-term returns.
- 06/27/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
- Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 06/26/2024
|
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
- Vertex Pharmaceuticals recently turned heads with clinical trial results for VX-880, an off-the-shelf cellular therapy for type 1 diabetes patients. Treatment with VX-880 helped patients produce insulin independently and reduced their reliance on daily injections.
- 06/25/2024
|
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
- Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $474.95, signifying a +1.33% move from its prior day's close.
- 06/24/2024
|
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 06/24/2024
|
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive.
- 06/21/2024
|
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
- This magnificent drugmaker is much smaller than Eli Lilly, but is still large and successful. It has massive growth opportunities in multiple markets.
- 06/21/2024
|
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
- In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $467.28, indicating a -1.35% shift from the previous trading day.
- 06/18/2024
|
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation
- Vertex Pharmaceuticals has a lock on its market, generating funds for its R&D pipeline. Costco Wholesale is a near-perfect fit for its market.
- 06/18/2024
|
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
- Eli Lilly appears to be on course to become the first trillion-dollar healthcare stock. Novo Nordisk is one of the best ways to profit from the fast-growing obesity drug market.
- 06/15/2024
|
Final Trades: Nvidia, Abbvie, ConocoPhillips and Vertex Pharma
- The Investment Committee share their top stocks to watch for the second half.
- 06/14/2024
|
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the annual European Hematology Association (EHA) Congress, confirm the transformative, consistent and durable clinical benefits of CASGEVY over time. CASGEVY is the first and only approved.
- 06/14/2024
|
Vortex Energy Corp. Announces Private Placement
- NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 13, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it intends to complete a non-brokered private placement financing (the “Private Placement”) of up to 4,000,000 units of the Company (the “Units”) at a price of $0.25 per Unit for aggregate gross proceeds of up to $1,000,000. Each Unit shall consist of one common share (each a “Share”) and one common share purchase warrant (each a “Warrant”), with each Warrant entitling the holder thereof to purchase a Share at an exercise price of $0.30 for a period of 24 months from the date of issuance.
- 06/13/2024
|
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
- Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $475.79, signifying a -1.19% move from its prior day's close.
- 06/12/2024
|
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
- Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
- 06/12/2024
|
2 Healthcare Stocks to Buy Hand Over Fist in June
- Vertex Pharmaceuticals and Abbott Laboratories are innovative healthcare leaders. Both companies have robust businesses and excellent potential opportunities.
- 06/12/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 11:20 AM ET Company Participants David Altshuler - Chief Scientific Officer Charles Wagner - CFO Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good morning, everyone.
- 06/11/2024
|
Vertex Shares Rising on Expanded Therapy Offerings
- Global biotechnology company Vertex Pharmaceuticals Incorporated (VRTX) is a market-beating outlier stock.
- 06/11/2024
|
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 06/07/2024
|
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
- The top five biotech stocks today have several commonalities. Among them are strong ratings.
- 06/07/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) The 44th Annual William Blair Growth Stock Conference
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) The 44th Annual William Blair Growth Stock Conference June 4, 2024 5:00 PM ET Company Participants Reshma Kewalramani - Chief Executive Officer Conference Call Participants Myles Minter - William Blair Sami Corwin - William Blair Myles Minter All right, thank you very much. Welcome back to the William Blair Growth Stock Conference, the 44th Edition, as I understand it.
- 06/07/2024
|
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the European Union and in the U.K. as KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, were presented at this year's European Cystic Fibrosis Society's (ECFS) 47th European Cystic Fibrosis Conference held June 5-8, 2024, in Glasgow, Scotland. Data from a randomized, double-blind, Phase 3 study.
- 06/07/2024
|
Why Is Vertex (VRTX) Up 15.8% Since Last Earnings Report?
- Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
- 06/05/2024
|
Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
- Biotech companies, like Vertex Pharmaceuticals, benefit from patents, driving consistent growth. Vertex excels in cystic fibrosis treatments and boasts a promising pipeline of new drugs. Vertex's innovation spans pain management and kidney health, with late-stage developments like Vanzacaftor showing significant promise. Its non-opioid painkiller, Suzetrigine, could revolutionize pain management. Vertex's strong financials and growth potential make it a compelling investment. The company's strategic focus on innovation positions it for long-term success.
- 06/04/2024
|
Health Care Stocks Show Relative Strength as S&P 500 Stalls
- Several stocks are breaking out and trading near all-time highs.
- 06/04/2024
|
3 No-Brainer Stocks to Buy in June
- AbbVie covers all the bases for investors -- income, value, and growth. AstraZeneca is an inexpensive stock that has solid growth opportunities.
- 06/02/2024
|
5 Top Stocks to Buy in June
- SoundHound and Adobe offer two distinctly different ways to invest in AI. Vertex Pharmaceuticals continues to deliver for its shareholders.
- 06/02/2024
|
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
- Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.
- 06/01/2024
|
Vertex: Poised For Long-Term Growth Driven By Multiple Pipeline Catalysts
- Vertex Pharmaceuticals has a strong focus on cystic fibrosis, which is driving revenue growth and pipeline development. The company has outperformed Johnson & Johnson and the S&P 500 in terms of total returns. Near-term catalysts include advancements in CF treatment, pain treatment, sickle cell & beta thalassemia, type I diabetes, and IgA nephropathy.
- 05/30/2024
|
Why Vertex Pharmaceuticals (VRTX) is a Top Growth Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 05/30/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
- Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 05/30/2024
|
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
- Abbott and DexCom depend heavily on continuous glucose monitoring (CGM) device sales. Vertex is developing therapies that could cure type 1 diabetes.
- 05/30/2024
|
Got $500? 3 Pharma Stocks to Buy and Hold Forever
- Vertex Pharmaceuticals is in the midst of a major diversification plan. Eli Lilly's medicines for diabetes and obesity are incredibly hot sellers.
- 05/26/2024
|
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
- Vertex has achieved significant growth in recent years, but things have slowed lately. The company has many potential catalysts that could accelerate its growth rate.
- 05/26/2024
|
2 Biotech Stocks to Buy in May
- Vertex is diversifying, moving beyond a therapeutic area it has thoroughly dominated. Regeneron has three important growth drivers and a pipeline that should produce more.
- 05/25/2024
|
3 High-Flying Stocks That Could Soar Even More
- Eli Lilly is just getting started with its powerful obesity drug and a loaded pipeline. It's not too late to invest in scorching-hot Novo Nordisk.
- 05/25/2024
|
New Pain Drug Could Be Big For Vertex Stock As Shares Score Breakout
- Cystic fibrosis treatment leader Vertex scored a breakout from a cup base this week, just a few weeks after an earnings beat.
- 05/24/2024
|
Vertex to Participate in Upcoming June Investor Conferences
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4, 2024 at 4:00 p.m. CT. Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific O.
- 05/22/2024
|
Final Trades: Walmart, Vertex and the SMH
- The Investment Committee gives you their top stocks to watch for the second half.
- 05/22/2024
|
Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress
- While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
- 05/21/2024
|
Meridian Wealth Management LLC Has $323,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
- Meridian Wealth Management LLC lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 4.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 794 shares of the pharmaceutical company’s stock after purchasing an additional 31 shares during the quarter. Meridian Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $323,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds also recently made changes to their positions in VRTX. Arlington Trust Co LLC grew its stake in Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 33 shares during the period. Fortitude Family Office LLC bought a new stake in Vertex Pharmaceuticals during the 4th quarter worth approximately $30,000. Baystate Wealth Management LLC lifted its position in Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 25 shares in the last quarter. NBC Securities Inc. acquired a new position in shares of Vertex Pharmaceuticals during the third quarter worth about $34,000. Finally, Asset Dedication LLC boosted its position in Vertex Pharmaceuticals by 131.8% during the 3rd quarter. Asset Dedication LLC now owns 102 shares of the pharmaceutical company’s stock worth $35,000 after acquiring an additional 58 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock. Analyst Upgrades and Downgrades A number of analysts have recently commented on the stock. Wolfe Research initiated coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, February 15th. They issued an “outperform” rating and a $515.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $462.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 7th. JPMorgan Chase & Co. upped their target price on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Sanford C. Bernstein cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, February 2nd. Finally, StockNews.com raised Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $432.18. Get Our Latest Analysis on Vertex Pharmaceuticals Insider Activity at Vertex Pharmaceuticals In other news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is currently owned by corporate insiders. Vertex Pharmaceuticals Stock Up 1.0 % VRTX stock opened at $445.21 on Monday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $320.01 and a fifty-two week high of $448.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. The stock has a market capitalization of $114.89 billion, a price-to-earnings ratio of 28.89, a PEG ratio of 2.13 and a beta of 0.39. The business’s fifty day moving average price is $409.75 and its two-hundred day moving average price is $404.53. Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, topping the consensus estimate of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business had revenue of $2.69 billion during the quarter, compared to analysts’ expectations of $2.58 billion. During the same quarter in the previous year, the company earned $2.67 EPS. The business’s revenue was up 13.3% on a year-over-year basis. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.28 earnings per share for the current year. About Vertex Pharmaceuticals (Free Report) Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
- 05/20/2024
|
Jennifer Schneider Elected to Vertex Board of Directors
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more than two decades of experience in the health care industry as a physician, scientist and health care executive. She co-founded and serves as Chief Executive Officer of Homeward Health, a company committed to rearchitecting the delivery of health and care for nearly 60 million.
- 05/15/2024
|
Final Trades: Pfizer, Vertex, Freeport-McMoran and Qualcomm
- The Investment Committee give you their top stocks to watch for the second half.
- 05/14/2024
|
Vertex Is Writing A New Playbook For Pharma R&D. And It's Working.
- Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way, just may have authored a new playbook for life sciences R&D.
- 05/14/2024
|
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 05/14/2024
|
3 Cheap Biotech Stocks to Buy Now: May 2024
- The biotech industry is notably risky, but can produce stocks that see massive gains within a day. How can this happen?
- 05/14/2024
|
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy
- Vertex Pharmaceuticals is inching closer to a new approval in its central therapeutic area. The company's lineup is getting stronger, and its pipeline is progressing smoothly.
- 05/12/2024
|
2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade
- The healthcare and beauty spaces are two significantly large industries. Vertex Pharmaceuticals is capitalizing on the success of its mainstay products while working aggressively towards a stream of new product approvals.
- 05/12/2024
|
Will the Biotech Sector Shift From Lagger to Leader?
- The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).
- 05/10/2024
|
Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
- Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 05/08/2024
|
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
- Since 2012, Vertex has been the only drugmaker with treatments that address the root cause of cystic fibrosis. Vertex Pharmaceuticals recently received FDA approval for a gene therapy developed in partnership with CRISPR Therapeutics.
- 05/08/2024
|
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
- Vertex's (VRTX) first-quarter earnings and revenues surpass estimates. Higher sales of Trikafta/Kaftrio in U.S. and ex-U.S. markets drive the top line.
- 05/07/2024
|
Vertex Pharmaceuticals, Inc. (VRTX) Q1 2024 Earnings Call Transcript
- Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Susie Lisa - SVP, IR Reshma Kewalramani - CEO, President & Director Stuart Arbuckle - EVP & COO Charles Wagner - EVP & CFO Conference Call Participants Geoff Meacham - Bank of America Merrill Lynch Jessica Fye - JPMorgan Chase & Co. Salveen Richter - Goldman Sachs Group Olivia Brayer - Cantor Fitzgerald & Co. Liisa Bayko - Evercore ISI Terence Flynn - Morgan Stanley Debjit Chattopadhyay - Guggenheim Securities Evan Seigerman - BMO Capital Markets Philip Nadeau - TD Cowen Colin Bristow - UBS Operator Good day, and welcome to the Vertex Pharmaceuticals First Quarter 2024 Earnings Conference Call. [Operator Instructions].
- 05/06/2024
|
Vertex Pharmaceuticals Shines in the First Quarter
- Vertex's strong revenue growth was driven by Trikafta/Kaftrio sales, particularly in international markets. The biotech acquired Alpine Immune Sciences, and advanced several pipeline candidates.
- 05/06/2024
|
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates
- Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.76 per share, beating the Zacks Consensus Estimate of $4.10 per share. This compares to earnings of $3.05 per share a year ago.
- 05/06/2024
|
Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
- Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its cystic fibrosis treatments.
- 05/06/2024
|
Vertex Reports First Quarter 2024 Financial Results
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance. “Vertex delivered a strong start to 2024 with 13 percent product revenue growth and outstanding execution across the business. This quarter, we continued to expand our leadership in CF including completion of the regulatory submissions for the vanzacaftor triple, advanced the global.
- 05/06/2024
|
3 Biotech Stocks to Double Your Money in the Next 24 Months
- The biotechnology sector is renowned for its potential to deliver groundbreaking medical treatments while offering investors the possibility of significant returns. However, investing in these companies requires a nuanced understanding of their pipelines, regulatory landscapes and market dynamics.
- 05/06/2024
|
3 No-Brainer Stocks to Buy in May
- It's always a good time to buy shares of Eli Lilly. Pfizer is undervalued and underrated.
- 05/05/2024
|
Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radar
- Gene editing stocks are among the most intriguing in the biotech scene. The genomics revolution may be as exciting as the ongoing artificial intelligence one.
- 05/03/2024
|
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
- Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command exorbitant prices.
- 05/03/2024
|
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
- The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $400.16, representing a -0.49% change from its previous close.
- 05/02/2024
|
Unveiling Vertex (VRTX) Q1 Outlook: Wall Street Estimates for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Vertex (VRTX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
- 05/01/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
- Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 05/01/2024
|
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
- Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/29/2024
|
2 Top Growth Stocks to Buy Right Now and Hold Forever
- The healthcare industry tends to do well in all types of economies. Vertex just garnered a new blockbuster approval, and more could be around the corner.
- 04/28/2024
|
Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades.
- Amazon has multiple business moats and ways to continue growing. MercadoLibre is well positioned to capitalize on the massive opportunities in Latin America.
- 04/27/2024
|
2 Fantastic Growth Stocks to Buy Right Now
- Healthcare and digital advertising are mammoth industries. Vertex is widening its moat across the rare disease drug market.
- 04/25/2024
|
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
- Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
- 04/23/2024
|
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
- Vertex has built a billion-dollar business thanks to its expertise in treating cystic fibrosis. The biotech stock is cheaper today than it was earlier this year in relation to expected earnings.
- 04/23/2024
|
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today
- Vertex is a leader in cystic fibrosis treatment but also is showing it can succeed in other disease areas. The company recently won approval for a gene-editing treatment for blood disorders.
- 04/22/2024
|
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
- One of these magnificent stocks could be a big winner in a new $4 trillion market. Another is a leader in using AI to automate online processes.
- 04/22/2024
|
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
- Great pharma companies tend to be entrenched in lucrative markets. Vertex Pharmaceuticals is managing to diversify off a strong base.
- 04/20/2024
|
3 Relatively Safe Growth Stocks You Can Buy and Hold
- Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.
- 04/20/2024
|
3 Biotech Stocks Set to Double by 2028
- Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies possesses the potential to deliver substantial returns in the coming years.
- 04/20/2024
|
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
- Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
- 04/19/2024
|
Is Vertex Pharmaceuticals Stock a Millionaire Maker?
- Vertex is growing beyond its highly successful cystic fibrosis business and into other areas of healthcare. The added growth opportunities should accelerate its growth rate, which slowed down last year.
- 04/19/2024
|
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
- Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $4.9 billion. Alpine Immune Sciences' leading candidate looks highly promising.
- 04/18/2024
|
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
- Vertex Pharmaceuticals (VRTX) closed at $394.17 in the latest trading session, marking a -0.8% move from the prior day.
- 04/16/2024
|
Is Vertex (VRTX) a Buy as Wall Street Analysts Look Optimistic?
- When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
- 04/16/2024
|
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
- Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 04/15/2024
|
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
- Vertex Pharmaceuticals is acquiring Alpine Immune Sciences. Alpine's lead asset could have a plurality of potential uses.
- 04/15/2024
|
Could This Stock Be the Next Biotech Buyout?
- Vera Therapeutics is developing a dual-action antibody to treat kidney disorders, with successful results from the first portion of a pivotal study. Recently, Vertex Pharmaceuticals acquired Alpine Immune Sciences, another company developing an antibody that binds to the same receptors as Vera Therapeutics' candidate.
- 04/13/2024
|
US biopharma first quarter earnings seen stable amid low expectations
- Expectations for US biopharma companies' first quarter earnings are low given the typical seasonality across the sector and new healthcare plan signups, analysts at the Bank of America believe. “We don't expect many guidance changes; a stable earnings season should warrant continued generalist interest in biopharma,” the analysts wrote in a note.
- 04/12/2024
|
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
- Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Immune stock fairly valued at $65?
- 04/11/2024
|
Vertex Pharmaceuticals: Buy, Sell, or Hold?
- Vertex generated nearly $10 billion in sales last year from its cystic fibrosis drugs. However, the giant drugmaker has seen its growth rate slow from a year ago.
- 04/11/2024
|
Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
- Vertex Pharmaceuticals Inc.'s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company's rare-disease franchise, analysts said Thursday.
- 04/11/2024
|
Alpine Immune Sciences soars on $4.9bn Vertex takeover
- Alpine Immune Sciences Inc shares continued higher in pre-market trading, after soaring on Wednesday following news of the firm's US$4.9 billion takeover by Vertex Pharmaceuticals Incorporated. Shares climbed 36.3% to US$64.10 before the market opened, adding to Wednesday's 20.8% gain.
- 04/11/2024
|
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch
- Vertex Pharmaceuticals (VRTX) will acquire clinical-stage immunotherapy company Alpine Immune Sciences (ALPN) in a deal valued at around $4.9 billion, both companies said Wednesday.
- 04/10/2024
|
Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal
- Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.
- 04/10/2024
|
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
- Vertex Pharmaceuticals (VRTX) reachead $397.58 at the closing of the latest trading day, reflecting a -1.71% change compared to its last close.
- 04/10/2024
|
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
- Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to heat up.
- 04/10/2024
|
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
- Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed.
- 04/10/2024
|
Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln
- Vertex Pharmaceuticals will acquire therapy developer Alpine Immune Sciences for $65 per share, or about $4.9 billion in cash, the companies said on Wednesday.
- 04/10/2024
|
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
- A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
- 04/10/2024
|
Vertex to Announce First Quarter 2024 Financial Results on May 6
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2024 Earnings Call.” The conference call will be webcast live and a link to the webcast can be a.
- 04/09/2024
|
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
- Vertex Pharmaceuticals is starting a late-stage study for a promising candidate. In a best-case scenario, it could be as successful as the biotech's current top-seller.
- 04/09/2024
|
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul
- The healthcare industry is full of promising opportunities for every type of investor. UnitedHealth Group's established presence spans insurance to managed care services.
- 04/05/2024
|
3 Underappreciated Healthcare Stocks to Buy Now: April 2024
- The healthcare sector is a constant source of innovation and growth. Yet, even amidst the spotlight on industry giants, a realm of underappreciated gems still exists.
- 04/03/2024
|
Biotech Sector Nears Breakout: Will it Outperform in Q2?
- The popular iShares Biotechnology ETF NASDAQ: IBB has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout.
- 04/03/2024
|
Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
- Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.
- 04/02/2024
|
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
- In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $420.48, denoting a +0.59% change from the preceding trading day.
- 04/01/2024
|
1 Top Growth Stock to Buy and Hold Forever
- Vertex Pharmaceuticals has an impeccable track record of innovation. The company recently reported important clinical progress.
- 03/31/2024
|
Brokers Suggest Investing in Vertex (VRTX): Read This Before Placing a Bet
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 03/28/2024
|
Three top U.S. biotech stocks to buy in April
- “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.
- 03/28/2024
|
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
- As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performance relative to the broader market.
- 03/26/2024
|
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
- In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.
- 03/25/2024
|
Vertex (VRTX) Continues to Diversify Beyond CF Franchise
- While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.
- 03/25/2024
|
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
- Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.
- 03/22/2024
|
Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
- Vertex Pharmaceuticals has a dominant Cystic fibrosis franchise and plans to launch five new products by 2028, including a next-generation CF drug and a non-opioid pain management drug. VRTX stock has stalled in 2024 due to lower revenue growth projections for the year, which is unappealing for growth investors. The long-term potential of its drug pipeline may justify buying for long-term growth investors.
- 03/21/2024
|
3 Biopharma Stocks Predicted to Soar in Q2 2024
- Biopharma stocks have been among the most popular and well-performing stocks this year. With recent trends in weight loss drugs and clinical advancements in treating illnesses, this market is set for significant advances this year.
- 03/20/2024
|
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
- Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
- 03/19/2024
|
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
- In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $411.38, denoting a +0.91% change from the preceding trading day.
- 03/18/2024
|
2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
- Vertex Pharmaceuticals is still making progress in its core area while diversifying its lineup. HCA Healthcare's entrenched position in its industry will help it benefit from long-term trends.
- 03/17/2024
|
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
- Investors need not be concerned about the FDA's approval delay for Eli Lilly's Alzheimer's drug. Novo Nordisk recently picked up a regulatory win that makes the stock even more attractive.
- 03/17/2024
|
Forget Tesla, Buy This Magnificent Healthcare Stock Instead
- Tesla faces an uncertain future as rising competition and shrinking margins are putting pressure on its business. Vertex Pharmaceuticals has a bright future ahead with multiple growth catalysts, which can bolster its top line.
- 03/17/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Leerink Partners Global Biopharma Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Leerink Partners Global Biopharma Conference Call March 11, 2024 4:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief Financial Officer David Altshuler - Chief Scientific Officer Conference Call Participants David Risinger - Leerink Partners David Risinger Good afternoon, everyone. My name is Dave Risinger.
- 03/11/2024
|
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
- Madrigal Pharmaceuticals could be days away from winning its first FDA approval. Regeneron Pharmaceuticals expects several key regulatory decisions this year.
- 03/09/2024
|
The Top 3 Biotech Stocks to Buy in March 2024
- Investing in biotechnology (biotech) stocks is often thought of as being too risky for most investors. That's not necessarily the case.
- 03/06/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 44th Annual Health Care Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) TD Cowen 44th Annual Health Care Conference Call March 5, 2024 10:30 AM ET Company Participants David Altshuler - Executive Vice President, Research and Chief Scientific Officer Charlie Wagner - Executive Vice President and Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen's 44th Annual Healthcare Conference. I am Phil Nadeau, one of the biotech analysts, and it's my pleasure to moderate a fireside chat with Vertex, one of the bellwethers of the industry.
- 03/05/2024
|
GSK vs. VRTX: Which Stock Is the Better Value Option?
- Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with GSK (GSK) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
- 03/05/2024
|
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
- Vertex Pharmaceuticals is angling to treat acute pain with its new drug. Compass Pathways will have a major data update sometime in Q4.
- 03/05/2024
|
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
- The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment opportunities in 2024.
- 03/05/2024
|
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
- If you're looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ: IBB ) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U.S. companies in the biotech industry.
- 03/04/2024
|
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
- ChatGPT stock predictions could be more than shots in the dark by AI. The processing and inferential power of artificial intelligence progresses seemingly exponentially every day.
- 03/04/2024
|
3 Magnificent Growth Stocks to Buy in March
- Eli Lilly could have the world's future best-selling drug in its lineup. Moderna is poised to expand beyond COVID with several new products potentially on the way.
- 03/02/2024
|
These 4 Stocks Are the "Magnificent Seven" of Healthcare
- The Magnificent Seven are stealing the show this year on the market. They're all technology companies -- but there are opportunities elsewhere, too.
- 03/01/2024
|
3 Biotech Stocks Bound to Blast Off By 2029
- Biotech stocks have long been a speculative, albeit rewarding way to invest in the advancement of medical technology. This industry has a wide range of companies, from start-up firms that are researching their first treatment to pharmaceutical giants that are among the largest and most powerful companies in the world.
- 02/27/2024
|
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
- Vertex is a leader in the billion-dollar cystic fibrosis treatment market. The company recently expanded beyond this specialty area with a newly approved blood disorder therapy.
- 02/27/2024
|
The Ultimate Growth Stock to Buy With $1,000 Right Now
- Vertex Pharmaceuticals' positives include strong profitability and multiple growth drivers. The stock doesn't have the negatives of nosebleed valuation, intense competition, or super-high risk.
- 02/26/2024
|
3 Secret Stocks to Double Your Money by 2028
- Uncovering the illusive secrets with stocks to double your money is an endeavor that captures the imagination of many. But the quest for lucrative opportunities becomes increasingly challenging with the constant noise.
- 02/22/2024
|
Vertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar Market
- Vertex brought in more than $9.8 billion last year thanks to its flagship cystic fibrosis drugs. The company is moving closer to the finish line with a new cystic fibrosis treatment that may even beat its biggest blockbuster.
- 02/20/2024
|
3 Revolutionary Biotech Stocks Poised for 10X Surge
- Investing in high-potential biotech stocks should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapult to $3.08 trillion by 2030, with a compound annual growth rate of 14%.
- 02/19/2024
|
Could This News Upset Vertex Pharmaceuticals' Prospects in the Billion-Dollar Pain Management Market?
- Vertex plans on submitting its pain candidate to regulators by mid-year. A young biotech company just announced it's working on a very similar pain candidate.
- 02/18/2024
|
Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.
- Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products.
- 02/17/2024
|
2 Healthcare Growth Stocks That Are No-Brainer Buys Right Now
- Surgical robotics and the rare disease drug market are two rapidly growing areas of healthcare. Intuitive Surgical makes most of its money from recurring revenue, a business model that has held up.
- 02/17/2024
|
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade.
- Vertex Pharmaceuticals is in the middle of an extremely formative period for its business. Netflix is seeing a windfall of growth from its ad-supported tier, and profits are flowing.
- 02/15/2024
|
Gene therapy: Why does it cost millions for a single treatment?
- Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.
- 02/15/2024
|
Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?
- Vertex's P/S ratio is very high, relative to most other biopharma stocks. It's important, though, to look to the future rather than the past when considering the company's valuation.
- 02/15/2024
|
Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders
- Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.
- 02/14/2024
|
Stock-Split Watch: Is Vertex Pharmaceuticals Next?
- Vertex Pharmaceuticals' shares have climbed nearly 80% in two years. Its share price recently reached an all-time high, and key catalysts ahead could push it higher.
- 02/14/2024
|
2 Healthcare Stocks That Could Help Set You Up for Life
- Healthcare spending represents a tremendous, multitrillion-dollar market opportunity. Vertex just earned another product approval, and more growth could be just over the horizon.
- 02/12/2024
|
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
- The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024.
- 02/11/2024
|
Cooling Off? 3 Popular Stocks With Recent Target Cuts
- While many S&P 500 stocks are reaching recent highs, Wall Street analysts are also reassessing their price targets and issuing outlook changes and downgrades for a number of companies. Today, we introduce three stocks with price target cuts.
- 02/11/2024
|
Is Vertex Pharmaceuticals Stock a Buy Now?
- Drugmaker and cystic fibrosis specialist Vertex expects modest growth for 2024. The company has promising products in its pipeline, but they could still be years away.
- 02/10/2024
|
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
- The rare disease drug market and telehealth market are two expanding areas of healthcare. CF specialist Vertex had another great year in 2023, and the long-term horizon looks even rosier.
- 02/10/2024
|
2 No-Brainer Healthcare Stocks to Buy Right Now
- Its essential nature helps the healthcare industry generate more consistent consumer spending. DexCom is raking in profits from its latest product, and it's still looking at a vast long-term opportunity.
- 02/10/2024
|
3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List
- Healthcare stocks are one of the best sectors to capture long-term innovation and sector strength. After all, healthcare needs are perennial, especially as the global population lives longer and can generally afford more than the bare minimum of care.
- 02/09/2024
|
Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates
- Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.
- 02/06/2024
|
This High-Flying Stock Just Got Some Bad News: Should You Sell?
- Vertex Pharmaceuticals' acute pain candidate was not as impressive as hoped in a late-stage study. Still, the drugmaker has an excellent lineup and multiple highly promising pipeline candidates.
- 02/06/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2023 Earnings Call Transcript
- Vertex Pharmaceuticals Incorporated (VRTX) Q4 2023 Earnings Call Transcript
- 02/05/2024
|
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates
- Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.20 per share, beating the Zacks Consensus Estimate of $4.10 per share. This compares to earnings of $3.76 per share a year ago.
- 02/05/2024
|
PLTR, VRTX, NXPI Earnings Just Released
- Palantir's (PLTR) 4Q adjusted EPS came in at $0.08 versus an estimated $0.08 and revenue came in at $602.41M versus an estimated $603.48M. Vertex Pharmaceuticals' (VRTX) 4Q adjusted EPS came in at $4.20 versus an estimated $4.08 and revenue came in at $2.52B versus an estimated $2.50B.
- 02/05/2024
|
Vertex's triple combination CF drug meets main late-stage trial goals
- Vertex Pharmaceuticals experimental triple combination cystic fibrosis (CF) treatment met all late-stage study goals when tested in patients aged 12 years and older, the company said on Monday.
- 02/05/2024
|
Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?
- Vertex's cystic fibrosis portfolio has been a raging success for the company. The biotech's next potential product addresses the extremely common problem of pain -- and could become its next blockbuster.
- 02/02/2024
|
Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements
- Healthcare stocks are one part of the stock market that has a lot of room to grow until 2024. The healthcare industry is growing because of the growing focus on health and well-being around the world.
- 02/01/2024
|
Buy Alert: 3 Stocks Sitting in the Sweet Spot
- An investment sweet spot is often informally defined as the ideal entry point for buying based on recent macroeconomic developments. Technically, it's a price entry point that guarantees maximum profits or a high probability of a successful reversal trade.
- 01/31/2024
|
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
- Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.
- 01/31/2024
|
Stay Ahead of the Game With Vertex (VRTX) Q4 Earnings: Wall Street's Insights on Key Metrics
- Beyond analysts' top -and-bottom-line estimates for Vertex (VRTX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
- 01/31/2024
|
Why Vertex Pharmaceuticals Stock Topped the Market Today
- The big biotech might just have a winner on its hands with an investigational pain treatment. VX-548 performed well in late-stage clinical testing, although there were some caveats.
- 01/30/2024
|
Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain
- The trial results bring the biotech company one step closer to developing a drug that can provide strong pain relief without the addictive potential of opioids.
- 01/30/2024
|
Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here's Why
- Vertex Pharmaceuticals (VRTX) closed at $435.82 in the latest trading session, marking a +1.31% move from the prior day.
- 01/29/2024
|
Here's My Top Growth Stock to Buy Right Now
- This stock is already highly profitable with a huge cash stockpile thanks to a monopoly in its core niche market. It offers tremendous growth potential with multiple near-term catalysts.
- 01/27/2024
|
Where Will Vertex Pharmaceuticals Be in 10 Years?
- Vertex Pharmaceuticals' work in cystic fibrosis isn't done yet. The company also stands to make headway in other areas over time.
- 01/25/2024
|
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
- Sarepta Therapeutics and Vertex Pharmaceuticals both go after rare diseases. Sarepta has made headway in its core area, but there is more work to be done.
- 01/25/2024
|
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
- From CRISPR gene editing to modify ideal agricultural traits, synthetic biology to promote eco-friendly engineering, or even that relating to biofuels, the field of biotechnology, also known as biotech, offers exciting disruptive solutions with the potential to expand to market caps worth trillions! With new catalysts such as artificial intelligence and quantum computing offering methods to unlock complicated data sets to hasten drug development pipelines, it's no wonder that this market has a projected compound annual growth rate of 13.96% from 2024 to 2023.
- 01/25/2024
|
PBYI or VRTX: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a better bang for their buck right now?
- 01/24/2024
|
Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?
- The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
- 01/24/2024
|
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
- Vertex Pharmaceuticals (VRTX) reachead $439.70 at the closing of the latest trading day, reflecting a -0.09% change compared to its last close.
- 01/23/2024
|
2 gene editing stocks to keep on your 2024 watchlist
- Gene therapy will get its share of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP CRISPR/Cas9-based treatment for sickle cell disease (SCD) in December 2023 kicked off the gene-editing revolution and mainstream attention.
- 01/23/2024
|
3 Must-Buy Healthcare Stocks for a Healthy 2024
- Healthcare stocks remain a focal point for investors seeking stability and growth. The convergence of technology and an increased emphasis on global health has created an environment for ripe investment opportunities.
- 01/22/2024
|
3 Unstoppable Growth Stocks That Can Make You Richer in 2024
- Amazon's profits are improving significantly, and generative AI is providing it with a major ongoing tailwind. MercadoLibre has tremendous growth prospects in Latin America.
- 01/20/2024
|
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
- Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $433.76, signifying a -0.85% move from its prior day's close.
- 01/17/2024
|
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
- This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
- 01/17/2024
|
CRISPR-derived drug gets green light for second indication
- The Food & Drug Administration has approved a second indication for a drug developed using a gene editing process called CRISPR. Casgevy, initially authorised in December for sickle cell disease treatment, the groundbreaking gene therapy is now also sanctioned for treating transfusion-dependent beta-thalassemia.
- 01/17/2024
|
FDA Approves New CRISPR Gene-Editing Treatment
- The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusion-dependent beta thalassemia—marking the second major U.S. regulatory approval for the emerging gene-editing technology.
- 01/16/2024
|
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
- The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a rare blood disorder requiring regular blood transfusions, in patients 12 years and older, Vertex said on Tuesday.
- 01/16/2024
|
My 3 Highest-Conviction Growth Stocks to Buy in 2024
- Amazon is well positioned to remain a leader in e-commerce and cloud services. Brookfield Renewable has almost sure-fire growth prospects with the rising demand for renewable energy.
- 01/14/2024
|
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
- AI should provide a huge tailwind for Alphabet. MercadoLibre has major growth opportunities in Latin America's e-commerce and fintech markets.
- 01/14/2024
|
3 Unstoppable Stocks to Buy in 2024
- Eli Lilly is growing by leaps and Zepbounds. Novo Nordisk is just getting warmed up after delivering a 53% gain last year.
- 01/13/2024
|
Final Trades: Uber, URNM, Abbott Labs and Vertex Pharma
- Brenda Vingiello, Sand Hill Global Advisors CIO, Bryn Talkington, Requisite Capital Management managing partner, Jim Lebenthal, Cerity Partners chief equity strategist, and Josh Brown, Ritholtz Wealth Management CEO, join CNBC's 'Halftime Report' to share their final trades.
- 01/11/2024
|
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
- In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $421.01, indicating a +0.45% shift from the previous trading day.
- 01/09/2024
|
Vertex Pharmaceuticals Incorporated (VRTX) J.P. Morgan 42nd Annual Healthcare Conference
- Vertex Pharmaceuticals Incorporated (VRTX) J.P. Morgan 42nd Annual Healthcare Conference
- 01/08/2024
|
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
- Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/08/2024
|
PBYI vs. VRTX: Which Stock Is the Better Value Option?
- Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Puma Biotech (PBYI) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a better bang for their buck right now?
- 01/08/2024
|
2 low-priced gene therapy stocks to speculate on
- Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.
- 01/08/2024
|
Is Vertex Pharmaceuticals Stock a Buy Now?
- Vertex has a huge competitive advantage in its core franchise, where it still has room to grow. It's also developing new medicines elsewhere and recently landed an important approval.
- 01/06/2024
|
2 Biotech Stocks With Huge Catalysts in 2024
- Vertex Pharmaceuticals' cystic fibrosis franchise is successful, but it's also running out of room to grow. Expected results from a trial with an experimental pain reliever called VX-548 could push Vertex Pharmaceuticals' stock price much higher in 2024.
- 01/05/2024
|
Gen Z's Top Picks for 2024: 7 Trending Stocks Among Young Investors
- Gen Z stocks aren't typical, because the generation has a unique relationship with the stock market. Just like Gen Z is the first to grow up fully immersed in digitization and the Internet culture, active market investing and trading is just another fact of life for a sizeable subset.
- 01/04/2024
|
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
- Betting on healthcare's future via healthcare stocks is one of the safest long-term bets you can make. Though changes and advances happen rapidly, healthcare is one industry that is here to stay.
- 01/03/2024
|
3 Biotech Stocks Set for Breakthroughs in 2024
- As we break into the new year, investors are on the hunt for the best biotech stocks to buy. Indeed, 2024 could witness groundbreaking advancements in technology and science.
- 01/02/2024
|
2 gene-editing stocks reshaping hereditary disease treatments
- Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle-cell disease treatment, Casgevy, utilizing gene-editing technology developed by Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP.
- 01/02/2024
|
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
- Cathie Wood has purchased a large stake in CRISPR Therapeutics for her ARK Invest ETFs. The company won a landmark regulatory approval this year, but analysts think the therapy may get off to a slow start commercially.
- 12/31/2023
|
2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now
- Healthcare and travel spending remain at all-time highs. Vertex just hit another huge business milestone.
- 12/29/2023
|
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
- In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $409.27, indicating a +0.3% shift from the previous trading day.
- 12/28/2023
|
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
- Vertex has a lock on the market for cystic fibrosis (CF) medicines. Now, it's also commercializing a promising, new gene therapy.
- 12/27/2023
|
3 Top Stocks to Buy Hand Over Fist Before the End of 2023
- Alphabet could extend its momentum with a strong economy and the launch of a powerful new AI model. D.R. Horton stands to benefit from potential interest rate cuts in 2024.
- 12/25/2023
|
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
- Vertex Pharmaceuticals will pay Editas Medicine to license its Cas-9 gene-editing technology. Editas can still license the same technology to other companies.
- 12/23/2023
|
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
- Sarepta Therapeutics and Vertex Pharmaceuticals already have a lot in common. Sarepta's focus market has a few peculiarities that could pose a problem.
- 12/22/2023
|
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
- The stock market has been responding to the recent approval of CRISPR Therapeutics' first drug. A successful commercial launch for Casgevy could make the biotech stock a top performer in 2024, but that's far from guaranteed.
- 12/22/2023
|
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone'
- Investors in search of high-risk, high-reward investments can often find them among the top biotech stocks to buy. Identifying worthwhile opportunities can be easier said than done when investing in biotech.
- 12/21/2023
|
Is Vertex Pharmaceuticals Sitting on a Gold Mine?
- Vertex's cystic fibrosis treatments have generated blockbuster revenue over time -- and growth continues. The company now is wrapping up a pivotal program meant to address one of the most common health problems.
- 12/21/2023
|
Biotech breakthroughs: Stocks that soared from medical innovations
- On the heels of the devastating COVID-19 pandemic, investor enthusiasm for biotech stocks waned as the Federal Reserve embarked on its aggressive rate-hiking campaign to bring down the red-hot inflation that ensued.
- 12/20/2023
|
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 a.m. ET/8:15 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on t.
- 12/18/2023
|
5 Big Drug Stocks That May Continue to Outperform in 2024
- Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
- 12/18/2023
|
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich
- These stocks are set to benefit from artificial intelligence and gene editing, two game-changing technologies. Companies investing in these technologies today could see their earnings take off over time.
- 12/18/2023
|
Wells Fargo's top pharma picks for 2024
- Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.
- 12/15/2023
|
Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data
- Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.
- 12/14/2023
|
Vertex (VRTX) Soars 13.2%: Is Further Upside Left in the Stock?
- Vertex (VRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 12/14/2023
|
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
- With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and how we can improve functioning within the body.
- 12/13/2023
|
Why Vertex Stock Is Soaring Today
- Vertex Pharmaceuticals' NaV1.8-inhibitor VX-548 measurably reduces peripheral neuropathic pain among diabetics. The drug, however, can be used to treat similar pain stemming from other health conditions.
- 12/13/2023
|
Stock Movers: J&J, Vertex Pharma and Tesla
- The “Halftime Report” Investment Committee debate the market movers they own.
- 12/13/2023
|
Vertex shares pop after non-opioid painkiller posts positive mid-stage trial results
- The results support Vertex's hopes of developing a drug that can provide strong pain relief without the addictive potential of opioid medications.
- 12/13/2023
|
Midday Movers: Vertex Surges on Gene-Editing Deal, Pfizer Falls on Guidance Miss
- U.S. equities were slightly higher at midday ahead of comments from the Federal Reserve following its last meeting of the year. It's expected the central bank won't raise interest rates any further to fight inflation, and investors will also be paying attention to whether policymakers indicate any rate cuts might be coming.
- 12/13/2023
|
Next Wave Biotech: 3 Stocks Poised for Breakthrough Success
- The pandemic pushed major biotech stocks into the spotlight as vaccine demands rose to unprecedented highs. Investors flocked to the industry in the next few years after the COVID-19 breakout.
- 12/13/2023
|
Vertex's stock heads for all-time high as non-opioid painkiller shows promise
- Vertex Pharmaceuticals Inc. shares VRTX, +10.68% were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.
- 12/13/2023
|
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
- Healthcare stocks rarely outperform the S&P 500 over long periods. Exact Sciences and Vertex Pharmaceuticals have been two of the rare exceptions over the prior 10 years.
- 12/13/2023
|
BLUE, CRSP & VRTX Down Despite FDA Nod to SCD Therapies
- The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.
- 12/11/2023
|
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
- Vertex and partner CRISPR Therapeutics just won FDA approval for blood disorders treatment exa-cel -- to be commercialized as Casgevy. Vertex is known for its cystic fibrosis drugs, which bring in billions of dollars in earnings annually.
- 12/10/2023
|
The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per person
- The FDA approved the first gene therapies for sickle cell anemia. The two approved treatments, Casgevy and Lyfgenia, will cost $2.2 million and $3.1 million.
- 12/09/2023
|
Forget the "Magnificent Seven": Buy This Stock Instead
- The "Magnificent Seven" are all great stocks to own, but none has an actual monopoly in its field. Vertex Pharmaceuticals does have a monopoly in selling certain medicines critical to patients' health.
- 12/09/2023
|
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
- The healthcare and e-commerce industries continue to generate substantial levels of consumer spending. Vertex Pharmaceuticals just marked another landmark approval, which could be the first of multiple new blockbusters in its profitable portfolio.
- 12/09/2023
|
Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed
- The FDA has granted approval to a CRISPR-based gene editing therapy for the first time in history, validating the approach. The therapy, called Casgevy, is approved to treat Sickle Cell Disease after showing positive results in clinical trials, functionally curing patients. Despite the approval, the stock prices of CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated did not surge today, possibly due to concerns about market potential and competition from another approved therapy.
- 12/08/2023
|
Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in US
- Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced Friday that the Food and Drug Administration (FDA) gave them approval for use of the first-ever gene-editing therapy using CRISPR technology in the U.S.
- 12/08/2023
|
Patients describe Casgevy gene-editing treatment as a cure, says Vertex CEO Reshma Kewalramani
- Reshma Kewalramani, CEO of Vertex Pharmaceuticals, and CNBC's Angelica Peebles join 'Power Lunch' to discuss the latest FDA gene-editing treatment approval, drug pricing, and more.
- 12/08/2023
|
Vertex/CRISPR price sickle cell disease gene therapy at $2.2 mln
- Vertex Pharmaceuticals and its partner CRISPR Therapeutics said on Friday their sickle cell disease gene therapy Casgevy would be available at a list price of $2.2 million in the United States.
- 12/08/2023
|
FDA greenlights first gene-editing treatment, Casgevy, for sickle cell disease
- CNBC's Angelica Peebles reports on the latest news in bioscience.
- 12/08/2023
|
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment
- Crispr Therapeutics AG CRSP, -5.37% and Vertex Pharmaceuticals Inc. VRTX, -1.25% on Friday got U.S. regulatory approval for a treatment for sickle-cell disease based on the transformative gene-editing technology Crispr.
- 12/08/2023
|
US approves two gene therapies for sickle cell disease
- The U.S. Food and Drug Administration on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics , as well as from bluebird bio.
- 12/08/2023
|
U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease
- Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.
- 12/08/2023
|
Healthcare Gems: 3 Essential Long-Term Stock Picks
- Healthcare stocks are a great way for investors to achieve long-term wealth creation. The healthcare sector is essential to solving some of the world's most pressing issues from heart disease, Alzheimer's, and cancer.
- 12/07/2023
|
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients
- The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.
- 12/07/2023
|
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
- Vertex Pharmaceuticals is trying to commercialize its gene therapy exa-cel. Researchers found some disturbing evidence about certain possible side effects.
- 12/07/2023
|
GSK vs. VRTX: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both GSK (GSK) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a better bang for their buck right now?
- 12/04/2023
|
Where Will Vertex Pharmaceuticals Be in 10 Years?
- Vertex has a solid cystic fibrosis portfolio that generates billions of dollars in annual earnings -- and that's set to continue for the long term. The biotech, expanding into other treatment areas, is expecting a regulatory decision on a new potential blockbuster in a matter of days.
- 12/04/2023
|
3 No-Brainer Growth Stocks to Buy in December
- Eli Lilly's weight-loss drug Zepbound should be a game changer. Novo Nordisk's momentum, driven by Ozempic and Wegovy, will likely keep going.
- 12/03/2023
|
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
- PayPal Holdings has faced multiple challenges, but it's now a bargain with a big comeback opportunity. Vertex Pharmaceuticals could soon have several new blockbuster drugs on the market.
- 12/03/2023
|
5 Top Stocks to Buy Before 2024
- Now is a great time to consider stocks that may boost your portfolio, both in the new investing year and over time. Companies offering steady earnings growth -- or the promise of earnings growth -- are a good place to start.
- 12/02/2023
|
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
- CRISPR and Vertex recently earned approval for a gene-editing treatment, Casgevy. Casgevy shows the potential of CRISPR's platform and should improve its financial results.
- 12/01/2023
|
3 Biotech Stocks That Could Be Multibaggers in the Making
- In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels with precision and personalization.
- 11/30/2023
|
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
- Investing in biotech stocks is not for risk-averse investors. However, if you're an investor who is serious about generating outsized gains, it's a sector that you can't overlook.
- 11/28/2023
|
3 Biotech Stocks To Watch Before December 2023
- Biotech stocks to check out in the stock market today.
- 11/27/2023
|
5 Stocks You Can Confidently Invest $500 In Right Now
- Amazon and Apple offer investors a solid growth track record -- and the potential for much more ahead. Add to these a couple of dividend giants and a biotech powerhouse and you have a great selection of solid stocks to choose from.
- 11/27/2023
|
This healthcare stock could skyrocket anytime
- Vertex Pharmaceuticals (NASDAQ: VRTX) boasts an impressive track record, establishing itself as a leading biotech firm over the last decade. The company has demonstrated a keen emphasis on addressing a specific rare lung disease, cystic fibrosis (CF).
- 11/26/2023
|
2 Healthcare Stocks That Could Help Set You Up for Life
- Vertex Pharmaceuticals is an innovative biotech with a robust portfolio and rich pipeline. HCA Healthcare leads an area of the healthcare industry that isn't easy to break into now.
- 11/25/2023
|
Vertex (VRTX) Gets EU Nod for Kaftrio Use in 2-5 Year Kids
- The European Commission approves Vertex's (VRTX) Kaftrio for expanded use to treat children aged two to five years with cystic fibrosis.
- 11/24/2023
|
Prediction: 3 Stocks That Could Trounce the Market
- Mastercard boasts a strong moat, rock-solid financials, and long-term trends that work in its favor. TransMedics Group is steadily disrupting the multibillion-dollar organ transplant market.
- 11/23/2023
|
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
- A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking prowess.
- 11/22/2023
|
Vertex (VRTX) Non-Cystic Fibrosis Pipeline Boosts Stock This Year
- Vertex Pharmaceuticals (VRTX) is likely to achieve multiple clinical milestones in late/2023 and 2024, both in its CF and non-CF portfolio.
- 11/21/2023
|
Is Vertex Pharmaceuticals Stock a Buy Now?
- Vertex Pharmaceuticals' core business is still firing on all cylinders. The biotech is expanding into other areas and diversifying its portfolio.
- 11/16/2023
|
Vertex Pharmaceuticals Incorporated (VRTX) Jefferies Global Healthcare Conference Call Transcript
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Jefferies Global Healthcare Conference Call November 14, 2023 3:30 AM ET Company Participants Stuart Arbuckle - Executive Vice President and Chief Operating Officer Conference Call Participants Michael Yee - Jefferies Michael Yee All right. Good morning, everybody.
- 11/14/2023
|
Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks
- Twilio could be poised to use AI to disrupt customer communications. Beam Therapeutics is a pioneer in developing therapies using a highly precise method of gene editing.
- 11/14/2023
|
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Biopharma Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) UBS Biopharma Conference November 9, 2023 12:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief Financial Officer David Altshuler - Chief Scientific Officer Conference Call Participants Colin Bristow - UBS Colin Bristow Good afternoon, and welcome to the UBS Biopharma Conference. I'm Colin Bristow, one of the biotech analysts here.
- 11/11/2023
|
1 No-Brainer Stock to Buy and Hold for 10 Years
- CRISPR is a leader in the young but promising gene-editing niche. The biotech is getting closer to earning its first major approval.
- 11/11/2023
|
3 Growth Stocks to Buy Right Now Without Any Hesitation
- AbbVie looks like a bargain that has stronger growth on the way. Axsome Therapeutics is in the early innings of what could be an exciting growth story.
- 11/11/2023
|
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
- Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment, and that business generates billions of dollars in annual revenue. The biotech has treatment candidate in another indication that's close to the regulatory finish line.
- 11/09/2023
|
Why you can make Vertex Pharmaceuticals a buy on any pullback
- Shares of Vertex Pharmaceuticals, Inc. NASDAQ: VRTX are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a slight miss on the top line.
- 11/08/2023
|
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
- Vertex's Q3 update could have made some investors at least a little more nervous. However, there are four reasons some might be concerned that are easily debunked.
- 11/08/2023
|
Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View
- Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.
- 11/07/2023
|
Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings Estimates
- Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $3.92 per share. This compares to earnings of $4.01 per share a year ago.
- 11/06/2023
|
Vertex Pharma misses sales estimates on weak demand for older CF treatments
- Vertex Pharmaceuticals missed Wall Street estimates for third-quarter sales on Monday, hurt by weaker-than-expected demand for its older cystic fibrosis (CF) treatments.
- 11/06/2023
|
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
- Vertex Pharmaceuticals and CRISPR Therapeutics just met with regulators at the Food and Drug Administration. The discussion was about the safety of their gene therapy candidate called exa-cel.
- 11/03/2023
|
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
- The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $376.55, representing a +1.95% change from its previous close.
- 11/02/2023
|
Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients
- The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.
- 10/31/2023
|
FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia
- Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease.
- 10/31/2023
|
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
- In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $355.28, denoting a -1.66% change from the preceding trading day.
- 10/27/2023
|
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money
- Vertex is looking to build on its cystic fibrosis drug franchise with promising new therapies. Lending platform Upstart employs AI and machine learning to evaluate potential borrowers.
- 10/27/2023
|
This Market-Beating Growth Stock Is Set to Outperform Yet Again in 2024
- Large-cap growth stocks with wide economic moats and top-shelf management teams have outperformed this year. Vertex Pharmaceuticals, a rare disease specialist, has been one of the strongest performers within the group.
- 10/26/2023
|
2 Best Healthcare Stocks to Buy Right Now
- The stock market may be volatile, but investors don't have to wait on the sidelines. Vertex Pharmaceuticals is forging its own path in the rare disease drug market.
- 10/26/2023
|
Vertex Pharmaceuticals: Buy at the High?
- Vertex is firing on all cylinders, with its billion-dollar cystic fibrosis business booming and its pipeline programs advancing. The company may be about to reach a big milestone: the potential regulatory approval of a product in a new treatment area.
- 10/26/2023
|
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
- In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $367.66, denoting a +1.6% change from the preceding trading day.
- 10/23/2023
|
GILD or VRTX: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?
- 10/19/2023
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
- 10/19/2023
|
4 Ways to Grow $100,000 Into $1 Million for Retirement
- Realty Income's total returns deliver. Alphabet is still turning investors into millionaires.
- 10/19/2023
|
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
- Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.
- 10/18/2023
|
Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again
- Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/17/2023
|
Vertex Pharmaceuticals (VRTX) Increases Yet Falls Behind Market: What Investors Need to Know
- In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $374, denoting a +0.81% change from the preceding trading day.
- 10/16/2023
|
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
- Healthcare stocks, on balance, haven't been great investments in 2023. Regeneron Pharmaceuticals and Vertex Pharmaceuticals have been two glaring exceptions to this trend.
- 10/16/2023
|
This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street
- Superstar investor Wood looks for innovators whose products could be game changers down the road. She goes for companies that are undervalued today considering their long-term potential.
- 10/16/2023
|
Is Vertex Pharmaceuticals Stock a Buy Now?
- Vertex's sales have been slowing down, and this year the top line may rise by less than 10%. The company has multiple assets in phase 3 trials, which could unlock more growth potential for the business.
- 10/15/2023
|
The Surprising $5 Billion Opportunity That Drove Vertex Pharmaceuticals Stock To A Record High
- Almost three-quarters of prescribed pain meds are opioids, and Vertex could change that. VRTX stock broke out to a record high Thursday.
- 10/12/2023
|
BEAM Focuses on Developing Gene Drug for Growth
- While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.
- 10/10/2023
|
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
- In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $355.20, indicating a -1.5% shift from the previous trading day.
- 10/09/2023
|
Cramer's Mad Dash: Vertex Pharmaceuticals
- CNBC's Jim Cramer delivers his daily Mad Dash.
- 10/09/2023
|
Cramer says Vertex has a drug that may address the 'largest market opportunity in the world'
- CNBC's Jim Cramer said investors keep an eye on Vertex Pharmaceuticals (VRTX) as the company develops a non-opioid pain drug.
- 10/09/2023
|
3 Biotech Stocks Ready to Break Out in 2024
- While the S&P 500 remains up on the year, the biotech sector is down. Even though the broader market is showing signs of strength in areas like AI and automation, those trends haven't benefited biotech stocks as much.
- 10/07/2023
|
3 No-Brainer Growth Stocks to Buy in October
- Eli Lilly is crushing the market because of its impressive product lineup and strong prospects. Novo Nordisk is just getting warmed up with a massive opportunity for Ozempic and Wegovy.
- 10/07/2023
|
3 Top Ranked Stocks with Superior Free Cash Flow Yield
- In the world of investing, there's one indicator that really stands out: Free Cash Flow (FCF) yield. Think of it as a sign that a company is good at making money and using it wisely.
- 10/05/2023
|
3 No-Brainer Stocks to Buy With $1,000 Right Now
- Short-term traders have been whipsawed by volatility for more than three years. However, patience is a powerful moneymaking tool for investors.
- 10/04/2023
|
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
- In the landscape of modern medicine, a trio of biotech giants may rewrite the rules of healthcare. In a world where precision and personalization have become the holy grail of treatment, these three companies are emerging as pioneers, guiding the world into a new era of therapeutic possibilities.
- 10/03/2023
|
2 Top Biotech Stocks to Buy in October
- Vertex Pharmaceuticals is awaiting a regulatory decision on what may become its next blockbuster. Axsome Therapeutics aims to launch several products over the next few years.
- 10/03/2023
|
2 Brilliant Growth Stocks to Invest $2,000 in Right Now
- The rare-disease drug industry and the lending industry both serve huge addressable markets. Vertex has built a profitable business on the back of its cystic fibrosis drug franchise, and it's still early days.
- 10/01/2023
|
5 Top Stocks for October
- These five stocks could hardly be more different, but they have one important thing in common: All look like great buys in October 2023. From retail to biotech, these stocks showcase their resilience and strategic adaptability amid unpredictable market fluctuations.
- 10/01/2023
|
Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs
- Clinical trials are a difficult and grueling process for companies. The FDA and other regulatory agencies require the highest possible standards in order to approve new drugs.
- 09/30/2023
|
Don't Miss the Boom: 3 Biotech Stocks Set to Explode Higher
- In the dynamic investment realm, one sector that continues to stand out is the area of biotech stocks. Though risky, especially when assessing established firms with market-ready drugs and vast research and development (R&D), the rewards can be significant.
- 09/26/2023
|
Buying These 2 Remarkable Growth Stocks in Any Market Could Be a Genius Move
- Regardless of what happens with the economy, people continue to spend money on pets and healthcare. Chewy is building a powerhouse business on the back of recurring revenue streams and diversification.
- 09/25/2023
|
3 Magnificent Growth Stocks to Buy Right Now
- Some might overlook AstraZeneca, but the stock has strong growth prospects. Eli Lilly continues to fire on all cylinders, with especially big opportunities for Mounjaro.
- 09/24/2023
|
2 Healthcare Stocks That Could Make You Richer
- Vertex has almost no weak spots thanks to a solid core franchise and several promising programs. DexCom is helping improve the lives of diabetes patients, and the company still has lots of room to grow.
- 09/22/2023
|
3 Unstoppable Stocks to Buy and Hold for the Next 20 Years
- Brookfield Infrastructure should deliver strong organic growth and continue to expand via acquisitions. Microsoft is a leader in nearly all of the top technologies of the future.
- 09/21/2023
|
Vertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded Use
- Vertex's (VRTX) Kaftrio gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use to treat younger age groups of two to five years old with cystic fibrosis.
- 09/18/2023
|
A Bull Market Is (Still) Coming: Here Are 3 Spectacular Stocks to Buy Sooner Rather Than Later
- Amazon should deliver strong growth over the short term and long term. Mastercard's moat and growth opportunities make it an attractive pick.
- 09/10/2023
|
1 Top Pharma Growth Stock to Buy Today and Hold Forever
- Vertex Pharmaceuticals has many avenues for chasing growth both big and small. Its cystic fibrosis medicines continue to remain a rock-solid base of revenue.
- 09/08/2023
|
2 Top Biotech Stocks to Buy in September
- Vertex and Regeneron have delivered solid financial results and stock market performance. Both biotechs have exciting pipelines that should produce key new approvals or label expansions.
- 09/08/2023
|
Could These Be Vertex Pharmaceuticals' Most Promising Candidates?
- Vertex Pharmaceuticals is trying to replicate its winning cystic fibrosis formula in other areas. These efforts could yield even better financial results than its potential gene-editing therapy.
- 09/08/2023
|
September Rally? 3 Stocks to Buy Before Liftoff
- September is not known as a good month to buy stocks. In fact, historically it's the worst month.
- 09/08/2023
|
3 Must-Know Tricks for Investing in Big Pharma Stocks
- Pharma companies often have detailed plans for when new revenue will occur. They also sometimes describe periods when sales will be shrinking.
- 09/08/2023
|
3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains
- In the grand tapestry of the investment world, one thread that continues to shine is biotech stocks to buy and hold. It's no secret that delving into biotech investments can be incredibly challenging, even when zeroing in on established firms with market-ready drugs and expansive research and development pipelines.
- 09/05/2023
|
The 3 Best Biotech Stocks to Buy Now: September 2023
- Biotech stocks have underperformed in the U.S. stock market by a wide margin this year. The sector's most popular index, the iShares Biotechnology ETF (NASDAQ: IBB ), is down 5% since Jan. 27.
- 09/04/2023
|
2 Spectacular Growth Stocks You Can Buy in September With No Hesitation
- D.R. Horton is a Warren Buffett stock that's a bargain and has great growth potential. Vertex Pharmaceuticals has multiple growth drivers that could make it an even bigger winner than it already is.
- 09/03/2023
|
As Medicare drug-price negotiations inch forward, some states are flexing new powers to cut costs for a broader swath of drugs
- As Medicare's years-long drug-price negotiation process is being hotly debated and litigated, some states are plowing ahead with wide-ranging efforts to bring down costs for a potentially much broader set of prescription drugs.
- 09/01/2023
|
The 3 Most Promising Biotech Stocks to Own Now
- Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards of minority voters. This commitment to economic inclusivity bodes well for overall economic health and long-term growth.
- 08/31/2023
|
Got $600? Here are 3 No-Brainer Stocks You Absolutely Must Buy
- The stock market recovered nicely from last year's debacle. The Nasdaq Composite Index in particular went from a 34% loss in 2022 to a 29% gain so far this year.
- 08/24/2023
|
3 Strong Biotech Performers To Watch As Sector Nears Breakout
- The biotech sector, iShares Biotechnology ETF NASDAQ: IBB, has been trading in a tight consolidation for several months. The ETF has a 50-day range of $124.38 and $131.81.
- 08/17/2023
|
Vertex Pharmaceuticals Still Looks Attractive
- Vertex Pharmaceuticals' Q2 financials showed strong revenue growth. The company's core portfolio of drugs for cystic fibrosis treatment has additional market opportunities. Also, Vertex has some undervalued pipeline opportunities.
- 08/13/2023
|
Could Vertex Pharmaceuticals Stock Help You Become a Millionaire?
- Vertex Pharmaceuticals is a leader in cystic fibrosis treatments. The company is working on expanding its business, which will open up more growth opportunities.
- 08/10/2023
|
2 Supercharged Growth Stocks That Could Make You Richer
- Growth stocks have stormed back to life in recent weeks. Exact Sciences and Vertex Pharmaceuticals should benefit from this shift in sentiment, thanks to their strong innovation, rising sales, and stellar long-term outlooks.
- 08/09/2023
|
Is Vertex Pharmaceuticals Stock a Buy Now?
- Vertex Pharmaceuticals is diversifying from making solely cystic fibrosis drugs. It could soon commercialize a pair of gene therapies for hereditary conditions.
- 08/09/2023
|
2 Top Biotech Stocks to Buy in August
- Vertex's business should get a major boost in the coming years with new approvals. Eli Lilly's expanding portfolio of new products will help it maintain its recent momentum.
- 08/06/2023
|
3 Top Healthcare Stocks to Buy for August
- Humana delivered better-than-expected second-quarter earnings. Vertex Pharmaceuticals has three potential blockbuster therapies on the way.
- 08/05/2023
|
2 Nasdaq 100 Stocks That Are Surefire Buys in August and 1 to Avoid
- The Nasdaq 100 has come roaring back after a tumultuous 2022. Two Nasdaq 100 companies have the competitive edges and sustained long-term catalysts needed to reward patient investors handsomely.
- 08/04/2023
|
Here's Why Investors Should Buy These 2 Medical Stocks After Earnings
- Following their favorable Q2 reports now looks like a good time to buy Encompass Health (EHC) and Vertex Pharmaceuticals (VRTX) stock.
- 08/03/2023
|
Vertex Pharmaceuticals (VRTX): A Fairly Valued Stock with Strong Growth Prospects
- Vertex Pharmaceuticals Inc ( VRTX , Financial) saw a daily gain of 3.07%, with an Earnings Per Share (EPS) (EPS) of $12.56. But is the stock fairly valued?
- 08/02/2023
|
Vertex (VRTX) Beats on Q2 Earnings & Sales, Raises '23 View
- Vertex Pharmaceuticals' (VRTX) second-quarter 2023 earnings and sales beat estimates. Based on strong Trikafta uptake, management raises its financial guidance for 2023.
- 08/02/2023
|
Vertex Pharmaceuticals Incorporated (VRTX) Q2 2023 Earnings Call Transcript
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Susie Lisa - CFA, Senior Vice President of Investor Relations Reshma Kewalramani - President & Chief Executive Officer Stuart Arbuckle - Executive Vice President & Chief Operating Officer Charlie Wagner - Executive Vice President & Chief Financial Officer Conference Call Participants Phil Nadeau - Cowen & Company Liisa Bayko - Evercore ISI Salveen Richter - Goldman Sachs Geoff Meacham - Bank of America Robyn Karnauskas - Truist Securities David Risinger - Leerink Partners Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo Michael Yee - Jefferies Evan Seigerman - BMO Capital Markets Colin Bristow - UBS Operator Good afternoon and welcome to the Vertex Pharmaceuticals Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
- 08/01/2023
|
Vertex Pharmaceuticals (VRTX) Q2 Earnings and Revenues Top Estimates
- Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.89 per share, beating the Zacks Consensus Estimate of $3.85 per share. This compares to earnings of $3.60 per share a year ago.
- 08/01/2023
|
Vertex Pharma raises full-year revenue forecast on cystic fibrosis treatment strength
- Vertex Pharmaceuticals raised its full-year sales forecast on Tuesday, banking on strong demand for its cystic fibrosis (CF) treatment.
- 08/01/2023
|
3 Biotech Stocks to Buy Before the Breakout
- During this Q3 of 2023, there have been many changes to U.S. healthcare at different levels. At the state level, there were changes to gender-affirming care.
- 07/28/2023
|
3 Biotech Stocks You Better Be Buying on Each and Every Dip
- Biotechnology is one of the most exciting and innovative sectors in the market, offering investors the potential for high returns coupled with groundbreaking discoveries. However, due to regulatory hurdles, clinical failures and intense competition, biotech investing also comes with high risks.
- 07/27/2023
|
If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names
- The biotechnology industry is simply amazing, always advancing and bringing new drugs to fight complicated and serious diseases. If you are thinking about investing in this sector, it is crucial to know the best biotech stocks that can give you great returns.
- 07/26/2023
|
2 No-Brainer Cathie Wood Stocks to Buy Right Now
- Cathie Wood is having an exceptional 2023. Vertex Pharmaceuticals and Pfizer are two of Wood's holdings that stand out as top buys right now.
- 07/26/2023
|
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
- Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/25/2023
|
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
- Growth investors are frequently looking for biotech stocks to buy. So what exactly is a biotech stock?
- 07/24/2023
|
Better Big Biotech Buy: Vertex vs. Biogen
- Vertex Pharmaceuticals is heading for a big moment -- a regulatory decision on a potential new blockbuster. Biogen recently won regulatory approval for a drug that may become its new growth driver.
- 07/24/2023
|
Drug Stock Vertex May See Boost From Non-Opioid Painkillers, Says Analyst
- Leerink Partners analyst David Risinger raised his price target to $442 from $396. His new target indicates a 20% upside from the recent price of $365.
- 07/21/2023
|
My Take: 4 Strong Growth Stocks to Buy This Week
- Eli Lilly's emphasis on diabetes and obesity drugs sets it apart. Royal Caribbean is benefiting as people return to travel experiences.
- 07/20/2023
|
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
- Vertex dominates the cystic fibrosis market and is dipping its toes in new areas. Moderna's mRNA vaccine platform could lead to major approvals in the coming years.
- 07/19/2023
|
2 Monster Stocks to Buy Without Any Hesitation
- These two companies -- giants in the worlds of biotech and pharma -- have a great earnings track record. And they both may be about to enter a new era of growth.
- 07/17/2023
|
Vertex Pharmaceuticals: Buy at the High?
- Vertex shares have advanced almost 20% since the start of the year. Investors are optimistic about Vertex's prospects in its specialty area of cystic fibrosis and beyond.
- 07/14/2023
|
3 Pharma Stocks That AI is Loving in July
- When it comes to investing in pharmaceutical stocks, an intriguing area for future growth is gene editing. This is an exciting field that may provide a solution to some of our most vexing diseases, such as cancer and diabetes.
- 07/13/2023
|
3 Top Biotech Stocks Defying the Bear Market
- Vertex Pharmaceuticals' strong pipeline is positioning the company for the future. Viking Therapeutics' stock is soaring as the market anticipates its candidate drugs hitting the marketplace.
- 07/13/2023
|
3 Biotech Stocks to Buy for Long-Term Gains
- Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated assets, meaning their value is sensitive to changes in interest rates.
- 07/13/2023
|
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
- Axsome Therapeutics' current drugs and pipeline programs look especially promising. Brookfield Renewable could double in six years if it hits the low end of its projected growth range.
- 07/13/2023
|
Is Now the Right Time to Embrace Biotech ETFs?
- Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.
- 07/12/2023
|
3 Biotech Stocks That AI is Loving in July
- Artificial intelligence (AI) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amounts of data and recognize patterns makes it an ally in identifying high-potential stocks.
- 07/12/2023
|
3 Things About Vertex Pharmaceuticals That Smart Investors Know
- Vertex Pharmaceuticals may be about to show it can expand beyond its billion-dollar specialty area. The company is waiting for a regulatory decision on its blood disorders candidate -- but this may only be the start of its new growth story.
- 07/12/2023
|
Sitting on Cash? These 2 Stocks Are Great Buys
- Vertex Pharmaceuticals is already delivering billions of dollars in earnings annually, and a potential new product could offer more growth soon. Coca-Cola offers investors a growing passive income stream -- and a steady business they can count on.
- 07/11/2023
|
Want to Get Richer? 2 Unstoppable Stocks to Invest $1,000 In This Week
- The market is showing signs of investor optimism about the rest of 2023. Airbnb isn't banking only on traditional forms of travel -- it continues to innovate to meet the needs of every type of traveler.
- 07/09/2023
|
3 No-Brainer Stocks You Can Buy Right Now
- Some investors are fearful about AbbVie right now, but it's better to be greedy with the stock. Pfizer offers a solid dividend and great growth prospects.
- 07/08/2023
|
Vertex (VRTX) Gets Nod in EU for Orkambi Expanded Indication
- Vertex's (VRTX) Orkambi gets approval from the European Commission in the EU for the treatment of cystic fibrosis in patients (aged 1 to
- 07/06/2023
|
2 Growth Stocks That Might Be Too Cheap to Ignore
- Vertex Pharmaceuticals is starting to widen and diversify its lineup of medicines, which could make it even more successful than it already is. Teladoc remains down despite the progress it has made and the exciting future of the telemedicine market in which it operates.
- 07/06/2023
|
2 Supercharged Growth Stocks to Invest In Before the Next Bull Market
- Fintech and healthcare are two spaces on rapid growth trajectories. Upstart is growing on multiple key fronts that could pave the way for a very promising future.
- 07/06/2023
|
3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025
- Investing in the biotech sector is mostly about risk and reward. When a company achieves FDA approval on a drug or therapeutic, it frequently has a source of revenue and profit that can last for years.
- 07/05/2023
|
The 3 Best Biotech Stocks to Buy In July
- Although it's been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at small and midsized biotech companies in the U.S. These are the incubators for medical advancements and where important scientific breakthroughs are happening.
- 07/05/2023
|
Vertex: Promising Prospects Amid Stretched Valuation
- Vertex Pharmaceuticals saw a 13% increase in Q1 2023 product revenue to $2.37 billion, primarily due to the robust uptake of its cystic fibrosis treatments. The company's net income fell due to higher expenses. The FDA will conduct a priority review for Vertex and CRISPR Therapeutics' gene-edited therapy for severe sickle cell disease by December 2023, and a standard review for transfusion-dependent beta-thalassemia by March 2024. Vertex advanced VX-548 to a pivotal, Phase 3 trial for the treatment of acute pain. VX-548 has the potential to be a game-changer for pain due to its non-opioid properties.
- 07/04/2023
|
Vertex Pharmaceuticals Stock: Bear vs. Bull
- Vertex has climbed quite a bit this year -- and some potential good news may be priced in. Still, Vertex's late-stage programs offer it bright prospects down the road.
- 07/03/2023
|
Vertex to Announce Second Quarter 2023 Financial Results on August 1
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2023 financial results on Tuesday, August 1, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1(412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2023 Earnings Call.” The conference call will be webcast live and a link to the webcast can.
- 06/30/2023
|
Buying These 3 Stocks Could Be the Smartest Investing Move You'll Ever Make
- Amazon has major growth opportunities in AI, cloud services, and e-commerce. MercadoLibre dominates the Latin American e-commerce and fintech markets.
- 06/30/2023
|
Weight-loss drugs in development aim to replace injections with pills
- Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in development that could become alternatives to popular injectables like Wegovy and Ozempic.
- 06/26/2023
|
2 Unstoppable Growth Stocks That Could Turn $20,000 into $100,000 by 2030
- Growth stock investing can be unpredictable from year to year, but long-term investors tend to outperform over time. Shares of Etsy are trading at a reasonable price that could soar in the years ahead.
- 06/20/2023
|
2 Market-Beating Stocks With Major Catalysts on the Way
- Vertex's next blockbuster could generate billions of dollars in sales. Biogen is inching closer to a goal it's been working on for a long time.
- 06/17/2023
|
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
- Alphabet could shake things up with its AI and quantum computing efforts. Brookfield Renewable is helping change where our energy comes from.
- 06/15/2023
|
2 Magnificent Growth Stocks to Buy Before the Next Bull Market
- Investors are contending with a different environment than a few years ago, but that doesn't mean the best market days are in the past. Pinterest is growing where it counts, and user monetization is on the upswing.
- 06/15/2023
|
Vertex Pharmaceuticals Incorporated (VRTX) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Goldman Sachs 44th Annual Global Healthcare Conference Call June 13, 2023 5:40 PM ET Company Participants Reshma Kewalramani - President and Chief Executive Officer Stuart Arbuckle - Chief Operating Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good afternoon, everyone.
- 06/13/2023
|
3 No-Brainer Stocks to Buy in June
- Axsome Therapeutics is a rising star in biotech. Pfizer is too cheap to pass up.
- 06/10/2023
|
FDA Accepts Vertex (VRTX), CRISPR's BLA Filings for Exa-Cel
- The FDA grants priority review to Vertex (VRTX)/CRISPR's (CRSP) filings for exa-cel in SCD, with a final decision expected in December.
- 06/09/2023
|
2 Top Biotech Stocks to Buy in June
- The biotech sector remains a fertile place of innovation that can enrich an investor. Gilead has a potential oncology blockbuster, and the stock offers a sizable dividend.
- 06/09/2023
|
5 Top Stocks to Buy in June
- Investors should get in the habit of buying stocks on a regular basis. A diversified portfolio helps minimize the risk that comes with concentrating capital in too few companies or industries.
- 06/08/2023
|
Vertex (VRTX) Stock Poised Well for Growth in 2023: Here's Why
- Vertex Pharmaceuticals (VRTX) stock is likely to be driven by several catalysts this year. Multiple clinical milestones are likely to be achieved in 2023 and 2024, both in its CF and non-CF portfolio.
- 06/07/2023
|
A New S&P 500 Bull Market Is Nearly Here: 3 No-Brainer Stocks to Buy Sooner Rather Than Later
- Amazon is already in a bull market of its own and has plenty of room to run. Berkshire Hathaway offers broad exposure to more sectors than any other stock.
- 06/07/2023
|
Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?
- Vertex Pharmaceuticals' shares look pricey at first glance. But its revenue in the next half-decade should grow at a good pace.
- 06/03/2023
|
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade
- Vertex Pharmaceuticals' main franchise has no competition, and it boasts several promising programs. DexCom's opportunities in the continuous glucose monitoring market make it an attractive long-term pick.
- 06/03/2023
|
Why Is Vertex (VRTX) Down 6% Since Last Earnings Report?
- Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
- 05/31/2023
|
Got $1,000? 2 Amazing Growth Stocks That Could Help You Retire Richer
- The healthcare and lending markets represent multitrillion-dollar opportunities. Vertex Pharmaceuticals has a competitive edge and its foot in the door of multiple underserved markets.
- 05/31/2023
|
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 44th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, Chief Executive Officer and President, and Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat on Tuesday, June 13, 2023 at 2:40 p.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com i.
- 05/30/2023
|
Wall Street Thinks This Stock Will Only Rise 12%: Here's Why It Could Jump a Lot More
- Some analysts see Vertex's sales growth slowing with no immediate major impact from the anticipated approval of exa-cel. However, forward-looking investors could be excited by other big news from Vertex on the way.
- 05/28/2023
|
Want to Get Richer? 3 Top Stocks to Buy Now and Hold Forever
- Brookfield Infrastructure is poised to benefit from three major trends. MercadoLibre has tremendous growth opportunities in Latin America.
- 05/28/2023
|
2 Biotech Stocks That Could Help Set You Up for Life
- Axsome has two approved treatments as well as candidates in late-stage development Vertex has the dominant treatment for cystic fibrosis and is developing other products.
- 05/26/2023
|
2 Top Trends to Invest $5,000 in Right Now
- Vertex Pharmaceuticals is one of the few gene-editing companies that is already profitable. Brookfield Renewable Partners offers exposure to diverse parts of the renewable energy landscape.
- 05/25/2023
|
2 Hot Stocks to Buy and Hold Until You Retire
- Vertex Pharmaceuticals' robust pipeline is setting it up for the future. Airbnb is a strong player in the rapidly expanding travel and tourism industry.
- 05/22/2023
|
2 Stocks Near 52-Week Highs That Still Look Like Bargains
- Despite recently climbing to heights investors haven't seen in a long time, a few stocks are still trading at relatively low earnings multiples. Meta Platforms has returned to growth again, but you wouldn't know it by looking at the stock's recent valuation.
- 05/20/2023
|
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
- Both stocks have outpaced the S&P 500 so far this year. Vertex is a long-time leader in the treatment of cystic fibrosis.
- 05/19/2023
|
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
- The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affecting our society and healthcare system.
- 05/19/2023
|
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
- Vertex Pharmaceuticals Inc. NASDAQ: VRTX, maker of Cystic fibrosis drugs, rallied to a record high on May 2 after a better-than-expected first-quarter earnings report.
- 05/18/2023
|
Vertex Pharmaceuticals Offers Value Despite Recent Gains
- Investing in the pharmaceutical industry carries substantial risks because of the uncertainty surrounding it. Investors have to deal with both regulatory and economic uncertainty and closely monitor the progress of clinical trials to identify inflection points.
- 05/16/2023
|
Vertex Pharmaceuticals Incorporated (VRTX) Presents at BofA Securities 2023 Health Care Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) BofA Securities 2023 Health Care Conference May 9, 2023 12:20 PM ET Company Participants Charlie Wagner - EVP and CFO David Altshuler - CSO and EVP, Global Research Conference Call Participants Geoff Meacham - Bank of America Geoff Meacham Welcome to the first morning of the BofA Healthcare Conference. I'm Geoff Meacham.
- 05/13/2023
|
3 Growth Stocks to Buy and Hold
- Axsome's relatively new approval was only the first step in an exciting growth story. Eli Lilly has a strong pipeline that will help improve its already-solid financial results.
- 05/13/2023
|
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
- Investors will love Johnson & Johnson's commitment to dividend payments. Vertex Pharmaceuticals already delivers billion-dollar earnings -- and new programs could further lift growth.
- 05/11/2023
|
This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?
- Vertex Pharmaceuticals' cystic fibrosis drugs are extending the lives of child and adult patients. Now, babies as young as one month old may benefit from one of the company's treatments.
- 05/11/2023
|
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock
- Warren Buffett has a laser-like focus on owning companies with limited competition, stellar management, and sustainable profits. The rare disease specialist Vertex Pharmaceuticals ticks all of these boxes, despite operating in a fiercely competitive industry.
- 05/06/2023
|
2 Potentially Explosive Stocks to Buy in May
- Stag Industrial is a real estate investment trust that benefits from e-commerce expansion. Vertex Pharmaceuticals is a leader in cystic fibrosis therapies.
- 05/04/2023
|
Here's 1 Magnificent Reason to Buy Vertex Pharmaceuticals Stock
- It is the only company that has succeeded in treating the underlying causes of cystic fibrosis. The biotech is still working in this area, and given its track record, it's hard to bet against it.
- 05/03/2023
|
Vertex Pharmaceuticals Just Lost a Potential Rival. Is the Stock a Buy?
- Vertex has generated billions of dollars from its cystic fibrosis treatments. Another big drugmaker aimed to get into the market -- until recently.
- 05/02/2023
|
Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y
- Vertex Pharmaceuticals' (VRTX) first-quarter 2023 earnings and sales beat estimates. Management reiterates financial guidance for 2023.
- 05/02/2023
|
2 Supercharged Stocks to Buy for 2023 and Hold for at Least 10 Years
- These two healthcare giants have made names for themselves in two very different sectors. Vertex is a powerhouse in the rare disease drug space and also has several promising candidates.
- 05/02/2023
|
2 Incredible Growth Stocks That Could Turn $20,000 Into $100,000 by 2030
- Healthcare and tech aren't slowing down, and intriguing buying opportunities abound in both spaces. Vertex Pharmaceuticals is a profitable healthcare business that is only in the early innings.
- 05/02/2023
|
Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie
- AbbVie announced last week that it's shutting down its cystic fibrosis (CF) program. This decision makes Vertex's monopoly in CF even stronger.
- 05/02/2023
|
Vertex Pharmaceuticals Incorporated (VRTX) Q1 2023 Earnings Call Transcript
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Susie Lisa - CFA, Senior Vice President, Investor Relations Reshma Kewalramani - President and Chief Executive Officer Stuart Arbuckle - Executive Vice President and Chief Operating Officer Charlie Wagner - Executive Vice President and Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs David Risinger - SV8 Securities Mohit Bansal - Wells Fargo Geoff Meacham - Bank of America Phil Nadeau - Cowen and Company Andrew Tsai - Jefferies Will Pickering - Bernstein Jessica Fye - JPMorgan Colin Bristow - UBS Operator Good day, and welcome to the Vertex Pharmaceuticals First Quarter 2023 Conference Call. All participants will be in a listen-only mode.
- 05/01/2023
|
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Surpass Estimates
- Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.05 per share, beating the Zacks Consensus Estimate of $2.95 per share. This compares to earnings of $3.52 per share a year ago.
- 05/01/2023
|
2 Stocks That Could Turn $200,000 Into $1 Million by the Time You Retire
- Investing in all market environments is vital to growing your portfolio over time. Upstart is partnering with some pretty impressive names as it builds out its network and long-term growth vision.
- 04/30/2023
|
3 Unstoppable Stocks to Buy Right Now
- AbbVie has several blockbusters to drive growth despite facing sales declines for Humira. Pfizer has much better long-term prospects than might meet the eye.
- 04/29/2023
|
Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?
- Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 04/28/2023
|
2 Growth Stocks That Could Double in 5 Years
- Vertex Pharmaceuticals will significantly expand its lineup over the next five years. DexCom's continuous glucose monitoring system should have a long growth runway.
- 04/27/2023
|
3 Biotech Stocks To Watch Today
- Biotech stocks for your late-April 2023 watchlist.
- 04/25/2023
|
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 at 9:20 a.m. PT/12:20 p.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a.
- 04/25/2023
|
3 Healthcare Stocks That Could Help Make You a Fortune
- Vertex Pharmaceuticals is a leader in its field, bringing in billions of dollars in annual earnings. Teladoc Health has steadily grown revenue, and telemedicine visits, by at least double-digit percentages.
- 04/24/2023
|
Final Trades: Gilead, Vertex, Wynn & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 04/20/2023
|
Better Big Biotech Buy: Biogen vs. Vertex
- Biogen and Vertex are both waiting on big regulatory decisions for potential products. The companies each bring in billions of dollars in revenue every year.
- 04/20/2023
|
BMEZ: Attractive Discount On This Riskier Healthcare Fund
- BMEZ: Attractive Discount On This Riskier Healthcare Fund.
- 04/20/2023
|
Have $1,000? 2 Explosive Growth Stocks to Buy and Hold No Matter What the Market Does Next
- Long-term investors needn't fear the unpredictable highs and lows of the market. Vertex is the leader in cystic fibrosis treatment and is looking to broaden out its portfolio.
- 04/20/2023
|
Why Vertex (VRTX) Could Beat Earnings Estimates Again
- Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/18/2023
|
Got $5,000? Buy and Hold These Fast-Growing Stocks for Years
- Vertex stock could take off if a gene-editing therapy obtains approval this year. Shopify's stock has taken a beating, but it still has plenty of growth opportunities.
- 04/18/2023
|
3 High-Growth Biotech Stocks Poised for Success in 2023
- Many investors look for growth opportunities wherever they can find them. If that describes you, then there are some high-growth biotech stocks that could present an opportunity.
- 04/18/2023
|
The Fed Thinks a Recession Is More Likely: Here Are 3 Great Stocks to Buy Now
- Dollar General is arguably the ultimate recession-proof stock. Johnson & Johnson is a favorite safe-haven stock for investors during economic downturns.
- 04/18/2023
|
Prediction: These Will Be 3 of the Biggest Monster Stocks of the Decade
- MercadoLibre combines e-commerce, fintech, and emerging market opportunities in one fell swoop. The Trade Desk has a massive opportunity with the rapid growth in connected TV.
- 04/17/2023
|
2 Nasdaq Growth Stocks That Are Screaming Buys in April
- Vertex Pharmaceuticals has a relatively safe top line, and more growth on the way. CRISPR Therapeutics is on track to start realizing revenue growth like wild.
- 04/13/2023
|
Could This Move Make Vertex's Next Blockbuster Even Bigger?
- Vertex Pharmaceuticals recently completed regulatory requests for its blood disorder candidate, exa-cel. Exa-cel has what it takes to become a blockbuster over time.
- 04/12/2023
|
Vertex to Announce First Quarter 2023 Financial Results on May 1
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2023 financial results on Monday, May 1, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the “Vertex Pharmaceuticals First Quarter 2023 Earnings Call.
- 04/10/2023
|
My 5 Top Stocks to Buy in April
- Two of these stocks have technology ties, one in cloud hosting and the other in adtech. Two are in the energy sector and offer great dividends plus solid growth prospects.
- 04/10/2023
|
2 Winning Stocks That Could Turn $10,000 into $50,000 by 2030
- Even another market downturn could present opportunities for long-term investors. Vertex Pharmaceuticals isn't slowing down, but more growth opportunities could be on the near horizon.
- 04/09/2023
|
3 No-Brainer Stocks to Buy in a New Bull Market
- Novo Nordisk has exceptional growth prospects with its diabetes and obesity drugs. Pfizer isn't getting the respect it deserves.
- 04/08/2023
|
5 S&P 500 Stocks Showing Strength As Recession Fears Rise
- Medical stocks are holding up amid economic and market uncertainty. The post 5 S&P 500 Stocks Showing Strength As Recession Fears Rise appeared first on Investor's Business Daily.
- 04/07/2023
|
2 Once-in-a-Decade Buying Opportunities in a Growth Stock Bear Market
- The healthcare industry is full of intriguing and resilient investment opportunities. Intuitive Surgical has unrivaled market leadership and many sources of revenue.
- 04/07/2023
|
A Bull Market Is Coming: 2 Unstoppable Growth Stocks to Scoop Up Right Now
- Healthcare and athleisure are massive and fast-growing industries, and even a recession can't slow them down for long. Vertex Pharmaceuticals could be in the early days of its growth story.
- 04/07/2023
|
2 Smartest Growth Stocks to Buy Without Hesitation Right Now
- Growth stocks aren't all facing struggles right now. Vertex is boosting profits, and its product pipeline is more promising than ever.
- 04/06/2023
|
Where to Invest $2,500 Right Now
- Despite market volatility, there's always opportunity to invest in quality businesses. Vertex Pharmaceuticals is working on drugs that could revolutionize the rare disease drug market.
- 04/06/2023
|
2 Top Stocks to Buy Before the Next Nasdaq Bull Market
- The volatile market doesn't mean investors need to stay inactive on the sidelines. Vertex Pharmaceuticals is gearing up for another product launch in the not-too-distant future.
- 04/06/2023
|
Cathie Wood Boosts Biotech Holdings, Coinbase Stake - Beam Therapeutics (NASDAQ:BEAM), ARK Genomic Revolution ETF (BATS:ARKG), CRISPR Therapeutics (NASDAQ:CRSP), Ginkgo Bioworks Holdings (NYSE:DNA), Vertex Pharmaceuticals (NASDAQ:VRTX), Verve Therapeutics (NASDAQ:VERV), Coinbase Glb (NASDAQ:COIN), ARK Innovation ETF (ARCA:ARKK), Intellia Therapeutics (NASDAQ:NTLA)
- Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attractive in terms of valuations.
- 04/06/2023
|
Vertex Is 1 Step Closer to Bringing a New Blockbuster to Market. Time to Buy?
- Vertex Pharmaceuticals is a top seller of cystic fibrosis treatments -- but it's about to expand into a new growth area. Vertex and partner CRISPR Therapeutics have just completed the submission of their blood disorders treatment candidate to U.S. regulators.
- 04/04/2023
|
A Nasdaq Bull Market Could Begin in April: 3 Top Stocks to Buy Now
- Alphabet's valuation and long-term prospects look really attractive. The Trade Desk has plenty of room to run with the explosive growth of connected TV.
- 04/02/2023
|
5 Top Stocks for April
- The sell-off in growth stocks has been brutal. Bridging the gap between investor expectations and reality can lead to sizable stock rebounds.
- 04/02/2023
|
Have $2,000? 2 Exceptional Stocks to Buy In a Bear Market
- A turbulent market can be tough for investors, but great companies remain ripe for the picking. Intuitive Surgical has seen a slowdown in procedure volumes recently, but it's for short-term reasons.
- 03/31/2023
|
2 Top Stocks to Buy With $1,000 Right Now
- Growth stocks are facing headwinds at the moment, but not all such stocks are falling. Vertex continues to enrich investors in a turbulent market, and it's not hard to understand why.
- 03/30/2023
|
2 No-Brainer Stocks to Buy Before the Next Bull Market
- Investing consistently in both up and down markets can help you toward your long-term financial goals. Vertex boasts a profitable portfolio, and it could see another approval around the corner.
- 03/30/2023
|
2 No-Brainer Growth Stocks to Buy and Hold for Years
- Even if another bear market happens, these businesses have what it takes to thrive and survive over the long haul. Vertex Pharmaceuticals serves a growing addressable market with its portfolio of profitable cystic fibrosis drugs.
- 03/30/2023
|
Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie
- Vertex and AbbVie both beat the bear market last year. Both these top companies have reached an important moment in their stories -- and more growth may be on the horizon.
- 03/29/2023
|
Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
- Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.
- 03/28/2023
|
3 Small Financial Software Makers Showing Strong Chart Action
- While the enterprise software makers are in the doldrums, and the financial sector tries to recover from a battering, a few specialty software firms, including Intapp Inc. (NASDAQ: INTA), Vertex Inc. (NASDAQ: VERX), and GuidewIre Software Inc. (NYSE: GWRE) are headed toward greater profitability, and also boast strong chart action.
- 03/28/2023
|
Bullish News May Push Vertex Pharmaceuticals Above 52-Week High
- Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) is positioned to make a new run at the 52-week high of $325.19 as the stock is confirming a cup base pattern. The biotechnology company's stock is up 7.3% in the last month and just announced some news that could send the stock much higher.
- 03/28/2023
|
Want $1 Million in Retirement? Buy and Hold These 5 Stocks
- Two stocks that could make investors a lot of money are poised to benefit from the AI boom. One of the stocks is arguably more aligned with the U.S. economy's future than any other stock on the market.
- 03/26/2023
|
Nasdaq Bear Market: 2 Growth Stocks to Buy That Keep Bucking the Trend
- The Nasdaq Composite index has been down for over a year now, but some of its components are soaring. Vertex Pharmaceuticals is the only drugmaker selling lifesaving treatments for patients who inherit a lethal disorder.
- 03/25/2023
|
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 03/24/2023
|
This Is My Highest-Conviction Stock to Own in 2023 and Beyond
- Vertex Pharmaceuticals' business is insulated from the effects of economic cycles. The biotech's history of innovation continues, and it's aiming to diversify its lineup.
- 03/23/2023
|
The Best Stocks to Invest $20,000 in Right Now
- Few tech giants are as attractively valued right now as Alphabet. Wall Street is especially bullish about Amazon -- and for good reason.
- 03/21/2023
|
Brokers Suggest Investing in Vertex (VRTX): Read This Before Placing a Bet
- According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic.
- 03/20/2023
|
12-Stock Portfolio -- 25 Growth Stocks to Buy Now
- If I were starting a new growth stock portfolio today, here are the stocks I'd buy.
- 03/19/2023
|
Worried About the Banking Turmoil? These 3 Stocks Shouldn't Skip a Beat
- Brookfield Renewable is poised to profit from an unstoppable trend. Dollar General should thrive even if the banking sector's troubles worsen.
- 03/19/2023
|
Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug
- Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.
- 03/10/2023
|
This HealthCare Company Is Gearing Up for Its Next Launch: Here Is Why The Stock Is a Buy
- Vertex's next launch could open the door to a multibillion-dollar opportunity. The company also has other treatment candidates, not to mention its flagship lineup.
- 03/10/2023
|
Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold
- CRISPR Therapeutics is a clinical-stage biotech company. The company's pipeline includes two promising wholly owned therapies.
- 03/09/2023
|
2 No-Brainer Growth Stocks to Buy Right Now
- Vertex Pharmaceuticals is a highly profitable and rapidly growing business with serious untapped potential. Airbnb benefits from multiple aspects of the travel economy, and that could give it remarkable resilience if economic tides rise.
- 03/08/2023
|
Vertex Pharmaceuticals Incorporated (VRTX) 43rd Annual Cowen Healthcare Conference Transcript
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) 43rd Annual Cowen Healthcare Conference March 7, 2023 2:50 PM ET Company Participants Reshma Kewalramani – President and Chief Executive Officer Charlie Wagner – Chief Financial Officer Conference Call Participants Phil Nadeau – Cowen Phil Nadeau [Call Starts Abruptly] Annual Healthcare Conference. I'm Phil Nadeau, one of Cowen's biotech analysts, and it's my pleasure to do a fireside chat with one of the bellwethers of the industry, Vertex.
- 03/07/2023
|
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
- The 2022 Nobel Prize in Chemistry went to Emmanuelle Charpentier and Jennifer Doudna for their work on developing tools to change the genetic code of living cells, tools called CRISPR/Cas. Yet long before their trip to Stockholm, they and other scientists had been diligently founding companies to monetize this new discovery.
- 03/06/2023
|
Here's How Much You Can Make From Investing Your Tax Return Every Year
- Doing this can strengthen your retirement plan.
- 02/27/2023
|
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
- These stocks have something to offer every type of investor.
- 02/21/2023
|
Got $1,500? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
- These companies are raking in profits and growing at a speed that outpaces the competition.
- 02/19/2023
|
2 No-Brainer Growth Stocks to Buy Right Now
- Don't let these incredible businesses pass you by.
- 02/19/2023
|
3 Unstoppable Growth Stocks to Buy for 2023 and Beyond
- The future looks really bright for these businesses -- and their stocks.
- 02/13/2023
|
2 Top Stocks to Buy in February and Hold Forever
- These healthcare giants are profitable and have wide moats.
- 02/13/2023
|
3 Surefire Growth Stocks You Can Buy Right Now
- Maybe there's no such thing as a sure thing. But these stocks could come close.
- 02/11/2023
|
2 Biotech Stocks That Could Help Set You Up for Life
- The two companies have seen similar share growth over the past year.
- 02/11/2023
|
This Growth Stock Crushed the Market Last Year. 5 Words from the CEO Suggest There's More to Come.
- Vertex climbed 31% last year even as the overall market fell.
- 02/11/2023
|
Is Vertex Pharmaceuticals Stock a Buy Right Now?
- The drugmaker outperformed the broad market by a mile in 2022, but could there be further gains?
- 02/10/2023
|
Vertex Pharmaceuticals: As Strong As Ever In Cystic Fibrosis
- CF products bring in more than $2.3 billion in quarterly and almost $9 billion in annual revenues. The biggest earner is up for FDA approval for very young children in April.
- 02/09/2023
|
Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals?
- Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals.
- 02/09/2023
|
Vertex Pharmaceuticals: Pioneering Scientific Advances To Tackle Serious Diseases
- Vertex Pharmaceuticals focuses on creating transformative medicines for serious diseases, with a special emphasis on specialty markets. The company's research and development efforts have been successful, leading to the launch of four medicines for cystic fibrosis that funds the company's R&D projects.
- 02/08/2023
|
2 Top Biotech Stocks Defying the Bear Market
- These stocks soared in the double digits last year.
- 02/08/2023
|
Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging
- Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023.
- 02/08/2023
|
Here's What Key Metrics Tell Us About Vertex (VRTX) Q4 Earnings
- Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/08/2023
|
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2022 Earnings Call Transcript
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q4 2022 Earnings Conference Call February 7, 2023 4:30 PM ET Company Participants Susie Lisa – Senior Vice President-Investor Relations Reshma Kewalramani – Chief Executive Officer and President Stuart Arbuckle – Chief Operating Officer Charlie Wagner – Chief Financial Officer Conference Call Participants Salveen Richter – Goldman Sachs Geoff Meacham – Bank of America Phil Nadeau – Cowen Liisa Bayko – Evercore ISI David Risinger – SVB Robyn Karnauskas – Truist Mohit Bansal – Wells Fargo Jessica Fye – JPMorgan Evan Seigerman – BMO Capital Markets Operator Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter and Full Year 2022 Conference Call. All participants will be in a listen-only mode.
- 02/07/2023
|
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Beat Estimates
- Vertex (VRTX) delivered earnings and revenue surprises of 6.52% and 0.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/07/2023
|
Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views
- Vertex Pharmaceuticals offered an upbeat look for 2023 sales after reporting an earnings beat and in-line sales. But VRTX stock was muted.
- 02/07/2023
|
The 7 Best Biotech Stocks to Buy for February 2023
- While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy.
- 02/07/2023
|
Is Biotech Immunocore About To Make A 25% Price Move?
- The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.
- 02/07/2023
|
3 Top Stocks to Buy If There Is a Market Pullback
- All three of these stocks performed well as the market fell in 2022.
- 02/07/2023
|
3 Nasdaq 100 Stocks to Buy Hand Over Fist in February
- The growth-focused Nasdaq 100 is home to three exceptional deals.
- 02/07/2023
|
Is a Recession on the Way? Here's What the Top 7 Indicators Say.
- If these indicators were in a Magic 8 Ball, they'd probably say, "Ask again later."
- 02/06/2023
|
3 No-Brainer Stocks to Buy in February
- Going with these stocks should be an easy decision.
- 02/02/2023
|
A New Bull Market Could Arrive in February: 3 Stocks to Buy Now
- The bulls could be about to take over again. And these stocks are poised to be big winners.
- 02/01/2023
|
10 Biggest Companies Reporting Earnings in the Second Week of Feb 2023
- The fourth quarter 2022 earnings season continues to be subpar for the S&P 500.
- 01/31/2023
|
This Clue Helps Spot The Best Stocks To Watch, Including These 11
- The best stocks to watch often hail from the top-ranked industries. Here's a look 11 stocks, including VRTX ad ULTA, that fit that bill.
- 01/31/2023
|
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/31/2023
|
Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride
- Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.
- 01/27/2023
|
7 Cream-of-the-Crop Stocks to Buy Today
- Investors are scurrying to find stocks to buy as the market stages a strong uptrend this year. Of course, people make money when prices go up.
- 01/25/2023
|
BP Stock, Baidu Lead 5 Stocks Near Buy Points With Big Growth Potential
- BP and Chinese search leader Baidu lead this weekend's watch list of 5 stocks near buy points with strong growth opportunities. The post BP Stock, Baidu Lead 5 Stocks Near Buy Points With Big Growth Potential appeared first on Investor's Business Daily.
- 01/21/2023
|
3 Smart Stocks to Buy if a Recession Is on the Way
- Their products will enjoy strong demand regardless of what happens with the economy.
- 01/21/2023
|
The Best Stocks to Invest $5,000 In Right Now
- It's still a great time to be a long-term investor.
- 01/20/2023
|
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
- The healthcare industry isn't going anywhere.
- 01/20/2023
|
Why Vertex Pharmaceuticals (VRTX) is a Top Growth Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 01/18/2023
|
5 Reasons to Buy Vertex Pharmaceuticals Now
- Vertex shares are extending last year's gains, and that trend probably isn't over.
- 01/18/2023
|
3 Biopharma Stocks That Could Help Make You a Fortune
- All three are protected by sales of in-demand products, with more on the way.
- 01/16/2023
|
3 Dirt Cheap Stocks to Buy in January
- Bargains can easily be found as the new year gets underway.
- 01/14/2023
|
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
- Vertex is heading for a new phase of growth.
- 01/14/2023
|
1 Top Growth Stock Set to Crush the Market Again in 2023
- This company's long-term thesis looks impeccable.
- 01/12/2023
|
4 Growth Stocks to Buy and Hold Forever
- These stocks could be huge winners for patient investors.
- 01/12/2023
|
History Says Bull Should Bet On This Pharma Giant
- Shares of Vertex Pharmaceuticals (VRTX) have been in recovery mode since suffering a rapid fall from their Dec. 8 record peak of $324.75.
- 01/11/2023
|
Ranking The 10 Largest Biotechs By Pipeline
- The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights.
- 01/11/2023
|
3 Top Healthcare Stocks to Buy for January
- These healthcare stocks have a lot going for them in the new year.
- 01/11/2023
|
Royalty Pharma: An Attractive Business Model But An Uncertain Outcome For Vertex's CF Royalties
- Royalty Pharma purchases royalties on pharmaceutical products. Diversification provides some protection for investors and the company has invested in high quality assets.
- 01/09/2023
|
Vertex Pharmaceuticals Incorporated (VRTX) 41st Annual J.P. Morgan Healthcare Conference - (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) 41st Annual J.P. Morgan Healthcare Conference Call January 9, 2023 11:15 AM ET Company Participants Reshma Kewalramani - Chief Executive Officer and President Charlie Wagner - Chief Financial Officer Stuart Arbuckle - Chief Operating Officer David Altshuler - Executive Vice President, Global Research, and Chief Scientific Officer Conference Call Participants Jessica Fye - J.P.
- 01/09/2023
|
6 Favorite Biotech Bets For 2023
- Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's a six-pack of favorite biotech ideas for the coming year.
- 01/09/2023
|
2 Healthcare Stocks That Could Make You Richer
- The healthcare industry presents opportunities for both growth and value investors.
- 01/08/2023
|
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years
- Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.
- 01/07/2023
|
Looking for Growth in 2023? Where to Invest $5,000
- Over time, some of last year's losers could win big.
- 01/07/2023
|
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.
- These stocks look cheap if you take a long-term view.
- 01/07/2023
|
3 Biotech Companies to Watch in 2023
- Biotech stocks are in high demand right now, with good reason. Indeed, these biotech companies have the potential to revolutionize the medical world and offer solutions to unmet needs, while their relevance is recession-proof.
- 01/06/2023
|
10 Top Stocks That Can Make You Richer in 2023
- A new year brings new opportunities for investors to build their wealth on Wall Street.
- 01/04/2023
|
3 Stocks to Buy for 2023 That Are Practically Money Machines
- If money makes the world go round, these three stocks could have it really spinning.
- 01/03/2023
|
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
- Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.
- 12/30/2022
|
5 Stocks That Outperformed the S&P 500 in 2022
- According to the All-in-one Screener, a Premium feature of GuruFocus, five stocks that outperformed the Standard & Poor's 500 index in 2022 yet are modestly undervalued based on GuruFocus' GF Value measure are Vertex Pharmaceuticals Inc. ( VRTX , Financial), Air Products & Chemicals Inc. ( APD , Financial), Fiserv Inc. ( FISV , Financial), Marathon Petroleum Corp. ( MPC , Financial) and VMware Inc. ( VMW , Financial).
- 12/30/2022
|
3 Biotech Stocks to Watch Heading Into 2023
- Pharma and biotech stocks are enjoying tailwinds as part of the broad market rally today.
- 12/29/2022
|
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
- These two biotechs are flying high right now.
- 12/29/2022
|
FDA Approval, Top Funds Lift Drugmaker In Ailing Market
- Boosted by demand among the best mutual funds and an FDA approval, AbbVie shows strength in ailing market. The post FDA Approval, Top Funds Lift Drugmaker In Ailing Market appeared first on Investor's Business Daily.
- 12/29/2022
|
5 Unstoppable Trends to Invest $5,000 in for 2023
- These trends won't fade away, and some of the companies that are positioned to ride them should be big winners.
- 12/29/2022
|
Vertex: Progress Towards Expanding Cystic Fibrosis Market Continues
- CF product revenues grew by 18% in Q3 of 2022 to $2.33 billion. TRIKAFTA continues uptake in the U.S. but larger 49% sales growth was observed in territories outside of the U.S. VX-522 is being developed in collaboration with Moderna to treat 5,000 Cystic Fibrosis patients who do not currently respond to CFTR drugs available. Goal to replace functional CFTR gene.
- 12/28/2022
|
Is Vertex Pharmaceuticals a Buy?
- There's more growth ahead for this biotech giant.
- 12/27/2022
|
Here Are the Best Stocks To Own as 2022 Draws to a Close
- They have what it takes to deliver growth over time.
- 12/26/2022
|
After Doubling in the Past 6 Months, Is This Stock a Buy?
- This company has had a solid year, but there is still plenty of work ahead.
- 12/24/2022
|
Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
- For many investors, now would be an opportune time to take advantage of great stocks trading at a discount.
- 12/21/2022
|
Vertex Pharmaceuticals: Expect Growth Beyond Trikafta
- Vertex revenue grew 18% y/y in Q3 2022. The robust pipeline propels Vertex beyond the cystic fibrosis market.
- 12/20/2022
|
Where Will Vertex Pharmaceuticals Be in 10 Years?
- Expect a bigger, more diversified, and more entrenched entity to emerge over the coming years.
- 12/18/2022
|
Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move
- These stocks have climbed by double digits this year.
- 12/18/2022
|
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
- Both stocks are heading for double-digit gains this year.
- 12/18/2022
|
My 3 Best Stocks of 2022 -- and Why I Think They'll Win Again in 2023
- The momentum for these high-flying stocks should continue in the new year.
- 12/18/2022
|
Should You Buy Stocks If a Recession Is Coming in 2023? Here's What History Shows.
- Stocks usually go down during recessions, but long-term investors can still come out on top.
- 12/17/2022
|
4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
- Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.
- 12/16/2022
|
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 12/14/2022
|
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 12/14/2022
|
Vertex (VRTX) to Start Clinical Study on mRNA-based CF Therapy
- Following clearance of the IND application by the FDA, Vertex (VRTX) intends to start a clinical study evaluating a single ascending dose of VX-522 in cystic fibrosis patients in the coming weeks.
- 12/13/2022
|
NASDAQ Stocks For The Santa Claus Rally
- Here are strong NASDAQ stocks for the holiday season.
- 12/13/2022
|
More Likely to 5X First: Johnson & Johnson vs. Vertex Pharmaceuticals
- This contest isn't even close.
- 12/13/2022
|
3 High-Flying Stocks to Buy and Hold If a Recession Is on the Way
- An economic downturn shouldn't hurt these stocks.
- 12/13/2022
|
3 Non-Energy S&P 500 Stocks With Enough Energy to Boost Returns
- Though energy companies have been among the best-performing stocks in the S&P 500 index, here we discuss some top-performing non-energy S&P 500 stocks like MRK, VRTX and MCK.
- 12/12/2022
|
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
- BOSTON and ZUG, Switzerland--( BUSINESS WIRE )--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced an oral, encore presentation of clinical data from patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT) treated with the investigational therapy exagamglogene autotemcel (exa-cel) in CLIMB-111 or CLIMB-121 and followed in CLIMB-131, a long-term follow-up study. Vertex will also present new health economics and outcomes research from multiple studies in patients with SCD and TDT.
- 12/10/2022
|
3 High-Flying Stocks in 2022 That Should Keep Soaring in 2023
- These stocks' tailwinds should continue blowing in the new year.
- 12/10/2022
|
Our 7 Top Biotech Stock Picks for 2023
- If there's a silver lining regarding the coronavirus pandemic, it's that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 crisis proved that when humanity comes together, it can foster incredible advancements at breakneck speed.
- 12/09/2022
|
3 Reasons Growth Investors Will Love Vertex (VRTX)
- Vertex (VRTX) could produce exceptional returns because of its solid growth attributes.
- 12/08/2022
|
2 Sector ETFs Hovering Around a 52-Week High
- We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.
- 12/06/2022
|
3 Stocks to Buy Before 2023 That Can Set You Up for Life
- These stocks are already good buys right now.
- 12/06/2022
|
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
- The company has already made plenty of investors happy.
- 12/06/2022
|
GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe
- GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.
- 12/05/2022
|
Is This Biotech Stock a Buy Following a Landmark Approval?
- You may not want to be too quick to pull the trigger.
- 12/04/2022
|
3 Stocks to Buy Hand Over Fist in December
- These stocks could be big winners.
- 12/03/2022
|
My 2 Top Growth Stocks to Buy for 2023 and Beyond
- Long-time shareholders of these companies can testify that both have patterns of beating the market.
- 12/03/2022
|
12 Top Stocks to Buy in December
- Add this dandy dozen to your stocking this month.
- 12/03/2022
|
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts - Beam Therapeutics (NASDAQ:BEAM), BioNTech (NASDAQ:BNTX)
- Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding around 0.5% on Thursday.
- 12/02/2022
|
Vertex Pharmaceuticals Incorporated present at 5th Annual Evercore ISI HealthCONx Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) 5th Annual Evercore ISI HealthCONx Conference November 30, 2022 9:15 AM ET Company Participants Stuart Arbuckle - COO Conference Call Participants Liisa Bayko - Evercore ISI Liisa Bayko Hi there. This is Liisa Bayko, Biotech Analyst at Evercore ISI.
- 12/01/2022
|
7 Undervalued Biotech Stocks to Buy Before They Boom
- You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.
- 11/29/2022
|
Vertex Pharmaceuticals: Growth Outside Of Cystic Fibrosis Critical For Additional Value Creation
- Vertex reported strong results in the third quarter, driven by growth in ex-U.S. markets. The cystic fibrosis franchise will soon peak due to very high penetration rates and the company will need to rely on pipeline and business development for additional value creation.
- 11/29/2022
|
2 Stocks Near 52-Week Highs That Could Climb Higher
- This pair of stocks are bucking the trend and they could climb even higher.
- 11/28/2022
|
Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead
- The ARK Invest founder might regret trimming her position in this biotech stock.
- 11/25/2022
|
7 Stocks on the Perfect 10 List
- A stock that scores a perfect 10 should be on every investor's list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I'd considering a perfect 10.
- 11/23/2022
|
We still think there's more room for biotech to go higher, says Jefferies' Yee
- Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late to 'nibble' on stocks in the sector.
- 11/22/2022
|
Why Vertex Pharmaceuticals (VRTX) is a Top Value Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 11/21/2022
|
3 Unstoppable Growth Stocks to Buy and Hold
- These businesses are built for the long run.
- 11/19/2022
|
3 Top Growth Stocks to Buy Sooner Rather Than Later
- There's no time like the present to invest in these great companies.
- 11/18/2022
|
VRTX or TECH: Which Is the Better Value Stock Right Now?
- VRTX vs. TECH: Which Stock Is the Better Value Option?
- 11/17/2022
|
Vertex Pharmaceuticals Incorporated (VRTX) Jefferies London Healthcare Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Jefferies London Healthcare Conference November 16, 2022 4:10 AM ET Company Participants Stu Arbuckle – Executive Vice President and Chief Operating Officer Conference Call Participants Michael Yee – Jefferies Michael Yee Good morning, everyone. Well, thank you for joining us on day 2 of the 2022 London Global Healthcare Conference here at Jefferies; I'm Michael Yee, Managing Director and Biotechnology Analyst.
- 11/16/2022
|
2 Hot Growth Stocks That Can Continue to Soar in 2023
- Next year could be another strong one for both of these businesses.
- 11/16/2022
|
5 Top Stocks to Buy Before 2023
- These stocks have what it takes to win over time.
- 11/15/2022
|
This Biotech's Bull Signal Has Never Been Wrong
- Biotechnology concern Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has been a standout during the past year, joining some of its sector peers in notable annual returns.
- 11/14/2022
|
Vertex Pharmaceuticals: Buy at the High?
- Vertex is submitting a potential blockbuster to regulators this month.
- 11/14/2022
|
Vertex: High Growth For Years Ahead
- Vertex is the market leader company for Cystic Fibrosis disease. The company reports unexpected sales and earnings growth in recent quarters Q3.
- 11/13/2022
|
Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait a Decade
- These top stocks could be wise additions to a well-rounded investment portfolio.
- 11/12/2022
|
3 Top Healthcare Stocks Defying the Bear Market
- These healthcare companies haven't been slowed by macroeconomic conditions.
- 11/10/2022
|
Here is Why Growth Investors Should Buy Vertex (VRTX) Now
- Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 11/08/2022
|
Got $1,000? 2 Smart Stocks to Consider Buying Right Now
- Don't overlook these major healthcare names on your next stock-buying spree.
- 11/06/2022
|
Got $1,000? 2 No-Brainer Stocks to Buy and Hold for at Least the Next Decade
- Don't let these stocks pass you by.
- 11/06/2022
|
4 Growth Stocks to Buy and Hold Forever
- If you're hunting for top growth stocks on sale, you've come to the right place.
- 11/05/2022
|
TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down
- TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
- 11/04/2022
|
2 Biotech Stocks That Could Make You Richer
- Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.
- 11/04/2022
|
Bear Market Investing: Should You Buy Today's Top Performers?
- Some stocks are defying the bear market.
- 11/03/2022
|
3 Nasdaq 100 Stocks to Buy Hand Over Fist in November
- The innovation-packed Nasdaq 100 has three screaming bargains that are ripe for the picking.
- 11/03/2022
|
Is Vertex Pharmaceuticals About to Become a Dividend Stock?
- The big biotech has a cash stockpile of nearly $10 billion. Here's how Vertex plans to use the money.
- 11/02/2022
|
Here's a No-Brainer Stock to Buy Now That's Trouncing the Market
- There are five great reasons this stock should continue to soar.
- 10/31/2022
|
The Best Stocks to Invest $20,000 in Right Now
- A long-term investment in any of these powerhouse stocks could reap generous returns for many years to come.
- 10/30/2022
|
This Bear Market Could Be the Best Investing Opportunity in More Than a Decade
- It could be time to party like it's 2009.
- 10/29/2022
|
Why Shares of Vertex Pharmaceuticals Jumped 9.03% on Friday
- A strong earnings report after the close on Thursday pushed the stock higher all day Friday.
- 10/28/2022
|
Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance
- Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022.
- 10/28/2022
|
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2022 Earnings Call Transcript
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q3 2022 Earnings Conference Call October 27, 2022 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Dr. Reshma Kewalramani - President and CEO Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Salveen Richter - Goldman Sachs Phil Nadeau - Cowen & Company Evan Seigerman - BMO David Risinger - SVB Securities Kripa Devarakonda - Truist Securities Jessica Fye - JPMorgan Operator Good day. And welcome to the Vertex Pharmaceuticals Third Quarter 2022 Earnings Call.
- 10/27/2022
|
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates
- Vertex (VRTX) delivered earnings and revenue surprises of 8.67% and 4.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/27/2022
|
Vertex Pharmaceuticals Jumps After Quarterly Beat, Raises 2022 Outlook
- Vertex Pharma beat third-quarter expectations Thursday and raised its sales outlook, helping VRTX stock shrug off some regular session pain. The post Vertex Pharmaceuticals Jumps After Quarterly Beat, Raises 2022 Outlook appeared first on Investor's Business Daily.
- 10/27/2022
|
2 Monster Stocks to Buy Without Any Hesitation
- These stocks are crushing the bear market.
- 10/26/2022
|
Which Stocks Are Most Likely to Thrive in a Recession? Here's What History Shows
- Recession-proof stocks must offer something that makes investors want to buy them even when the economy is tanking.
- 10/23/2022
|
2 Powerhouse Stocks That Could Go Parabolic
- These stocks could take you by surprise.
- 10/22/2022
|
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
- Procrastination could be problematic with these three bargain stocks.
- 10/22/2022
|
S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength
- S&P 500 giant Vertex and Cheniere Energy, the largest U.S. liquefied natural gas producer, are setting up bullishly in the bear market. The post S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength appeared first on Investor's Business Daily.
- 10/22/2022
|
This Beaten-Down ETF Is Still a Screaming Bear-Market Buy
- Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund.
- 10/21/2022
|
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
- Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
- 10/20/2022
|
2 Unstoppable Stocks That Are Beating the Bear Market
- Is it too late to buy these stocks or are their shares likely to continue rising?
- 10/19/2022
|
3 Red-Hot Stocks That Could Continue to Beat the Market
- Investors are betting on these companies' revenue growth prospects.
- 10/13/2022
|
Vertex Pharmaceuticals' (VRTX) New AAT Corrector Enters Clinic
- The FDA clears Vertex's (VRTX) Investigational New Drug application for VX-634, a small molecule AAT corrector, thereby allowing the company to initiate a first-in-human clinical study in healthy volunteers.
- 10/12/2022
|
Silicon Carbide Leader Drives EVs, 5G — And Strong Sales
- With plans to build the world's largest silicon carbide plant and big EPS estimates ahead, Wolfspeed looks to charge up a fresh breakout. The post Silicon Carbide Leader Drives EVs, 5G — And Strong Sales appeared first on Investor's Business Daily.
- 10/10/2022
|
Here's Why You Should Invest in Vertex (VRTX) Stock Now
- Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.
- 10/10/2022
|
These 7 Biotech Stocks Are Set to Boom in 2023
- Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure.
- 10/10/2022
|
2 Cathie Wood Stocks That Are Beating the Market This Year
- One is doing much better than the other year to date, but they both have solid prospects ahead.
- 10/07/2022
|
4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire
- This quartet of stocks has plenty of growth ahead and is already profitable.
- 10/07/2022
|
This Biotech Stock Nears Buy Point As It Expands Into Other Markets
- Vertex Pharmaceuticals is approaching a buy point as this biotech stock expands into other markets, gains institutional investors. The post This Biotech Stock Nears Buy Point As It Expands Into Other Markets appeared first on Investor's Business Daily.
- 10/06/2022
|
Why Vertex Pharmaceuticals' Shares Rose 2.8% in September
- The company has a potential blockbuster drug that was granted rolling review status by the FDA.
- 10/05/2022
|
3 Healthcare Stocks That Could Make You Richer
- It's all about much-needed products.
- 10/05/2022
|
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
- Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- 10/04/2022
|
1 Growth Stock That'll Beat Amazon and 1 That Probably Won't (for Now)
- The two companies are collaborators, but they aren't equally likely to be a better purchase than Amazon.
- 10/04/2022
|
Vertex Pharmaceuticals: A Buy For Growth Potential
- Vertex's cystic fibrosis franchise is the main source of value at present. Q2 revenue was up 22% from the year-earlier.
- 10/04/2022
|
Spiros Segalas Snatches Up Vertex Pharmaceuticals, Sells Snap
- Spiros Segalas (Trades, Portfolio), manager of the Harbor Capital Appreciation Fund, disclosed his 13F portfolio for the third quarter of 2022 last week.
- 10/03/2022
|
Vertex Among 9 Stocks To Watch In Struggling Market
- As the market indexes work through a downturn, Vertex is among nine stocks to watch showing relative strength. The post Vertex Among 9 Stocks To Watch In Struggling Market appeared first on Investor's Business Daily.
- 10/03/2022
|
3 Growth Stocks Poised to Skyrocket
- Two of these three stocks are already soaring this year.
- 10/01/2022
|
Got $1,000? 2 Safe Stocks to Buy This Month
- The stocks can lend growth and peace of mind as you add to your portfolio.
- 09/30/2022
|
What's Driving Vertex Pharmaceuticals Stock Higher?
- Vertex Pharmaceuticals stock (NASDAQ: VRTX) has seen a 33% rise this year, significantly outperforming the broader S&P500 index, down 23%.
- 09/29/2022
|
Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy
- Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.
- 09/28/2022
|
The 2 Best Stocks to Invest $5,000 in Right Now
- These companies are successful today, and they're on track to be successful tomorrow too.
- 09/28/2022
|
Why Vertex Pharmaceuticals Stock Triumphed On Tuesday
- The biotech's exa-cel will be the subject of a rolling review by the FDA.
- 09/27/2022
|
CRISPR, Vertex say FDA granted rolling review to experimental CRISPR therapy
- CRISPR Therapeutics Inc. CRSP, +7.21% and Vertex Pharmaceuticals Inc. VRTX, +3.04% said Tuesday that the Food and Drug Administration granted a rolling review to the exagamglogene autotemcel, the therapy the companies are developing to treat sickle cell disease and transfusion-dependent beta thalassemia. CRISPR's stock was up 3.1% in premarket trading on Tuesday, while Vertex shares gained 1.1%.
- 09/27/2022
|
Is Now the Right Time to Be Buying Growth Stocks?
- There are plenty of fierce headwinds in play, but that doesn't mean you should sit on the sidelines.
- 09/25/2022
|
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
- S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market. The post S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market appeared first on Investor's Business Daily.
- 09/24/2022
|
Recession Fears Increasing: Here's the Best Stock to Buy Right Now
- There's a lot to like about this high-flying stock.
- 09/24/2022
|
7 Growth Stocks to Buy During a Stock Market Crash
- If investors weren't already worried, they should be following the disclosure of inflation numbers on Sept. 13. The U.S. had already experienced two straight quarters of GDP contraction.
- 09/23/2022
|
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
- Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- 09/21/2022
|
Should You Buy Stocks Right Now?
- The correct answer: It depends.
- 09/20/2022
|
Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook
- Vertex shares may be undervalued, as DCF analysis suggests little value is assigned to the pipeline. Vertex has a remarkably profitable CF franchise, but the quality advancing pipeline offers an opportunity for substantial growth over a 5-10 year time frame.
- 09/19/2022
|
3 Stocks to Buy and Hold Forever
- These businesses are built for the long run.
- 09/17/2022
|
Vertex Pharmaceuticals Holds Steady In Stormy Market
- Strong earnings and outlook position Vertex well in this uncertain market. The post Vertex Pharmaceuticals Holds Steady In Stormy Market appeared first on Investor's Business Daily.
- 09/16/2022
|
3 Top Healthcare Stocks Defying the Bear Market
- There's reason to favor these stocks -- and hold on for the long term.
- 09/15/2022
|
Fed Could Boost Stocks On Sub 8% Inflation: Buy Vertex Pharmaceuticals, Sell Peloton
- Investors will pour cash into stocks if August inflation rises less than the expected 8%. Here is how to profit.
- 09/12/2022
|
3 Growth Stocks That Are Crushing It This Year
- These three biotech companies have bucked the trend of declining shares prices in their sector.
- 09/10/2022
|
Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?
- Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
- 09/09/2022
|
4 Phenomenal Growth Stocks Billionaires Are Buying Hand Over Fist
- Not even a bear market can keep select billionaire investors from piling into these fast-paced companies.
- 09/09/2022
|
Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers
- Following FDA approval for label expansion, Vertex Pharmaceuticals' (VRTX) Orkambi is now approved for treating cystic fibrosis in children aged one year and older.
- 09/05/2022
|
These 3 Stocks Are the Future of Biotechnology
- Here's why three Fool.com contributors love Vertex Pharmaceuticals, Repligen, and Recursion Pharmaceuticals.
- 09/04/2022
|
Could Vertex Pharmaceuticals Stock Help You Retire a Millionaire?
- Vertex has been generating market-beating returns for years.
- 09/04/2022
|
2 Top Biotech Stocks to Buy Right Now
- They have what it takes to generate major revenue over the years to come.
- 09/04/2022
|
You can start to dip your toes into biotech here, says Jefferies' Yee
- Jefferies' Michael Yee joins 'Closing Bell' to discuss biotech stocks, which were one of the worst performers in today's sell-off. With CNBC's Michael Santoli.
- 09/02/2022
|
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 08/31/2022
|
My Hands-Down Favorite Stock to Buy in September
- This biotech stock offers a compelling risk-reward proposition.
- 08/31/2022
|
Are We in a New Bull Market or a Bear Market Bounce? Here's What History Shows
- The past looks encouraging for the future.
- 08/29/2022
|
3 Growth Stocks Poised to Skyrocket
- All of them could have huge catalysts on the way.
- 08/27/2022
|
5 Top Stocks Cathie Wood Is Selling This Week
- Shares of Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ) closed the week down about 2.5%, losing out on earlier gains during the week. However, retail investors haven't lost hope in ARKK, or Cathie Wood just yet.
- 08/26/2022
|
10 Stocks (Not In The Energy Sector) Are Up 30% Or More This Year
- It's been almost all about energy stocks in the S&P 500 this year. But not entirely.
- 08/26/2022
|
3 Stocks to Buy That Are Practically Inflation-Proof
- Inflation won't hurt these stocks and could actually help some of them.
- 08/26/2022
|
Where Will Vertex Pharmaceuticals Be in 1 Year?
- This top biotech has a lot to like, but will things change in the next 12 months?
- 08/23/2022
|
Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?
- Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.
- 08/22/2022
|
These Are The Biggest Companies with Over 30% Sales Growth
- Sales growth is a very important financial metric that investors consider before making a buy decision.
- 08/18/2022
|
Did a Surefire Signal to Buy Stocks Just Flash?
- Peak inflation usually serves as a major catalyst for the stock market.
- 08/15/2022
|
3 Stocks to Buy and Hold Forever
- These stocks are keepers.
- 08/13/2022
|
VRTX Stock Provides Multiple Swing Trading Lessons
- Just because a stock doesn't work the first time doesn't mean you shouldn't try again. The post VRTX Stock Provides Multiple Swing Trading Lessons appeared first on Investor's Business Daily.
- 08/12/2022
|
Big Pharma Upheaval Coming -- This Stock Is Poised to Skyrocket, Anyway
- Major Medicare changes shouldn't impact this big biotech.
- 08/11/2022
|
Bull Call Spread On Vertex Pharmaceuticals Taps Into Stock's Newfound Strength
- Vertex Pharmaceuticals is showing is showing green check marks across the board, and today we will look at a bullish option strategy. The post Bull Call Spread On Vertex Pharmaceuticals Taps Into Stock's Newfound Strength appeared first on Investor's Business Daily.
- 08/08/2022
|
2 Top Biotech Stocks Defying the Bear Market
- These drugmakers are flying high right now.
- 08/06/2022
|
Vertex Makes Bullish Move On Earnings, Leading 5 Stocks To Watch
- Vertex Pharmaceuticals made a bullish move on earnings amid a confirmed market rally, leading five stocks to watch this week. The post Vertex Makes Bullish Move On Earnings, Leading 5 Stocks To Watch appeared first on Investor's Business Daily.
- 08/06/2022
|
Vertex Q2: Betting Big On Quality Over Quantity
- Vertex's unique pipeline is going against the modern biotech grain. Valuation and risk metrics are favorable compared to the industry.
- 08/06/2022
|
Stock Market Takes Bullish Jobs Report In Stride; Vertex Pharmaceuticals Finds Support After Earnings
- The stock market fell sharply early Friday on news of strong job growth in July, but indexes pared losses by the close. The post Stock Market Takes Bullish Jobs Report In Stride; Vertex Pharmaceuticals Finds Support After Earnings appeared first on Investor's Business Daily.
- 08/05/2022
|
Why Vertex Pharmaceuticals Stock Was Soaring Today
- The company's popular Trikafta continues to boost the fundamentals.
- 08/05/2022
|
Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales Guidance
- Vertex Pharmaceuticals' (VRTX) Q2 earnings and sales beat estimates. The company increases its revenue guidance for 2022.
- 08/05/2022
|
Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2022 Results - Earnings Call Transcript
- Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Charles Wagner - EVP & CFO Reshma Kewalramani - CEO, President & Director Stuart Arbuckle - EVP & COO Conference Call Participants Salveen Richter - Goldman Sachs Group Michael Yee - Jefferies Liisa Bayko - Evercore ISI Geoffrey Meacham - Bank of America Merrill Lynch Brian Abrahams - RBC Capital Markets Hartaj Singh - Oppenheimer Olivia Brayer - Cantor Fitzgerald & Co. Mohit Bansal - Wells Fargo Securities David Risinger - SVB Securities Evan Seigerman - BMO Capital Markets Colin Bristow - UBS Operator Good day, and welcome to the Vertex Pharmaceuticals Second Quarter 2022 Earnings Call. [Operator Instructions].
- 08/04/2022
|
Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates
- Vertex (VRTX) delivered earnings and revenue surprises of 3.45% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Watch These Leaders With Earnings Due, Buy Zones In Focus
- With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones. The post Watch These Leaders With Earnings Due, Buy Zones In Focus appeared first on Investor's Business Daily.
- 08/01/2022
|
My Top Stock to Buy If We're in a Recession
- This stock checks off all the boxes.
- 07/31/2022
|
3 Winning Evergreen Stocks to Buy and Hold for the Next 25 Years
- These companies have cornered the right markets and are chasing the right long-term trends.
- 07/26/2022
|
10 Best Low-Volatility Stocks to Buy Now
- The stock market is suffering a turbulent 2022 so far – and with inflation still running at a 40-year high, the Federal Reserve locked in a significant rate-hiking cycle and midterm elections just months away, it's likely the volatility is going to remain for the time being. Investors looking for a smoother market ride should consider buying low-volatility stocks as a way to manage risk.
- 07/25/2022
|
Is This Vertex Pharmaceuticals' Biggest News Yet?
- Vertex's good news has been multiplying.
- 07/25/2022
|
Final Trades: Foot Locker, Vertex, BlackRock & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 07/20/2022
|
4 Profitable Companies With Solid Financial Conditions
- When screening the market for value opportunities, investors may want to consider stocks that represent companies with high profitability and robust financial conditions. The companies below meet these criteria, as they have GuruFocus profitability and financial strength ratings of at least 6 out of 10.
- 07/20/2022
|
Vertex to Announce Second Quarter 2022 Financial Results on August 4
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2022 financial results on Thursday, August 4, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1 (412) 902-6510 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2022 Earnings Call”. The conference call will be webcast live and a link to the webcast c
- 07/18/2022
|
The Overlooked Difference in June's Inflation Report
- Today's reaction to a high CPI print is the opposite of what we saw last month.
- 07/13/2022
|
Vertex (VRTX) to Buy ViaCyte to Speed Up VX-880 Program
- Vertex (VRTX) will acquire ViaCyte for $320 million in cash.
- 07/12/2022
|
Vertex: Expanding Product Line To Drive Future Growth
- Vertex Pharmaceuticals is expanding its product line to diversify its portfolio, which will reduce its dependency on a single product line. The company has high cash reserves of $8.2 billion, which will help in research and development for future growth.
- 07/11/2022
|
Top Health Care Stocks To Buy Right Now? 4 To Watch
- Check these health care stocks out for your watchlist right now
- 07/09/2022
|
This Company Could Ease the Pain in a Bear Market
- New product candidates aim to diversify into areas with a large unmet medical need.
- 07/09/2022
|
The 3 Leaders of the Gene Editing Revolution
- There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. The post The 3 Leaders of the Gene Editing Revolution appeared first on InvestorPlace.
- 07/08/2022
|
7 Moonshot Investments Upending a $10 Trillion Industry
- Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on InvestorPlace.
- 07/08/2022
|
This Hot Growth Stock Is Still a Buy After Enormous Gains
- This biotech stock is worth holding onto for a while.
- 07/08/2022
|
Want to Beat the Bear Market? Try These 2 Stocks
- There's plenty of growth ahead for these companies.
- 07/08/2022
|
Vertex (VRTX) VX-880 Early Study Sees Lifting of Clinical Hold
- The FDA lifts clinical hold on Vertex's (VRTX) study on VX-880, its stem-cell-derived, fully differentiated islet replacement therapy that could offer a functional cure for type 1 diabetes patients.
- 07/06/2022
|
3 Unstoppable Growth Stocks To Buy in 2022 and Beyond
- They're weathering the bear market better than many.
- 07/06/2022
|
2 Reasons to Buy Vertex Pharmaceuticals Now
- The stock gained momentum in the first half.
- 07/05/2022
|
3 Stocks You Can Buy and Hold for Decades
- These companies are built to last.
- 07/02/2022
|
The Best Biotech Stock on the Market Right Now
- It's not a close contest.
- 06/29/2022
|
5 High-Performing Cathie Wood Stocks as of June
- As investors continue grappling with a volatile stock market, five stocks in Catherine Wood (Trades, Portfolio)'s first-quarter 13F equity portfolio that have high GF Scores and have outperformed the Standard & Poor's 500 Index year to date are Vertex Pharmaceuticals Inc. ( VRTX , Financial), Rada Electronics Industries Ltd. ( RADA , Financial), Check Point Software Technologies Ltd.
- 06/28/2022
|
Vertex: In A Class By Itself, Promising Pipeline Of Game-Changing Drugs
- Vertex Pharma develops, manufactures, and commercializes small molecule drugs for patients with serious diseases. The company has obtained approval for several products that treat forms of cystic fibrosis ("CF"). The firm's drug pipeline includes treatments for sickle cell disease, beta-thalassemia, Type 1 diabetes, APOL1-mediated kidney diseases, pain management, and more.
- 06/28/2022
|
3 Cheap Stocks to Buy That Are Crushing the Market
- All three could continue their winning ways.
- 06/23/2022
|
Where to Invest $10,000 in a Bear Market
- It's time to prepare your portfolio for long-term growth.
- 06/22/2022
|
5 Stocks in S&P 500 ETF That Gained Last Week
- The S&P 500 wrapped up its worst week since March 2020, tumbling 5.8%. Despite the massive decline, some of the stocks in SPY?
- 06/20/2022
|
Strength Seen in Vertex (VRTX): Can Its 4.8% Jump Turn into More Strength?
- Vertex (VRTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 06/20/2022
|
Buy the Dip on These 3 Healthcare Stocks
- Here's why our roundtable likes Vir Biotechnology, OrthoPediatrics, and Vertex Pharmaceuticals.
- 06/19/2022
|
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani on Goldman Sachs 43rd Annual Healthcare Conference (Transcript)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Goldman Sachs 43rd Annual Healthcare Conference June 15, 2022 4:20 PM ET Company Participants Reshma Kewalramani - CEO, President and Director Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon, everyone. Thanks for joining us.
- 06/15/2022
|
2 Hot Stocks to Buy and Hold Until You Retire
- What market downturn? These stocks are bucking the trend.
- 06/12/2022
|
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that five scientific abstracts on the company's portfolio of cystic fibrosis (CF) medicines will be presented at the European Cystic Fibrosis Society's (ECFS) 45th European Cystic Fibrosis Conference held June 8-11, 2022, in Rotterdam, the Netherlands. Vertex will present the first analysis of data collected in the U.S. CF Foundation Patient Registry (CFFPR) of over 16,000 people with CF treated with TRI
- 06/10/2022
|
Vertex (VRTX) Kidney Drug Gets FDA Breakthrough Designation
- Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.
- 06/09/2022
|
AbbVie's Failure Solidifies Vertex Pharmaceuticals' Cystic Fibrosis Leadership Position
- Vertex's competitor AbbVie said its triple combination did not achieve the efficacy threshold to push the program into pivotal development. AbbVie will start a phase 2 trial of a new triple combination in early 2023 but success is far from certain and Vertex is now in a stronger position.
- 06/06/2022
|
My 3 Highest-Conviction Growth Stocks Right Now
- I'm especially confident about the prospects for these great stocks.
- 06/04/2022
|
3 Simple Steps to Make a Fortune When Market Corrections Come
- They're simple to understand -- but not always easy to follow.
- 05/28/2022
|
3 Healthcare Stocks You Can Buy and Hold for the Next Decade
- They're leaders in their fields.
- 05/26/2022
|
Have $2,000? 2 Market Crash-Ready Stocks to Buy
- These stocks have great long-term prospects.
- 05/22/2022
|
3 Stocks That Could Make You a Fortune Over the Next 10 Years
- They have one key common denominator.
- 05/21/2022
|
3 of the Smartest Stocks to Buy in a Fed-Induced Bear Market
- A plunging stock market is the ideal time to put your money to work in these time-tested companies.
- 05/19/2022
|
Vertex (VRTX) Outperforms Industry This Year So Far: Here's Why
- Vertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.
- 05/18/2022
|
Here's the No. 1 Reason to Buy Vertex Pharmaceuticals Now
- The company's current treatments dominate the cystic fibrosis market, but it's the pipeline that makes this stock so intriguing.
- 05/14/2022
|
Karen Firestone's top stock picks: Vertex Pharma, Moderna
- Kari Firestone, Aureus Asset Management, joins 'Closing Bell: Overtime' to discuss the biotech bounce and her top stock picks.
- 05/13/2022
|
Got $3,000? These 3 Stocks Are Screaming Buys During the Market Sell-Off
- You don't need a mountain of money to build wealth on Wall Street.
- 05/12/2022
|
Is Vertex Pharmaceuticals' Billion-Dollar Business Getting Even Bigger?
- The company may extend its leadership in cystic fibrosis treatment.
- 05/09/2022
|
One Biotech Stock to Hold; Another to Dump Right Now
- Biotech stocks have been successful in going public without revenues because the story of a pharmaceutical firm gaining FDA approval for a new drug is attractive to many investors.
- 05/07/2022
|
Vertex: Q1 Results Solid, If Unspectacular, But Pipeline Progress Makes Bull Case
- Vertex announced Q122 results yesterday, reporting revenues of $2.1bn and guiding for FY revenues of ~$8.5bn. Net profit margin was ~17%, while operating margin is >50% - highly impressive.
- 05/06/2022
|
Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked
- Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.
- 05/06/2022
|
Vertex Pharmaceuticals Incorporated (VRTX) CEO Dr. Reshma Kewalramani on Q1 2022 Results - Earnings Call Transcript
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Michael Partridge - SVP of IR Reshma Kewalramani - CEO, President and Director Stuart Arbuckle - Executive VP and COO Charles Wagner - Executive VP and CFO Bastiano Sanna - Executive VP, Chief of Cell and Genetic Therapies and VCGT Site Head David Altshuler - Executive VP of Global Research and Chief Scientific Officer Conference Call Participants Cory Kasimov - JPMorgan Jason Zemansky - BofA Robyn Karnauskas - Truist Securities Salveen Richter - Goldman Sachs Michael Yee - Jefferies Phil Nadeau - Cowen & Company Colin Bristow - UBS Mohit Bansal - Wells Fargo Evan Seigerman - BMO Capital Markets Liisa Bayko - Evercore ISI Michael Partridge Good evening. This is Michael Partridge.
- 05/05/2022
|
Vertex Pharmaceuticals (VRTX) Q1 Earnings Miss Estimates
- Vertex (VRTX) delivered earnings and revenue surprises of -2.22% and 0.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Parnassus Comments on Vertex Pharmaceuticals
- Our biggest winner was Vertex Pharmaceuticals ( VRTX , Financial). It contributed 0.44% to the Fund's relative return, as its stock soared 18.8%.
- 05/05/2022
|
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
- FATE reports a narrower loss and higher collaboration revenues in the first quarter.
- 05/05/2022
|
This Stock Is Trouncing the Market in 2022 -- and Its Prospects Just Got Even Better
- The big biotech's winning ways are likely to continue.
- 05/05/2022
|
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
- Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
- 05/04/2022
|
5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week
- Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.
- 05/04/2022
|
How Bad Is This News for Vertex Pharmaceuticals?
- A potentially game-changing candidate faces a delay.
- 05/04/2022
|
Vertex Pharma's Stem Cell Derived Diabetes Treatment Trial Put On Hold
- The FDA has instituted a clinical hold on Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) VX-880 Phase 1/2 study due to a determination that there is insufficient information to support dose escalation with the product. VX-880 is an investigational stem cell-derived,.
- 05/02/2022
|
Why Vertex Pharmaceuticals Shares Are Falling
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower by 3.42% to $263.88 during Monday's pre-market session after the company announced VX-880 Phase 1/2 has been placed on clinical hold by the FDA due to “a determination that there is insufficient information to.
- 05/02/2022
|
2 Biotech Stocks to Buy and Hold for 10 Years
- These two companies have moved in opposite directions on the stock market so far this year, but now seem set to move up and to the right.
- 04/30/2022
|
5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates
- Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.
- 04/29/2022
|
5 Top Stocks for May
- Looking for deals in today's market? These five stocks span many industries.
- 04/29/2022
|
Many Big Pharma Stocks Have Outperformed. It Isn't Too Late to Buy.
- The companies' earnings don't depend on the strength of the economy. Drug demand doesn't waver when consumers tighten their budgets.
- 04/28/2022
|
Where Will Vertex Pharmaceuticals Be in 5 Years?
- It'll almost certainly be competing in a few new markets.
- 04/25/2022
|
3 Safe Stocks That Outperformed the S&P During the Great Recession
- These stocks are still great buys in case there's a downturn soon.
- 04/24/2022
|
Vertex to Announce First Quarter 2022 Financial Results on May 5
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1 (412) 902-6510 (International) and reference the “Vertex Pharmaceuticals First Quarter 2022 Earnings Call”. The conference call will be webcast live and a link to the webcast can be
- 04/21/2022
|
J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy
- Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.
- 04/21/2022
|
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
- Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/20/2022
|
3 Fantastic Biotech Stocks to Buy in April
- These stocks are bright spots in an overall dismal market for biotech stocks.
- 04/18/2022
|
3 Reasons Vertex Pharmaceuticals Is a Top Stock to Buy Now
- A research engine fueled by a $7.6 billion-per-year franchise is cranking out one hit after another.
- 04/16/2022
|
Top 5 High-Flying Nasdaq Stocks Amid Index's YTD Meltdown
- We have narrowed our search to five Nasdaq listed stocks that have witnessed double-digit rally year to date. These are: VRTX, SPLK, HSIC, CHKP and JKHY.
- 04/13/2022
|
Another Nasdaq Bear Market on the Way? 3 Great Stocks to Buy Anyway
- Bear, shmear. These stocks are great picks to buy no matter what the Nasdaq does next.
- 04/13/2022
|
You Might Kick Yourself Later for Not Buying This Growth Stock Right Now
- This stock is really that good.
- 04/10/2022
|
Vertex (VRTX) Stock Rallies 27% in a Year: What Lies Ahead?
- In 2022, Vertex (VRTX) expects continued revenue growth as there are more than 25,000 patients who are addressable with Vertex's CF therapies.
- 04/06/2022
|
Vertex Pharma sees positive results in Phase 2 trials of new non-opioid pain killer
- Reshma Kewalramani, Vertex Pharmaceuticals CEO, joins 'Power Lunch' to discuss the data behind a pain relieving medicine that's different from opioids, what the Phase 3 trials will look like and more.
- 04/04/2022
|
A Recession Could Be Coming: 3 Stocks to Buy to Be Prepared
- One potential early warning sign of a recession is already flashing.
- 04/03/2022
|
Worried About Rising Interest Rates? These 2 Growth Stocks Could Help
- Rate hikes shouldn't rattle these stocks as their businesses carry relatively modest debt.
- 04/01/2022
|
Why April Has the Bulls Beaming
- April is the best month for the Dow since 1950 - averaging about a 2% gain.
- 03/31/2022
|
Vertex Pharmaceuticals reports positive data on non-opioid pain medicine
- CNBC's Meg Tirrell joins 'Squawk Box' to report the details from a mid-stage study conducted by Vertex Pharmaceuticals over its non-opioid pain medicine.
- 03/31/2022
|
Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
- Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
- 03/29/2022
|
Biotech is ‘oversold': top stocks to capitalize on the pullback
- The SPDR S&P Biotech ETF is down close to 25% year-to-date but Michael Yee sees several names in this space that look promising at current valuations. Why did XBI recover in recent weeks?
- 03/28/2022
|
3 No-Brainer Stocks to Buy if the U.S. Dips Into a Recession
- This stock trio can help patient investors thrive if an economic contraction becomes a reality.
- 03/27/2022
|
ORIC Stock Plunges on Discontinuation of Oncology Candidate
- ORIC declines on discontinuation of pipeline candidate ORIC-101 following planned interim analyses of two phase Ib studies.
- 03/23/2022
|
Vertex (VRTX) to Begin Pivotal Study on Kidney Candidate
- Vertex's (VRTX) pivotal phase III study on VX-147 targeting a broad patient population with proteinuric kidney disease mediated by two mutations in the APOL1 gene (AMKD) is expected to begin later this month.
- 03/23/2022
|
Missed Out on Moderna? My Best Biotech Stock to Buy and Hold
- This company is working with Moderna on an exciting program.
- 03/23/2022
|
Vertex: More Opportunities Ahead
- The core cystic fibrosis business has an opportunity to grow further.
- 03/22/2022
|
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
- Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $248.52, moving +0.62% from the previous trading session.
- 03/16/2022
|
Is Vertex Pharmaceuticals Stock Bound for a Pop?
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is up 1.6% at $240.25 at last check.
- 03/14/2022
|
Nervous About Stagflation? Buy These 2 Growth Stocks
- It's harder for stagflation to hurt a company's bottom line when costs don't change much.
- 03/12/2022
|
Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call - (Transcript)
- Vertex Pharmaceuticals, Inc. (VRTX) Presents at Cowen Health Care Broker Conference Call - (Transcript)
- 03/08/2022
|
3 Biotech Stocks That Can Make You Richer in March (and Beyond)
- These biotechs have promising near-term and long-term prospects.
- 03/06/2022
|
1 Healthcare Stock That Could Fly Higher After a Strong Q4
- This pharmaceutical company is growing revenue and profits from drugs it doesn't market or sell.
- 03/05/2022
|
What's Next For Vertex Pharma, The World's Largest Cystic Fibrosis Drugmaker?
- For more than a decade, the world has known Vertex Pharmaceuticals as the cystic fibrosis biotech. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.
- 03/04/2022
|
2 Stocks to Buy No Matter What Happens in March
- Keep your eyes on the prize.
- 03/01/2022
|
4 Stocks With a History of Operating Income Margin Growth
- When the operating income margin continues to grow, it means a company is becoming more efficient in generating profits from its operating activities.
- 02/27/2022
|
Should Value Investors Pick Vertex Pharmaceuticals (VRTX) Stock?
- Let's see if Vertex Pharmaceuticals Incorporated (VRTX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
- 02/21/2022
|
Vertex Could Be a Seller or Buyer in Biotech M&A
- As measured by its current market cap, Vertex Pharmaceuticals ( VRTX , Financial) would be the most expensive among the 10 companies identified by Fierce Biotech as the top M&A targets, with Adaptimmune Therapeutics plc ( ADAP , Financial) being the cheapest.
- 02/16/2022
|
VRTX vs. TECH: Which Stock Should Value Investors Buy Now?
- VRTX vs. TECH: Which Stock Is the Better Value Option?
- 02/15/2022
|
Will the Rally of These 5 Big Drugmakers Continue in 2022?
- Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.
- 02/11/2022
|
Why Investors Should Be Watching Vertex Pharmaceuticals
- The company has several big opportunities on the horizon.
- 02/11/2022
|
These Safe Stocks Can Succeed in a Higher Interest Rate Environment
- These companies are stable picks for investors seeking to generate long-term portfolio value.
- 02/08/2022
|
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Momentum Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 02/07/2022
|
Is this Beaten-Down Biotech Making a Comeback?
- It's climbed 15% since the start of the year.
- 02/04/2022
|
Vertex: Best Of The Nasdaq 100
- 88% technical buy signals. 12 new highs and up 15.95% in the last month. 30.71+ Weighted Alpha.
- 02/03/2022
|
4 Top Biotech Stocks to Gain Amid Industry Challenges
- New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.
- 02/01/2022
|
Here's What to Know About Vertex Pharmaceuticals' Earnings Report
- Its plan to diversify into new therapy areas is continuing to take shape.
- 02/01/2022
|
5 Stocks With Recent Price Strength Amid Wall Street Turmoil
- Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are DAC, ESTE, HAFC, ADM and VRTX.
- 02/01/2022
|
3 Biotech Stocks That Could Boom or Bust in Q1
- The biotech industry is exploding. Biotech stocks provide lots of opportunities for investors who are taking a risk on the medicine's future.
- 02/01/2022
|
Why Vertex Is One Of The Best Biotech Stocks To Own
- Why Vertex Is One Of The Best Biotech Stocks To Own
- 01/31/2022
|
Vertex Pharmaceuticals: DCF Modeling Of Legacy CFTR Portfolio Supports A Long Position
- CFTR modulators portfolio of Vertex Pharmaceuticals supports a value of $297 per share. Relative to this, the share price of $228.22 (as of Jan 27, 2022) represents an undervaluation of at least 30%. The four CFTR modulators portfolio of VRTX are expected to generate a revenue of $7.9B in 2022 and grow to $9.4B in 2026.
- 01/30/2022
|
Market Dip? Here's Why This Bargain Biotech Is a Smart Buy Now
- This company is a market leader -- and business is growing.
- 01/28/2022
|
The Smartest Stocks to Buy With $500 in 2022
- A relatively small amount of money can go a long way when invested in high-quality companies.
- 01/28/2022
|
Looking for a Growth Stock? 3 Reasons Why Vertex (VRTX) is a Solid Choice
- Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 01/27/2022
|
Vertex's Q4 2021 Earnings: More Of The Usual
- Vertex beat Q4 2021 earnings and revenue estimates and guided for 2022 revenue above the Street consensus. The results are not surprising given the company's beat-and-raise history.
- 01/27/2022
|
Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q4 2021 Results - Earnings Call Transcript
- Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q4 2021 Results - Earnings Call Transcript
- 01/26/2022
|
Vertex Pharmaceuticals (VRTX) Surpasses Q4 Earnings and Revenue Estimates
- Vertex (VRTX) delivered earnings and revenue surprises of 2.74% and 4.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 01/26/2022
|
5 Buy-Ranked Stocks Likely to Beat on Earnings This Week
- The Zacks Rank and ESP are still a solid combination to predict earnings beats.
- 01/25/2022
|
Vertex Investors Look Out...AbbVie Data In Cystic Fibrosis Coming Soon
- AbbVie will be releasing Phase 2 data for its experimental Cystic Fibrosis (CF) drugs that could potentially compete with Vertex's drugs. VRTX stock may move up or down, inversely related to the AbbVie data set.
- 01/25/2022
|
Vertex: Growth At An Acceptable Valuation
- AFT is a closed end fund focusing on leveraged loans. The vehicle provides for a natural inflation hedge given the floating rate nature of the underlying loans.
- 01/25/2022
|
Should You Buy Vertex Pharmaceuticals (VRTX) Ahead of Earnings?
- Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 01/24/2022
|
PTC Gearing Up for Q1 Earnings: What is in the Offing?
- PTC is likely to have reported higher year-over-year revenues in first-quarter fiscal 2022, driven by significant growth across all product segments and regions.
- 01/24/2022
|
3 Unstoppable Biotech Stocks to Buy Right Now
- All of them have tremendous growth prospects.
- 01/24/2022
|
6 Must-Buy Large-Cap Stocks Ahead of Q4 Earnings Next Week
- Six large-cap companies will report earnings next week. These are: TSLA, URI, FCX, VRTX, STLD and BRO.
- 01/21/2022
|
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
- Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/20/2022
|
4 Stocks With Impressive Interest Coverage Ratio to Invest In
- A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as ArcBest (ARCB), Advanced Micro Devices (AMD), AGCO Corporation (AGCO) and Vertex (VRTX) are sound enough to meet financial obligations.
- 01/20/2022
|
4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022
- New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.
- 01/20/2022
|
Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks
- Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.
- 01/19/2022
|
Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
- BOSTON ----(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International). The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com i
- 01/18/2022
|
Buy These Stocks If You Want 126% to 206% Returns, Says Wall Street
- These two biotechs have potential catalysts to look forward to in 2022.
- 01/18/2022
|
5 Top Biotech Stocks To Watch In January 2022
- Could these biotech stocks be poised for gains in 2022?
- 01/16/2022
|
4 Biotech Acquisitions We'd Like to See in 2022
- These potential corporate combinations would make a lot of sense.
- 01/14/2022
|
Vertex (VRTX) Kaftrio Gets Europe Nod for CF in Children
- The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.
- 01/12/2022
|
Is Vertex (VRTX) a Solid Growth Stock? 3 Reasons to Think " Yes "
- Vertex (VRTX) could produce exceptional returns because of its solid growth attributes.
- 01/11/2022
|
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
- Vertex Pharmaceuticals (VRTX) closed at $223.96 in the latest trading session, marking a +0.95% move from the prior day.
- 01/10/2022
|
Vertex Pharmaceuticals (VRTX) CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call Transcript
- Vertex Pharmaceuticals (VRTX) CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call Transcript
- 01/10/2022
|
3 No-Brainer Big Pharma Stocks to Buy in 2022
- There's a lot to like about each of these companies.
- 01/09/2022
|
Better Buy: Vertex Pharmaceuticals vs. Biogen
- In this battle of biotech giants, one emerges as the clear winner.
- 01/07/2022
|
Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:00 a.m. ET. A live webcast of management's remarks will be available through Vertex's website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology
- 01/04/2022
|
Vertex Pharmaceuticals Stock: Bull vs. Bear
- Here are two differeing views on the big biotech stock.
- 12/31/2021
|
2 Unstoppable Stocks That Could Go Parabolic
- It's not too late to snag these stocks before they go skyward.
- 12/30/2021
|
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
- Vertex Pharmaceuticals (VRTX) closed at $223.32 in the latest trading session, marking a +0.63% move from the prior day.
- 12/29/2021
|
3 Biotech Stocks That Sank in 2021 but Could Soar in 2022
- These stocks could rebound nicely in the new year.
- 12/26/2021
|
Vertex: Waiting For The Pipeline Success
- VRTX's legacy business is valued at $279 per share. Despite the VX-814 and VX-864 failures, Vertex's pipeline looks solid and promising.
- 12/21/2021
|
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
- Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $215.41, moving +0.41% from the previous trading session.
- 12/20/2021
|
3 Biotech Stocks That Are Too Cheap to Ignore
- These stocks have been beaten down in 2021. But their prospects remain bright.
- 12/19/2021
|
5 Unstoppable Trends to Invest $5,000 In for 2022
- They could be like PCs in the 1980s and the internet in the 1990s.
- 12/19/2021
|
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
- In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $209.24, marking a +0.52% move from the previous day.
- 12/14/2021
|
3 Biotech Stocks That Could Make You Richer in December (and Beyond)
- These stocks could be just what you need to put in your stocking.
- 12/12/2021
|
Could Vertex Have a Cure for Type 1 Diabetes on the Way?
- It's still early, but a potential cure for the disease isn't out of the question.
- 12/11/2021
|
Will Vertex Pharmaceuticals Stock See Higher Levels?
- The stock price of Vertex Pharmaceuticals stock has seen a rise of 7.5% over the last month, while it is up 11% over the last ten trading days. The recent rise can be attributed to positive results from a mid-stage study evaluating VX-147 in treating patients with focal segmental glomerulosclerosis.
- 12/10/2021
|
Got $1,000? These 3 Stocks Could Be Bargain Buys for 2022 and Beyond
- Sales are climbing at these biotech companies -- and more potential products are on the horizon.
- 12/10/2021
|
Wells Fargo makes a bullish call on five big pharma stocks
- The "Halftime Report" traders debate Wells Fargo's bullish call on big pharma
- 12/09/2021
|
Recent Pipeline Updates Show Vertex Is Not Just About Cystic Fibrosis
- Recent Pipeline Updates Show Vertex Is Not Just About Cystic Fibrosis
- 12/07/2021
|
Got $10,000? 5 Unstoppable Stocks to Buy to End the Year Right
- Buying innovators and disruptors at a discount is a smart way to set yourself up for long-term success.
- 12/05/2021
|
Is Vertex Pharmaceuticals Stock a Buy Now?
- Positive clinical trial read-outs bode well for this big-name biotech stock.
- 12/04/2021
|
Got $1,000? Check Out These 3 Top Biotech Stocks
- Two big biotechs and one smaller one that could be winners over the long term.
- 12/03/2021
|
Why Is Vertex (VRTX) Up 8.4% Since Last Earnings Report?
- Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
- 12/02/2021
|
Vertex Pharmaceuticals (VRTX) Just Reclaimed the 200-Day Moving Average
- Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
- 12/02/2021
|
Vertex Pharmaceuticals (VRTX) Recently Broke Out Above the 20-Day Moving Average
- Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
- 12/02/2021
|
3 Stocks Cathie Wood Is Selling That Are Still Great Picks to Buy and Hold
- The ARK Invest founder might regret selling shares of these growth stocks.
- 12/02/2021
|
Vertex Pharmaceuticals (VRTX) Stock: Why The Price Increased Today
- The stock price of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) increased by over 8% during intraday trading today. This is why it happened.
- 12/01/2021
|
Why Are Vertex Pharmaceuticals Shares Trading Higher Today?
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) claimed its second early-stage win after announcing positive results in a small study of VX-147 on a genetically defined form of chronic kidney disease. The 16-patient, Phase 2 trial focused on patients with focal segmental glomerulosclerosis, a rare disease where kidneys cannot filter blood properly.
- 12/01/2021
|
Kymera's Protein Degrader Platform Tech Moves Forward With 3rd Candidate; Updated Data On KT-474 In December At R&D Day
- Kymera's Protein Degrader Platform Tech Moves Forward With 3rd Candidate; Updated Data On KT-474 In December At R&D Day
- 11/30/2021
|
7 Drug Stocks to Buy Now While They're Still on Sale
- Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. The post 7 Drug Stocks to Buy Now While They're Still on Sale appeared first on InvestorPlace.
- 11/30/2021
|
Will This Beaten-Down Stock Bounce Back? 3 Things to Know
- All the elements are in place for a rebound.
- 11/29/2021
|
CRISPR's Life-Saving Technology Has Massive Potential
- CRISPR's Life-Saving Technology Has Massive Potential
- 11/22/2021
|
Better Buy: Vertex Pharmaceuticals vs. CRISPR
- The companies are collaborating on a potential blockbuster.
- 11/20/2021
|
2 Beaten-Down Growth Stocks You Can Buy Right Now
- These companies' struggles are temporary.
- 11/17/2021
|
Vertex Stock: Slowing Growth, But It's Attractively Valued Now
- Vertex Pharmaceuticals Incorporated is a leading biotech company that specializes in the treatment of genetic cystic fibrosis. Over the past five years, Vertex grew its revenue rapidly by a CAGR of 33.18%.
- 11/16/2021
|
Vertex's Q3 Report As Good As One Could Expect
- Vertex's cystic fibrosis franchise continues to exceed expectations and the third quarter report was as good as one could expect.
- 11/12/2021
|
The Key Behind Vertex's Great Q3 Results
- One cystic fibrosis drug is powering Vertex's strong revenue and earnings growth.
- 11/11/2021
|
3 Stocks Than Can Turn $10,000 Into $50,000 by 2025
- Revenue already is growing at these companies -- but there's more to come.
- 11/11/2021
|
Can Vertex Make Billions With a New Game-Changing Treatment? The Answer May Be Just Ahead
- The company is moving closer to success in a new therapeutic area.
- 11/05/2021
|
Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises '21 View
- Vertex Pharmaceuticals' (VRTX) earnings and sales beat estimates for the third quarter of 2021. The company raises its product revenue guidance for the year.
- 11/03/2021
|
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani on Q3 2021 Results - Earnings Call Transcript
- Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani on Q3 2021 Results - Earnings Call Transcript
- 11/02/2021
|
Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings and Revenue Estimates
- Vertex (VRTX) delivered earnings and revenue surprises of 14.10% and 7.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/02/2021
|
Could This Drug Become Vertex Pharmaceuticals' Next Blockbuster?
- The company has a plan to move beyond its lucrative portfolio of drugs.
- 11/02/2021
|
3 Biotech Stocks That Could Make You Richer
- The best may be yet to come for these companies.
- 10/30/2021
|
4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates
- Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
- 10/29/2021
|
Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX)
- Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 10/29/2021
|
VRTX vs. PRTA: Which Stock Is the Better Value Option?
- VRTX vs. PRTA: Which Stock Is the Better Value Option?
- 10/28/2021
|
How Big Is Vertex's News for Its Potential Diabetes Cure?
- The biotech reported encouraging results, but there's a long way to go.
- 10/28/2021
|
4 Healthcare Stocks to Top Q3 Estimates Amid Coronavirus Woes
- Factors like an aging populace and demand for products and services are likely to reflect on the Q3 results of ACAD, MD, ACHC and VRTX.
- 10/26/2021
|
Can Vertex (VRTX) Climb 42% to Reach the Level Wall Street Analysts Expect?
- The mean of analysts' price targets for Vertex (VRTX) points to a 42.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 10/21/2021
|
If I Could Only Own 1 Healthcare Stock, This Is What It Would Be
- Investing gets simple if you have to put all of your eggs in one basket.
- 10/21/2021
|
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
- In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $185.49, marking a +0.04% move from the previous day.
- 10/20/2021
|
Is This Beaten Down Biotech a Bad News Buy?
- It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?
- 10/20/2021
|
Why Are Investors Ignoring Vertex's Good News?
- Vertex announced promising trial data for its type 1 diabetes treatment candidate.
- 10/20/2021
|
Vertex's (VRTX) Early Type I Diabetes Study Data Promising
- Vertex's (VRTX) single infusion drug candidate, VX-880, for type I diabetes shows restoration of insulin production and robust improvements in multiple measures in a phase I/II study
- 10/19/2021
|
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
- BOSTON--(BUSINESS WIRE)--Vertex today announced positive data for the first patient from the Phase 1/2 clinical trial of VX-880, for the treatment of type-1 diabetes.
- 10/18/2021
|
2 Stocks You'll Probably Never Want to Sell
- Both are biotech stocks with tremendous long-term opportunities.
- 10/17/2021
|
3 No-Brainer Biotech Stocks to Buy Right Now
- Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Viatris should have plenty of room to run.
- 10/16/2021
|
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
- Vertex Pharmaceuticals (VRTX) closed at $181.34 in the latest trading session, marking a +0.63% move from the prior day.
- 10/13/2021
|
Why the Earnings Surprise Streak Could Continue for Vertex (VRTX)
- Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/13/2021
|
2 Beaten-Down Growth Stocks to Buy Hand Over Fist
- For those focused on the long game, the recent poor stock performances of Vertex Pharmaceuticals and Veeva Systems may present buying opportunities.
- 10/09/2021
|
Vertex Needs to Sell or Make a Big Acquisition
- Should investors holding shares of Vertex Pharmaceuticals Incorporated ( VRTX , Financial) follow the axiom, “Good things come to those who wait?”
- 10/06/2021
|
Vertex Pharmaceuticals Stock Is Likely To Rebound From $180 Levels Currently
- We believe that Vertex Pharmaceuticals stock is a good buying opportunity at the present time. VRTX stock trades near $180 currently and it is, in fact, down 27% from its pre-Covid high of $248 in February 2020 – just before the coronavirus pandemic hit the world.
- 10/04/2021
|
3 Stocks to Buy Without Any Hesitation If There's an October Stock Market Crash
- October is sometimes a scary month for investors. But you don't have anything to be afraid about buying these stocks.
- 10/03/2021
|
Vertex Pharmaceuticals (VRTX) Stock Moves -0.46%: What You Should Know
- In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $181.38, marking a -0.46% move from the previous day.
- 09/30/2021
|
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
- The best is yet to come for these top healthcare stocks.
- 09/30/2021
|
3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better
- A stock market that soured on biotech stocks in general is presenting some bargain opportunities.
- 09/30/2021
|
3 Winning Biotech Stocks to Buy Hand Over Fist
- Here are the top biotech picks from three Motley Fool contributors.
- 09/30/2021
|
Reasons To Buy Vertex Below $200
- Reasons To Buy Vertex Below $200
- 09/29/2021
|
September Sell-Off Alert: Buy Vertex Pharmaceuticals on the Dip
- Shares of this highly successful biotech stock are trading at an all-time low earnings multiple.
- 09/25/2021
|
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
- Vertex Pharmaceuticals (VRTX) closed at $185.09 in the latest trading session, marking a +0.44% move from the prior day.
- 09/23/2021
|
5 Top Ranked Stocks on Sale Right Now
- These stocks are disconnected from their earnings outlook as the analysts remain bullish but the Street is bearish.
- 09/23/2021
|
VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?
- VRTX vs. PRTA: Which Stock Is the Better Value Option?
- 09/23/2021
|
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace
- New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, and HZNP well amid the economic recovery.
- 09/23/2021
|
Is Now the Time to Ditch Pharma Stocks?
- With drug pricing reform on the horizon, investors may want to analyze their allocation.
- 09/21/2021
|
3 Winning Stocks Down 33% (or More) to Buy Hand Over Fist
- When great companies go on sale, it's time for investors to pounce.
- 09/19/2021
|
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
- Vertex Pharmaceuticals (VRTX) closed at $188.30 in the latest trading session, marking a +0.64% move from the prior day.
- 09/17/2021
|
5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now
- New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups should drive sales of Vertex's (VRTX) cystic fibrosis drug, Trikafta sales higher.
- 09/15/2021
|
2 Top Biotech Stocks to Buy Right Now
- Both have underperformed the market recently. And both are primed for a comeback.
- 09/11/2021
|
3 Top Healthcare Stocks to Buy for September
- Catalysts are on the horizon for these bargain stocks.
- 09/10/2021
|
What Makes Vertex (VRTX) a New Strong Buy Stock
- Vertex (VRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 09/09/2021
|
3 Stocks to Buy Hand Over Fist if There's a Stock Market Crash
- Market declines are a surefire opportunity for investors to scoop up great companies at a discount.
- 09/04/2021
|
Insider Buying at These Biotech Firms Indicates Value
- According to Wall Street legend, a young person approached one of the top businessmen in the U.S. (said to be J.P. Morgan, the founder of his namesake bank J.P.
- 09/03/2021
|
7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In
- Covid-19 showed us how rapid advances in medicine and technology could create significant growth opportunities for healthcare stocks. The post 7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In appeared first on InvestorPlace.
- 09/02/2021
|
3 Large Biotech Stocks Worth Adding to Your Portfolio
- REGN, MRNA & VRTX are the three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
- 09/02/2021
|
7 Beaten-Down Stocks to Buy for September
- Let's take a look at these seven beaten-down stocks to buy that are poised to gain traction in the coming months ahead. The post 7 Beaten-Down Stocks to Buy for September appeared first on InvestorPlace.
- 08/30/2021
|
The 3 Best Biotech Stocks to Buy Right Now
- Let your portfolio reflect your personality.
- 08/27/2021
|
7 Best Biotech Stocks to Buy in 2021 with Huge Upside
- Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.
- 08/25/2021
|
3 Cathie Wood Stocks to Buy and Hold for Decades
- If you own these companies, the hardest thing to do is sit back and forget about them -- and possibly the best.
- 08/25/2021
|
Vertex Pharmaceuticals: Cystic Fibrosis Leader With Lean Operating Model
- The company has a 97% market share in the cystic fibrosis market with a forecasted 35% revenue growth in Trikafta drug in 2021.
- 08/24/2021
|
Got $10,000? 5 Perfect Stocks to Buy Right Now
- These dominant stocks are worth buying, even with the market near an all-time high.
- 08/24/2021
|
Vertex Pharmaceuticals: Why I'm Buying This Undervalued Monopoly
- VRTX's long-term drug patents will protect profits for decades. VRTX's dominance over the cystic fibrosis market continues to deter competitors.
- 08/23/2021
|
2 Biopharma Growth Stocks to Buy and Hold for Years
- Both of these companies are packed with opportunities.
- 08/21/2021
|
Bet on 5 Top-Ranked Stocks With Rising P/E
- Inside the top-ranked stocks that can beat earnings estimates in their next releases.
- 08/18/2021
|
3 Smartest Healthcare Stocks to Buy With $1,000 Right Now
- It doesn't take a brainiac to balance risk and reward.
- 08/18/2021
|
3 Beaten-Down Biotech Stocks to Buy Right Now
- These biotech stocks might be down, but they're not out.
- 08/18/2021
|
Buying Vertex Pharmaceuticals Stock Now Could Double Your Money Within 5 Years: Here's How
- The big biotech has a clear path to growth if it executes well.
- 08/16/2021
|
No, a Stock Market Crash Probably Isn't Imminent: Here's How to Prepare Anyway
- There are smart moves you can take regardless of what happens with the market.
- 08/15/2021
|
7 Falling Knife Stocks To Sell Before Your Portfolio Bleeds Out
- These seven falling knife stocks have been losing their values of-late and likely have a bumpy road ahead. The post 7 Falling Knife Stocks To Sell Before Your Portfolio Bleeds Out appeared first on InvestorPlace.
- 08/12/2021
|
5 Supercharged Stocks to Buy if the Stock Market Crashes 10%
- A crash or steep correction would be the perfect opportunity to buy into these proven winners.
- 08/08/2021
|
Bull of the Day: Vertex Pharmaceuticals (VRTX)
- Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence
- 08/06/2021
|
4 Stocks Insiders Are Buying
- When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
- 08/05/2021
|
Here is Why Growth Investors Should Buy Vertex (VRTX) Now
- Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.
- 08/04/2021
|
Rising P/E: A Trick to Land on 5 Winning Stocks
- Want to try a different approach? Tap five stocks with increasing P/E ratios.
- 08/03/2021
|
Better Buy: Vertex vs. CRISPR
- Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run.
- 07/31/2021
|
Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up
- Vertex's (VRTX) earnings and sales beat estimates in the second quarter of 2021. The company raises revenue guidance for the year.
- 07/30/2021
|
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani on Q2 2021 Results - Earnings Call Transcript
- Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani on Q2 2021 Results - Earnings Call Transcript
- 07/29/2021
|
Vertex Pharmaceuticals (VRTX) Q2 Earnings and Revenues Surpass Estimates
- Vertex (VRTX) delivered earnings and revenue surprises of 15.61% and 4.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 07/29/2021
|
Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?
- On Vertex's (VRTX) second-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and pipeline progress.
- 07/26/2021
|
3 Biotechs That Could Make Big Acquisitions This Year
- They have ample motivation and cash to gobble up a smaller company.
- 07/22/2021
|
2 Top Biotech Stocks to Buy Right Now
- Both of these companies have successfully developed breakthrough medicines.
- 07/21/2021
|
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
- Vertex Pharmaceuticals (VRTX) closed at $196.55 in the latest trading session, marking a -1.35% move from the prior day.
- 07/20/2021
|
Apple, Array Tech, Vertex Pharma and More Tuesday Afternoon Analyst Calls
- With the trading day more than halfway over, the broad markets were rallying after the carnage on Monday.
- 07/20/2021
|
Vertex (VRTX) Initiates Phase II Study on Pain Candidate
- Vertex (VRTX) starts phase II study for VX-548 to treat acute pain after bunionectomy surgery & expects to start another phase II study to treat acute pain after abdominoplasty surgery in a few weeks.
- 07/20/2021
|
Have $2,000? 2 All-Weather Stocks to Buy This Month
- These two companies have what it takes to flourish in the next market crash.
- 07/20/2021
|
BioNTech, CyberArk, Vertex Pharma and More Monday Afternoon Analyst Calls
- With the trading day closing in on the halfway point, traders were feeling the heat as all the major indexes were ripping downward.
- 07/19/2021
|
3 Nasdaq 100 Stocks to Buy Hand Over Fist in July
- The high-growth Nasdaq 100 is harboring some serious value with this trio.
- 07/19/2021
|
Vertex to Announce Second-Quarter 2021 Financial Results on July 29
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2021 financial results on Thursday, July 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International). The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" sec
- 07/16/2021
|
VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?
- VRTX vs. PRTA: Which Stock Is the Better Value Option?
- 07/16/2021
|
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
- Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $197.89, moving -0.22% from the previous trading session.
- 07/14/2021
|
3 Reasons Growth Investors Will Love Vertex (VRTX)
- Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 07/13/2021
|
Vertex Pharma: Underestimated
- Vertex Pharma: Underestimated
- 07/10/2021
|
Can These 2 Beaten-Down Biotechs Rebound? Cathie Wood Thinks So.
- Recent trial disappointments scared off some investors.
- 07/06/2021
|
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
- Vertex Pharmaceuticals (VRTX) closed at $200.54 in the latest trading session, marking a -0.83% move from the prior day.
- 07/05/2021
|
Chart a Path to Financial Independence With These Unstoppable Stocks
- These game-changing businesses could be life-altering investments.
- 07/04/2021
|
What Are the Odds That Vertex Strikes a Big Acquisition Deal?
- It's a near certainty Vertex will make an acquisition -- unless it's acquired first.
- 07/03/2021
|
1 Biotech Stock Investors Should Really Have on Their Radars Right Now
- It's a big one with an attractive valuation.
- 07/01/2021
|
Could Vertex Pharmaceuticals Be a Prime Acquisition Target?
- It's not out of the question.
- 07/01/2021
|
Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients
- LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced a national reimbursement agreement with the French Health Authorities for the cystic fibrosis (CF) medicines KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor and SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor. Both medicines will be available for all eligible patients once the agreement has been published in the French Official Journal. “Today's announcem
- 06/28/2021
|
Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis
- LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has reached a new portfolio agreement with the Italian Medicines Agency, AIFA, for the reimbursement of all of Vertex's approved medicines for the treatment of cystic fibrosis (CF), including KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor. Italian patients ages 12 years and older with one F508del mutation and one minimal function mutation (F/MF) or two F508del muta
- 06/25/2021
|
3 Stocks Cathie Wood Is Buying That Should Be on Your List Too
- These beaten-down stocks could still be big winners over the long run.
- 06/24/2021
|
3 Top Growth Stocks to Buy in June
- Two unstoppable e-commerce stocks and one high-growth healthcare stock made the cut.
- 06/23/2021
|
5 Growth Stocks I've Bought Over the Past 2 Months
- These fast-paced companies should be absolute moneymakers over the long term.
- 06/21/2021
|
3 Blue-Chip Bargains That Could Soar 20+% In The Next Year
- Analyst 12-month price targets are the educated guesstimates that many obsess over, and can result in wild short-term price swings. According to JPMorgan, 94% of 12-month returns are luck, which is why I never base investment decisions on 12-month price targets.
- 06/20/2021
|
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation. With this approval, for the first time, approximately 1,100 eligible p
- 06/18/2021
|
Novavax And Lowe's Among Today's Trending Stocks
- Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Novavax and Lowe's among others.
- 06/17/2021
|
Vertex: Moving Past The Disappointing VX-864 Results
- The stock declined after disappointing phase 2 results of VX-864 in alpha-1 antitrypsin deficiency. Although Vertex is not giving up on this indication and will focus on next-generation candidates, I would not count on them creating shareholder value.
- 06/17/2021
|
Jim Cramer Thinks Powell Got It Right and Offers a Few Top Picks
- All the major indexes pulled back on again Wednesday, and again the Nasdaq led the charge lower.
- 06/17/2021
|
Cathie Wood Bought This Stock for a Bargain. Should You Follow?
- The company is one of Wood's biggest biotech holdings.
- 06/17/2021
|
Jim Cramer Has a Closer Look at Fed Policy, Energy Stocks, Snap and More
- All the major indexes pulled back on Tuesday, with the Nasdaq leading the charge. Despite this, crude oil jumped back above $72 a barrel, and Bitcoin was fairly stagnant at $40,000.
- 06/16/2021
|
Can Vertex Pharmaceuticals Recover From Its Latest Setback?
- Shares of the biotech industry leader have taken a big hit thanks to a clinical development pipeline that hasn't produced any big wins lately.
- 06/15/2021
|
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
- This biotech has likely reached its peak potential, for now.
- 06/15/2021
|
Nasdaq, Smartsheet, Twilio, Vaxart, Zoom Video and More Friday Afternoon Analyst Calls
- With the trading day about halfway over, the markets were sliding lower to close out the week.
- 06/11/2021
|
VRTX Stock: The Disappointing News Sending Vertex Pharma Shares Lower
- Vertex Pharma (VRTX) stock is dropping on Friday following the release of results from a Phase 2 clinical trial for VX-864. The post VRTX Stock: The Disappointing News Sending Vertex Pharma Shares Lower appeared first on InvestorPlace.
- 06/11/2021
|
What 11 Analyst Ratings Have To Say About Vertex Pharmaceuticals
- Analysts have provided the following ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 3 0 0 0 Somewhat Bullish 4 0 0 0 Indifferent 1 0 2 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 11 analysts have offered 12-month price targets for Vertex Pharmaceuticals. The company has an average price target of $258.91 with a high of $307.00 and a low of $205.00.
- 06/11/2021
|
Vertex (VRTX) Ends Further Study on AAT Deficiency Candidate
- Vertex (VRTX) to discontinue further development of AATD candidate, VX-864, as it appears unlikely to benefit patients.
- 06/11/2021
|
Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and sickle cell disease. Presenting data from two trials at the European Hematology Association annual meeting, the companies announced that three-month follow-up data of 22 patients with genetic blood disorders indicated a “consistent and sustained” response to the experimental drug CTX001.
- 06/11/2021
|
VRTX Plummets After Ditching Experimental Drug
- The shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) are down 11.7% at $191.50 at last check, after the company announced an experimental drug it was developing to treat a rare genetic condition did not translate into significant clinical benefits, and will therefore not advance into late-stage development.
- 06/11/2021
|
Why Vertex Pharmaceuticals Stock Is Getting Hammered Today
- Another clinical setback isn't sitting well with shareholders today.
- 06/11/2021
|
Biogen Gains, Vertex Pharmaceuticals Drops, and the Stock Market Keeps Rising
- Stocks look set for a higher open as a bipartisan group of senators reached an infrastructure deal.
- 06/11/2021
|
Vertex Pharmaceuticals stock tumbles to pace S&P 500 losers after disappointing drug trial data
- Shares of Vertex Pharmaceuticals Inc. tumbled 13.8% in premarket trading Friday, enough to pace the S&P 500's early decliners, after the biotechnology company released what was seen as disappointing data on its treatment for people with alpha-1 antitrypsin deficiency (AATD), which can lead to liver and lung disease. The stock was on track to open at the lowest price seen during regular-session hours since October 2019.
- 06/11/2021
|
Vertex Pharmaceuticals Nabs Key FDA Approval in Cystic Fibrosis
- The Food and Drug Administration has expanded eligibility for Trikafta to include amenable cystic fibrosis patients aged 6 to 11.
- 06/09/2021
|
Vertex Pharma's Trikafta Triplet Therapy Wins FDA Approval For Expanded Use In Children 6-11 Years With Cystic Fibrosis
- The FDA has approved Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 6 through 11 years. The approval covers children who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene responsive to Trikafta vitro data.
- 06/09/2021
|
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know
- In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $209.16, marking a -0.37% move from the previous day.
- 06/07/2021
|
3 Value Stocks That'll Make You Richer in June (and Beyond)
- Value stocks have historically outperformed growth stocks during the early stages of an economic recovery.
- 06/03/2021
|
Vertex Pharmaceuticals: An Undervalued Pipeline
- Vertex Pharmaceuticals: An Undervalued Pipeline
- 06/02/2021
|
The Best Biotech Stocks to Buy With $500
- A modest amount goes a long way when you invest in biotech stocks.
- 05/31/2021
|
Vertex: Exceptional CF Franchise And Undervalued Pipeline Send Strong Buy Signals
- Vertex is an immensely profitable company thanks to its near-monopoly on treatments for Cystic Fibrosis. Its latest CF therapy, Trikafta, made $3.8bn sales in FY20, and $1.2bn in Q121 - FY21 total revenue forecast is for $6.8bn - up 10% year-on-year.
- 05/30/2021
|
3 Stocks to Hold for the Next 20 Years
- The time is right to invest in these top companies.
- 05/29/2021
|
Is Vertex Pharmaceuticals a Buy?
- This biotech's growth has stalled. Should you give its stock a chance?
- 05/22/2021
|
A Stock Market Crash May Be Near: 3 Stocks to Buy Hand Over Fist When It Happens
- History suggests a big decline is coming. But don't fret -- it's actually good news.
- 05/22/2021
|
3 Biotech Stocks You'll Be Glad You Bought at These Prices
- Their revenue prospects are the ticket to future share price performance.
- 05/19/2021
|
4 Surefire Value Stocks to Buy for a Biden Bull Market
- Value stocks have historically outperformed growth stocks during the early stages of an economic recovery.
- 05/16/2021
|
Vertex: While The Market Remains Indifferent, Now Is The Time To Commit
- Following excellent Q1 2021 results, Vertex shares remain underpriced. The company has established itself as the dominant force in cystic fibrosis treatment, and they have only begun their global penetration.
- 05/12/2021
|
5 Growth Stocks Rocketing Up My Prospective Buy List
- If the growth stock sell-off accelerates, this Fool will be looking to open a position in each of these innovative companies.
- 05/10/2021
|
With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger Market
- One company is setting itself apart in a crowded field.
- 05/07/2021
|
ARK Genomic Revolution ETF: Value Realization Will Take Time
- ARK Genomic Revolution ETF: Value Realization Will Take Time
- 05/03/2021
|
Vertex (VRTX) Q1 Earnings Beat Estimates, Revenues Up Y/Y
- Vertex (VRTX) beats both earnings and sales estimates in Q1 and keeps product sales outlook for 2021.
- 04/30/2021
|
Have $1,000 to Invest? Buy These 2 Growth Stocks Right Now
- Make every dollar count.
- 04/30/2021
|
Here's How Vertex Pharmaceuticals Beat Expectations in Q1
- The biotech's improving fortunes relied on one drug.
- 04/30/2021
|
Vertex Pharmaceuticals Incorporated (VRTX) CEO Dr. Reshma Kewalramani on Q1 2021 Results - Earnings Call Transcript
- Vertex Pharmaceuticals Incorporated (VRTX) CEO Dr. Reshma Kewalramani on Q1 2021 Results - Earnings Call Transcript
- 04/30/2021
|
Vertex Pharmaceuticals: Q1 Earnings Insights
- Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 16.41% over the past year to $2.98, which beat the estimate of $2.69.
- 04/29/2021
|
2 Must-Own Biotech Stocks to Buy in May
- After a stellar rally in 2020, biotech stocks have been selling off over the past couple of months. This offers investors a buying opportunity to scoop up quality biotech stocks at cheaper prices.
- 04/29/2021
|
What's in Store for Vertex (VRTX) This Earnings Season?
- On Vertex's (VRTX) first-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and the company's pipeline progress.
- 04/26/2021
|
Is Vertex Pharmaceuticals a Good Stock to Buy Right Now?
- See if the formerly high-flying biotech deserves a place in your portfolio.
- 04/23/2021
|
Vertex Pharma Inks Research, Licensing Agreement With Obsidian Therapeutics For Controllable Genetic Therapies
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Privately-held Obsidian Therapeutics have entered into a research collaboration and licensing agreement to discover novel therapies that regulate gene editing. The collaboration leverages Obsidian's cytoDRiVE platform technology to discover gene-editing medicines whose therapeutic activity can be precisely controlled using small molecules.
- 04/22/2021
|
3 Top Value Stocks in Healthcare to Buy Right Now
- Well-known guidance from Warren Buffett can help us identify opportunities in an expensive market.
- 04/21/2021
|
Key Decisions Coming on Products From Vertex, AstraZeneca and Other Pharmas
- Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important updates about key products.
- 04/20/2021
|
Vertex Pharmaceuticals Raises Bet on CRISPR Therapeutics
- The amended collaboration agreement comes with a big up-front payment.
- 04/20/2021
|
Vertex to Announce First-Quarter 2021 Financial Results on April 29
- BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International). The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" sec
- 04/19/2021
|
The Growth Stock Sale of 2021 Has Arrived: 3 Stocks to Buy Now
- Bargains abound if you're shopping for high-quality growth stocks.
- 04/18/2021
|
3 Cathie Wood Stocks You Can Buy at a Bargain Right Now
- They're among the top 10 holdings in one of Ark Invest's biggest funds.
- 04/17/2021
|
3 Biotech Stocks Ripe for Spring Portfolio Cleaning
- All down 45% or more from their 52-week highs, should you consider cutting your losses?
- 04/16/2021
|
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
- Vertex Pharmaceuticals (VRTX) closed at $217.13 in the latest trading session, marking a +0.55% move from the prior day.
- 04/14/2021
|
Here's Why Vertex Pharmaceuticals Stock Is Undervalued At $215 Levels
- We believe that the stock price of Vertex Pharmaceuticals is undervalued at current levels of $215. VRTX stock is up a mere 6% off the March 2020 bottom compared to the S&P which moved 85%.
- 04/14/2021
|
On Sale: Glitter From The Healthcare Wreckage, Biotech Edition
- On Sale: Glitter From The Healthcare Wreckage, Biotech Edition
- 04/12/2021
|
Does 2021's Best Biopharma to Work for Belong in Your Portfolio?
- Horizon Therapeutics has a clear path to significant sales growth.
- 04/07/2021
|
3 Top Biotech Stocks to Buy in April
- These big biotechs check off all the boxes.
- 04/07/2021
|
3 Value Stocks That'll Make You Richer in April (and Beyond)
- Value stocks are historically the place to be when the U.S. economy is rebounding from a recession.
- 04/05/2021
|
ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
- ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
- 04/02/2021
|
Vertex: An Undervalued Business With A Promising Pipeline
- Vertex's shares represent an excellent investment opportunity based on the undervaluation of the current drug portfolio. If the VX-864 drug proves effective in the Phase 2 of clinical trials, it may become the closest driver for the growth of shares.
- 03/29/2021
|
3 Top Biotech Stocks to Buy Right Now
- All three should have solid long-term growth prospects.
- 03/28/2021
|
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation
- LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label extension of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination with ivacaftor 150 mg tablets for the treatment of cystic fibrosis (CF) in all patients ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conduct
- 03/26/2021
|
3 Blue Chips That Could Triple Your $1400 Stimulus Check
- 3 Blue Chips That Could Triple Your $1400 Stimulus Check
- 03/25/2021
|
Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation
- LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Australian Therapeutic Goods Administration (TGA) has approved the use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for people with cystic fibrosis (CF) ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation worldwide. Up to 90% of people living with CF worldwide h
- 03/24/2021
|
